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Ultraviolet B radiation 
 
General considerations 
Sunlight and its adjacent spectral regions, ultraviolet (UV) and infrared are basic 
requirements for life on earth and humankind has always been exposed to their 
influence. Health benefits to sun exposure were reported in ancient times. Several 
therapeutic actions of UV radiation (UVR) are now supported by sound scientific 
evidence. However it became clear that solar UVR is also the major environmental 
insult to the skin.  
The word ultraviolet means “beyond violet” and refers to electromagnetic 
radiation with a wavelength shorter than visible violet light but longer than X-rays 
(Maverakis et al. 2010). UVR represents approximately 5% of terrestrial solar 
radiation and is divided according to the wavelength into UVA (315-380 nm) 
separated into UVA1 (340-380 nm) and UVA2 (315-340 nm), UVB (280 to 315 nm) 
and UVC (100 to 280 nm). Solar UVR at sea level is approximately 95-98% UVA and 
2 to 5% UVB while UVC is completely absorbed by stratospheric ozone that also 
attenuates UVB. Little UVB radiation reaches the earth's surface. However, UVB 
radiation has much more energy than UVA (energy is inversely proportional to 
wavelength) and is approximately 1000 times more erythematogenic than UVA. In 
other words, although more UVA reaches the earth, it is mainly UVB that “burns” the 
skin.  
UVR ionizes molecules and induces chemical reactions. When UVR strikes the 
skin, part is remitted (reflected and scattered), part is absorbed in various layers by 
molecules termed chromophores, and part is transmitted inward until the energy has 
been dissipated. Photochemical reactions convert chromophores (proteins, DNA and 
other components of epidermal cells) into new molecules and these photoproducts 
activate cellular signal transduction pathways leading to biochemical changes and 
different cellular responses.  
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The two major processes limiting the penetration of UVR into skin (absorption 
and scattering) vary with wavelength (Anderson and Parrish 1981). The depth of 
penetration is directly proportional to the wavelength of the radiation and UVB is 
mainly absorbed in the epidermis while UVA can penetrate deep into the dermis 
(Anderson and Parrish 1981).  
An action spectrum indicates which wavelengths produce a photochemical 
response most effectively. The rate at which the radiant energy is delivered to the skin 
is expressed as W/cm2 and is called irradiance. The total radiant energy delivered per 
unit area of skin surface is called the exposure dose or fluence and is the product of 
irradiance and time:  
[irradiance (W/cm2) x time (seconds) = exposure dose (J/cm2)]
 
The magnitude of the response to UVR is determined by the exposure dose at a 
particular wavelength. 
Exposure of human skin to UVB results in several distinct pathophysiological 
responses that may be divided into acute and chronic. The most prominent cutaneous 
acute effects are the sunburn reaction, tanning, immunosuppression, and vitamin D 
synthesis. Photoaging and skin cancer are the consequences of chronic exposure. UVR, 
especially UVB, is a major causal factor for all types of skin cancer and UVB 
signature mutations in p53 tumour suppressor gene are very prevalent in these tumours 
(Raj et al. 2006).  
Acute UVB irradiation causes apoptosis and the term “sunburn cell” refers to 
keratinocytes undergoing apoptosis. This programmed cell-death of UV-damaged skin 
cells is a definitive cancer-prevention pathway.  
After UVB irradiation, two photoproducts are well recognized, the four-
membered ring structure called cyclobutyl pyrimidine dimers (CPDs) that lead to DNA 
damage (Freeman et al. 1989) and previtamin D3 (Holick et al. 1987). The action 
spectrum for sunburn (erythema) closely correlates with the absorption spectrum of 
DNA and is within the UVB range.  
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UVB also increases cyclooxygenase-2 (COX-2) expression in cultured human 
keratinocytes (Buckman et al. 1998; Van Dross et al. 2007) and COX-2 protein levels 
become elevated in the epidermis of human skin following UVB irradiation (Buckman 
et al. 1998).  
UVR has been shown to activate phospholipase A2 in human skin and 
keratinocytes (De Leo et al. 1984), thereby releasing arachidonic acid. UVR also 
stimulates a biphasic rise in diacylglicerol (DAG) production in melanocytes and 
keratinocytes resulting from diacylglycerol kinase and phospholipases C and D 
activation and their action on plasma membrane phospholipids (Punnonen and Yuspa 
1992; Carsberg et al. 1995). 
It is recognized that UVB and UVA radiation enhance reactive oxygen species 
(ROS) production. This oxidative stress in epidermal cells plays an important role in 
the photodamage pathway (Portugal-Cohen et al. 2011).  
UVB increases intracellular calcium (Ca2+) level in both keratinocytes cell 
culture (HaCat cells) and in human skin in vivo (Lee et al. 2009; Masaki et al. 2009). It 
has been difficult to identify the specific mechanism for UVB-induced Ca2+-channel 
activation. Recently it was demonstrated in keratinocytes (HaCat cells) that UVB 
radiation increases the intracellular Ca2+ via transient receptor potential vanilloid type I 
(TRPV1) activation (Lee et al. 2009). In addition UVB increases TRPV1 expression in 
both keratinocytes and human skin in vivo (Lee et al. 2009). A protein kinase C 
(PKC)-dependent activation of TRPV1 and subsequent Ca2+ influx was already 
suggested (Lee et al. 2009). Probably, PKC is not the initial chromophore or target 
molecule of UVB, but PKC activation occurs by UVB-induced release of DAG, 
arachidonic acid and ROS (Matsui et al. 1996). 
UVB activates the nuclear factor kappa B (NF-kB) that is a major inducer of 
inflammatory response. NF-kB induces the synthesis of proinflammatory interleukins 
(IL-1, IL-6, IL-8) and tumor necrosis factor alpha (TNFα) by keratinocytes (Wang et 
al. 1995; Portugal-Cohen et al. 2011).  
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Investigating the molecular targets and the signal transduction pathways 
activated by UVR will increase understanding of both detrimental and therapeutic 
effects of UVR. 
 
Melanogenesis 
Part of this topic has already been reviewed (see Videira I et al 2012, 
Introduction annex 1) 
In the skin, melanin is the first defense against UVR. This pigment is able to 
absorb and dissipate UVR as harmless heat. The increase of melanin in the epidermis 
after UV exposure, the so-called tanning, is understood as a host response against 
future photodamage. Melanogenesis has been the interest of research for many 
decades, however, until the 1990s the initiating molecular events of tanning were 
unknown.  
UVB and UVA induce tanning by different mechanisms. UVB induces a slow 
but stable type of pigmentation termed delayed tanning, which requires the increased 
synthesis of melanin following the stimulation of the entire melanogenic cascade 
(Alaluf et al. 2002; Tadokoro et al. 2005). In contrast UVA causes mainly immediate 
tanning, due to redistribution of melanosomes and generation of ROS via oxidation, 
polymerization or both of existing melanin or melanin precursors (Maeda and Hatao 
2004).  
Melanocytes, located in the basal layer of the epidermis, synthesize melanin in 
discrete organelles, the melanosomes, which once filled with melanin are transferred 
via long dendritic processes to the surrounding keratinocytes, where they form a 
supranuclear cap to protect DNA against UVR [reviewed by Schallreuter (Schallreuter 
2007)].  
The key enzyme in melanogenesis, tyrosinase, is located in melanosomes. The 
rate of melanin production at baseline and following UVB exposure depends on 
tyrosinase activity, rather than simply on total tyrosinase protein (Park et al. 1999). 
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Tyrosinase is a copper-containing membrane glycoprotein with the N-terminal located 
inside the melanosome, whereas the C-terminal sits in the melanocyte cytosol. The 
enzyme is activated when two serine residues close to C-terminal are phosphorylated 
by protein kinase C-β (PKC-β). Tyrosinase contains two cooper atoms in its active 
site, and when copper atoms are oxidized the enzyme is inactive. The rate-limiting step 
in melanogenesis is the oxidation of tyrosine to L-DOPA (Schallreuter 2007). L-
DOPA acts as a cofactor and also as a substrate for tyrosinase being oxidized into 
DOPAquinone. Although the exact interaction between tyrosinase and its substrates is 
not completely understood, kinetic studies suggest that L-tyrosine and L-DOPA have 
separate binding sites (Olivares et al. 2002; Schallreuter 2007).  
Catechol-O-methyltransferase (COMT) is present in melanocytes and catalyses 
the O-methylation of catecholic compounds such as L-DOPA (Shibata et al. 1993; 
Smit et al. 1994). A potential role of COMT in the regulation of melanogenesis was 
first suggested in the paper by Axelrod et al (Axelrod and Lerner 1963) and more 
recently it has been shown that skin tyrosinase activity is significantly increased in 
hairless COMT-deficient male pups but the role of COMT in melanogenesis is not yet 
clarified (Forsberg et al. 2004). 
Melanocytes and keratinocytes interact closely as a structural and functional unit, 
named “epidermal unit”. Melanogenesis is greater in intact skin or in co-cultures of 
melanocytes and keratinocytes than in isolated melanocyte cultures, suggesting that 
keratinocyte-derived products contribute to the UV-induced tanning (Archambault et 
al. 1995; Duval et al. 2001). Among the wide variety of autocrine and paracrine 
melanogenic factors produced by keratinocytes are, melanocyte-stimulating hormone 
(α-MSH), adrenocorticotropic hormone (ACTH), endotelin-1, nitric oxide, 
prostaglandins E2 and F2aα and granulocyte-macrophage colony stimulating factor 
(Suzuki et al. 1999; Kadekaro et al. 2003; Yamaguchi et al. 2007; Park et al. 2009; 
Choi et al. 2010). These factors can act alone or synergistically with each other to 
modulate melanocyte function. Some UVR-induced cytokines such as IL-1 and TNFα 
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inhibit melanogenesis suggesting a fine regulation between melanogenic stimulation 
and inhibition after UVR (Slominski et al. 2004).  
The most well known melanogenesis-regulating receptor on melanocytes is the, 
G-protein-coupled, melanocortin-1 receptor (MC1). Its activation increases 
intracellular cAMP and through protein kinase-A (PKA) induces microphthalmia-
associated transcription factor (MITF) transcription. MITF in turn upregulates the 
transcription of tyrosinase, tyrosinase-related-protein-1, tyrosinase-related-protein-2 
and PKC-ß genes, increasing melanin production (Shibahara et al. 2000; Schallreuter 
2007; Park et al. 2009; Choi et al. 2010). α-MSH and ACTH are among the MC1 
agonists.  
The key observation of the coinciding spectrum, within the UVB range, for 
producing a delayed tan (Parrish et al. 1982) and for induction of CPDs (Freeman et 
al. 1989) suggested for the first time a cause effect relation between DNA damage and 
melanogenesis. It was recognized that the tumor-supressor protein p53 is a 
transcription factor that plays a pivotal role in stimulating melanogenesis after UVB-
induced DNA damage (Khlgatian et al. 2002). In keratinocytes, UVB triggers a more 
than 30-fold increase in the formation of pro-opiomelanocortin (POMC) and of its 
cleavage product α-MSH (Lin and Fisher 2007; Choi et al. 2010). This UVB-induced 
α-MSH production by keratinocytes is regulated via a p53 consensus sequence in the 
POMC gene promoter (Cui et al. 2007). Keratinocyte-derived α-MSH then stimulates 
MC1 on melanocytes, suggesting the important role of keratinocytes for sensing UVR.   
Despite the strong influence of MC1 receptors on skin pigmentation, it is clear 
that other melanocyte receptors such as β2 adrenoceptor (Gillbro et al. 2004), M1, M3 
and M5 muscarinic receptors (Grando et al. 2006) and oestrogen receptors (Thornton et 
al. 2006) are also involved in melanogenesis regulation via adenylcyclase activation .  
UVR induces the release of DAG from plasma membrane lipids, which then 
activates PKC-β that in turn activates tyrosinase and stimulates melanogenesis 
(Punnonen and Yuspa 1992; Park et al. 1993; Park et al. 1999; Schallreuter 2007; Park 
Introduction and Aims 
 
29 
 
  
et al. 2009; Choi et al. 2010). DAG release after UVR may also be mediated indirectly 
via activation of endotelin-1 receptors or α1 adrenoceptors in melanocyte cell 
membranes (Park et al. 2009).  
Identification of factors that modulate UV-induced melanogenesis could increase 
opportunities for targeted therapeutics ranging from the development of cosmetics to 
the prevention of skin cancer.  
 
Therapeutic use 
Part of this topic has already been reviewed (see Osório F et al 2012, 
Introduction annex 2) 
UVR has been used in the management of skin diseases with great success and at 
a constantly increasing rate for decades, since Goeckerman first used it in 1925. 
Thereby UV phototherapy becomes an essential part of modern dermatological 
therapy.  
There are many types of phototherapy including: broadband UVB (280-320 nm), 
narrowband UVB (nbUVB) (311-313 nm), UVA1 (340-400 nm), and combination 
therapy of UVA (320-400 nm) plus the photosensitizer psoralen (PUVA). More 
recently handheld phototherapy technologies were developed to deliver UVB targeted 
to skin lesions.  
Psoriasis is the prototypic skin disease with a favourable response to UVB 
phototherapy. In 1977, Fischer (Fischer 1977) found that ultraviolet light at a 
wavelength of 313 nm was effective in clearing psoriatic plaques. Few years later, it 
was determined that the most effective wavelengths were between 295 and 313 nm, 
indicating that this wavelength may possess the optimal “phototherapy index” for 
clearing psoriasis (Parrish and Jaenicke 1981). Over the past 30 years, the introduction 
of fluorescent bulbs with a limited spectrum of 311–313 nm (nbUVB) has marked an 
advance in psoriasis phototherapy. Its success as therapeutic agent has stimulated 
studies about the underlying mechanisms involved in resolution of psoriatic plaques. 
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UVB exerts a multitude of biological effects within the skin, however it remains 
unclear which of these induce clearance of psoriasis and what is the reason for the 
marked interpatient variation in clinical responses (Ryan et al. 2010). In addition 
identification of molecular biomarkers of UV sensitivity may facilitate treatment 
predictability.  
The development of psoriasis is dependent on complex interactions between the 
innate imune system, dendritic cells and activated T-cells driving hyperproliferation of 
genetically predisposed abnormal keratinocytes. Most of the recent studies have 
highlighted the nbUVB immunosuppressive effect, leading, in the epidermis, to 
downregulation of T helper 17 and interferon signaling pathways (Racz et al. 2011), 
reduction of T cells (Krueger et al. 1995; Carrascosa et al. 2007; Erkin et al. 2007), 
depletion of Langerhans cells (Murphy et al. 1993) and induction of T regulatory cells 
(Schwarz et al. 2004). In addition, soluble factors induced upon UVB exposure, such 
as IL-10, IL-22, IL-17, IL-23, IL-8, vascular endothelial growth factor, TNFα, cis-
urocanic acid and vitamin D3, could also be involved in UVB therapeutic effect 
(Ullrich 1994; Beissert et al. 2001; Gorman et al. 2007; Cicarma et al. 2010; Coimbra 
et al. 2010; Ryan et al. 2010). Moreover it was observed that UVB 311nm induces 
significant keratinocytes apoptosis in lesional epidermis, and keratinocyte apoptosis 
was proposed as the key mechanism in psoriatic plaques clearance (Aufiero et al. 
2006; Weatherhead et al. 2011).  
Patients with moderate to severe psoriasis have been found to be at greater risk 
of developing comorbidities such as metabolic syndrome, obesity and cardiovascular 
diseases (McDonald 1989; Wakkee et al. 2007; Yiu et al. 2011). More recently an 
effect of phototherapy on inflammatory markers and circulating adipokine levels was 
described and a relation with clinical benefit was hypothesised (Coimbra et al. 2009; 
Coimbra et al. 2010; Kawashima et al. 2011; Shibata et al. 2011). 
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Endocannabinoid system 
 
Cannabinoid receptors 
In the mid-1960s the main psychoactive component of Cannabis sativa, the 
lipophilic compound ∆9tetrahydrocannabinol (THC) was discovered (Mechoulam and 
Gaoni 1965). More than two decades later, the first THC-specific receptor named 
cannabinoid receptor 1 (CB1) was identified in rat brain (Devane et al. 1988) and then 
cloned from mammalian tissues (Matsuda et al. 1990). Three years later, in 1993, a 
second cannabinoid receptor named CB2 was identified in the human promyelocytic 
leukemic cell line HL60 (Munro et al. 1993). The distinction between these two 
receptors is based on differences in their amino acid sequence, signalling mechanisms, 
tissue distribution, and sensitivity to selective agonists and antagonists.  
CB1 and CB2 receptors are G-protein-coupled receptors members of Gi/o family 
(Gi1, 2 and 3, and Go1 and 2), for review see (Howlett 2005). Both these receptors 
inhibit adenylcyclase in most cells via Gi, although CB1 receptors can signal via Gs and 
stimulate adenylcyclase in some experimental models (Glass and Felder 1997; Maneuf 
and Brotchie 1997; Calandra et al. 1999). 
Activation of CB1 and CB2 cannabinoid receptors leads to phosphorylation and 
activation of p42/p44 mitogen-activated protein kinases (MAPK) (Bouaboula et al. 
1995; Bouaboula et al. 1996), p38 MAPK (Derkinderen et al. 2001) and Jun N-
terminal kinase (JNK) (Rueda et al. 2000) as signaling pathways to regulate nuclear 
transcription factors. 
Evidence exists that CB1 receptor via Gi/o inhibits N- and P/K-types of voltage-
gated Ca2+ channels and stimulates A-type and inwardly rectifying potassium channels 
(Howlett 2005; Pertwee et al. 2010).  
The CB1 receptor possesses one or more allosteric sites and different ligands 
may enhance or inhibit the activation of this receptor by direct agonists (Price et al. 
2005; Horswill et al. 2007; Navarro et al. 2009).  
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It is well known that CB1 and CB2 receptors are much more widely distributed 
than originally believed and that both receptor types can control central and peripheral 
functions. The CB1 receptors are preferentially expressed in the central nervous 
system, being mainly distributed in brain areas associated with motor control, 
emotional responses, motivated behaviour and energy homeostasis, where they 
mediate inhibition of transmitter release (Matsuda et al. 1990). In the periphery, CB1 
receptors are expressed in the adipose tissue, pancreas, liver, gastrointestinal tract, 
skeletal muscles, heart and the reproduction system (Mackie 2008). While CB2 
receptors occur in the brain, pancreas, bone and adipose tissue, they are mainly 
expressed by immune cells (Munro et al. 1993; Patel et al. 2010). 
 
Endocannabinoids  
The discovery of CB1 and CB2 receptors opened the way to the identification of 
their cannabis-like endogenous ligands, named endocannabinoids. The N-
arachidonoylethanolamine (anandamide) was the first endocannabinoid to be 
discovered (Devane et al. 1992). Shortly after, it was observed that an already known 
endogenous metabolite, 2-arachidonoyl-glycerol (2-AG) also exhibits high affinity for 
cannabinoid receptors (Mechoulam et al. 1995; Sugiura et al. 1995). Meanwhile, other 
polyunsaturated fatty acids have also been proposed to be endocannabinoids including, 
N-dihomo-γ-linolenoylethanolamine, N-docosatetraenoylethanolamine, virodhamine, 
oleamide and N-arachidonoyl dopamine, but are less well-characterized (Di Marzo 
2008; Pertwee et al. 2010). Palmitoylethanolamide (PEA), an endogenous lipid 
congener of anandamide, with anti-inflammatory and anti-nociceptive properties, has 
been postulated to act by enhancing anandamide effects but it also activates transient 
receptor potential vanilloid receptor type 1 (TRPV1) (Petrosino et al. 2010). Therefore, 
anandamide and 2-AG are still referred as the “major” endocannabinoids.  
Anandamide and 2-AG have affinity for both CB1 and CB2 receptors with 
slightly greater affinity for CB1 (Pertwee et al. 2010; Cluny et al. 2012). The 
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endocannabinoids also activate other receptors, such as the deorphanized G-protein-
coupled receptor-GPR55, 5-HT3 receptors, opioid receptors, peroxisome proliferator-
activated receptors (PPARs), TRPV1 (anandamide, but not 2-AG) and TRPV4 (both 
anandamide and 2-AG) (Pertwee et al. 2010; Cluny et al. 2012).  
As lipids, endocannabinoids cannot be stored in vesicles, but are produced via 
several biosynthetic pathways, as needed (“on demand”) from membrane 
phospholipids in response to an increase in intracellular Ca2+ or after activation of G-
protein-coupled receptors (Alger and Kim 2011; Cluny et al. 2012). 
2-AG can be formed when Ca2+ stimulates phospholipase C which then 
transforms membrane phosphoinositides into DAG, from which 2-AG is liberated by 
DAG lipase (DGL) (Alger and Kim 2011). Alternatively DAG can be produced from 
phosphatidic acid, a reaction catalysed by either phospholipase A2 or D (Alger and 
Kim 2011).  Two isoforms of DGL have been cloned: DGLα and DGLβ, but DGLα 
seems to be sufficient for most endocannabinoid signalling (Alger and Kim 2011).  
There is no consensus as to which of the multiple pathways of anandamide 
synthesis is physiologically more relevant (Di Marzo 2009; Alger and Kim 2011; 
Cluny et al. 2012; Fowler 2012). N-Arachidonoyl-phosphatidyletanolamine (NArPE) 
is the major biosynthetic precursor of anandamide (Cadas et al. 1997; Di Marzo 2009). 
The enzyme that catalyses the direct conversion of NArPE to anandamide is known as 
N-acylphosphatidyl-ethanolamine specific phospholipase D (NAPE-PLD) (Di Marzo 
2009; Cluny et al. 2012) but other routes of synthesis are described since NAPE-PLD 
“knock-out” do not exhibit reduced levels of anandamide in most tissues (Leung et al. 
2006).  
Endocannabinoids are produced on demand and are rapidly cleared by a process 
of cellular uptake that is incompletely characterized, followed by enzymatic 
metabolism. There is general consensus that the enzyme fatty acid amide hydrolase 
(FAAH) is the key-enzyme of the breakdown of anandamide, (Di Marzo 2009). On the 
other hand, besides the major contribution of monoacylglycerol lipase (MAGL) for 2-
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AG metabolism, it may also be metabolized with a lesser extent by α/β hydrolase 6, 
α/β hydrolase 12 and FAAH (Di Marzo 2009; Alger and Kim 2011). While the 
searches for α/β hydrolases inhibitors are still in their beginning, a growing number of 
selective and potent inhibitors are now available to inhibit FAAH and MAGL activities 
(Petrosino and Di Marzo 2010; Feledziak et al. 2012).  
Enzymes of the arachidonic acid cascade such as COX-2 and lipoxygenases are 
also alternative pathways for 2-AG and anandamide metabolism, leading to the 
formation of active metabolites capable of acting at the cannabinoid, TRPV and PPAR 
receptors (Duggan et al. 2011; Vecchio and Malkowski 2011; Cluny et al. 2012). The 
biological relevance of these reactions remains to be established. 
 
Relevance of endocannabinoid system  
In recent years, it becomes clear that the functions of endocannabinoid system 
are exerted in the whole organism and are not limited to the central nervous system (Di 
Marzo 2008; Pacher and Mechoulam 2011). To date, it has been documented that 
endocannabinoid system-regulated functions include: neuronal transmission, pain 
initiation, thermogenesis, appetite and energy metabolism, inflammatory and immune 
responses, bone remodelling, lipid metabolism, cardiovascular, respiratory and 
reproductive functions, hormone release, as well as cellular proliferation and apoptosis 
(Calignano et al. 1998; Di Marzo 2008; Pacher and Mechoulam 2011).  
The endocannabinoid system is activated “on demand” and a pro-homeostatic 
effect has been claimed in different tissues. This “plasticity” of the endocannabinoid 
system is clearly observed in central nervous system, where it underlies adaptive 
responses to anxiety, chronic stress, neuronal damage and neuroinflammation 
(Bisogno and Di Marzo 2007; Moreira et al. 2008). The tissue localization of the 
cannabinoid receptors and metabolic enzymes also support this proposed pro-
homeostatic strategy of action.  
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The expression of cannabinoid receptors and also the tissue and plasma levels of 
the “major” endocannabinoids undergo significant changes following physiological 
and pathological stimuli. However, for the same pathological condition, there are often 
reports of both positive and negative changes and of both protective and deleterious 
effects of endocannabinoid system activation (Di Marzo 2008). It is becoming 
increasingly evident that within a certain tissue, the endocannabinoid system may be 
affected in different ways by the same stressful stimulus according to the duration of 
this stimulus.  
The endocannabinoid system is involved in various pathological conditions in 
central and peripheral tissues such as, neurodegenerative disorders, psychiatric 
conditions, cardiovascular disease, liver disorders, osteoporosis, inflammatory bowel 
disease, auto-immunity, cancer, obesity and metabolic syndrome (Di Marzo 2008; 
Moreira et al. 2008; Pacher and Mechoulam 2011). 
Obesity and metabolic syndrome are well- known pathological conditions 
associated with endocannabinoid system dysregulation. (Maccarrone et al. 2010; 
Cluny et al. 2012). Endocannabinoid system plays a major role in the regulation of 
energy homeostasis and is generally upregulated in chronic overeating (Maccarrone et 
al. 2010). The endocannabinoid plasma levels and FAAH activity in subcutaneous 
adipocytes are positively correlated with body mass index (BMI) (Cable et al. 2011) 
and in obesity elevated endocannabinoid plasma levels were associated with coronary 
circulatory dysfunction (Quercioli et al. 2011). It was demonstrated that 
endocannabinoids also play a key role in the development of fatty liver in response to 
high fat diets or chronic alcohol intake (Jeong et al. 2008). Furthermore hypothalamic 
endocannabinoids seem to be part of the neural circuitry involved in the modulating 
effects of leptin on energy homeostasis. 
Strategies for manipulating the endocannabinoid system for therapeutic reasons 
will require a thorough understanding of the roles of the different endocannabinoids, 
the stimuli that mobilize them and their sources and metabolism. Regulating 
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endocannabinoid levels in vivo represents an interesting therapeutic perspective.  
Several inhibitors of 2-AG and anandamide metabolizing enzymes have attracted 
growing interest as potential therapeutic drugs. Particularly, the FAAH inhibitors have 
demonstrated benefit in animal models of several disorders, including pain, anxiety 
and inflammatory bowel diseases, as well as against proliferation and migration of 
cancer cells (Clapper et al. 2010; Petrosino and Di Marzo 2010). 
Cannabinoid compounds have also been proposed as promising therapeutic 
agents in multiple sclerosis given their capability to alleviate symptoms (e.g., 
spasticity, pain) and reduction of inflammatory events by the activation of CB1 
receptors (de Lago et al. 2012). CB1 receptor antagonists have been explored, and 
found to be effective, as therapeutic agents for obesity and related cardiometabolic 
problems. However, the use of rimonabant, the first marketed CB1 receptor antagonist, 
has been suspended due to its anxiogenic and depressogenic effects (Kirilly et al. 
2011).  
 
Endocannabinoid system in the skin and appendages 
The skin and its appendages (hair follicle and sebaceous gland) function as a 
“neuro-immuno-endocrine” organ. Indeed, almost all skin cell types are capable of 
producing and releasing pro and/or anti-inflammatory mediators, hormones, growth 
factors, neuropeptides and vasoactive substances that can exert paracrine or autocrine 
regulation of skin cells functions (Roosterman et al. 2006).  
Recent evidences suggest that endocannabinoid system has an important role in 
this complex cutaneous network (Kupczyk et al. 2009). 
Anandamide and 2-AG are detectable in rodent skin (Calignano et al. 1998; 
Karsak et al. 2007) and the distribution and expression of CB1 receptors was uniformly 
found in human skin biopsies taken from different body sites (Stander et al. 2005).  
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CB1 and CB2 receptors were predominantly expressed on cutaneous nerves 
(Stander et al. 2005) and it was proposed that cannabinoid receptors present in the skin 
might act as cutaneous nociceptors (Ibrahim et al. 2005; Khasabova et al. 2008).  
In normal skin, CB1 and CB2 receptors were mostly present in suprabasal layers 
of the epidermis and in skin appendages like epithelial cells of hair follicles and 
sebocytes (Casanova et al. 2003; Stander et al. 2005).  
There is evidence that anandamide and 2-AG and both cannabinoid receptors are 
present on human keratinocytes, which also express the main enzymes involved in 
anandamide synthesis (NAPE-PLD) and degradation (FAAH) (Maccarrone et al. 2003; 
Ibrahim et al. 2005). 
Anandamide in a CB1 receptor-dependent manner inhibits keratinocyte 
differentiation by transcriptional downregulation of keratin 1, keratin 5, involucrin and 
transglutaminase 5 (Paradisi et al. 2008). These effects were mediated by an increase 
in DNA methylation through MAPK-dependent pathways (p38, p42/44) (Paradisi et al. 
2008).  
Published data on effects of cannabinoids on regulation of keratinocytes cell 
death are conflicting. Wilkinson et al (Wilkinson and Williamson 2007) found that 
phytocanabinoids such as ∆9-tetrahydrocannabinol as well as synthetic cannabinoid 
agonists inhibited growth of cultured transformed human epidermal keratinocytes 
(HPV-16E6/E7), yet these effects were CB1 and CB2 independent. In other study, 
activation of both cannabinoid receptors by synthetic agonists induced the apoptotic 
death of tumorigenic epidermal cells whereas the viability of non-tumorigenic human 
(HaCat cells) and murine (MCA3D) keratinocytes remained unaffected (Casanova et 
al. 2003). In contrast, recent data on CB1 and CB2 knockout mice suggest that 
cannabinoid receptors and the related signalling pathways might be involved in skin 
cancer development (Zheng et al. 2008). The effect of cannabinoids in keratinocytes 
death needs further investigation since manipulation of this pathway could become a 
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useful adjunct treatment option in hyperproliferative dermatoses such as psoriasis or 
keratinocytes-derived skin cancers.   
Despite this well documented endocannabinoid system in human keratinocytes 
the role of endocannabinoids in melanocytes has not yet been studied. There is one 
study (Blazquez et al. 2006) demonstrating that human and mouse melanoma cells 
contain cannabinoid CB1 and CB2 receptors. In vitro experiments on A353 and 
Meljuso melanoma cell lines, reveled that cannabinoids significantly decrease the 
number of viable melanoma cells by inducing apoptosis and that this effect was 
prevented by selective cannabinoid receptors antagonists (Blazquez et al. 2006). 
Interestingly proliferation of normal melanocyte cell lines was not inhibited (Blazquez 
et al. 2006). Furthermore, in the same paper, it was documented that CB2 receptor 
agonists inhibit melanoma progression and metastatic spreading in the mouse 
(Blazquez et al. 2006).  
In human scalp, it was demonstrated that hair follicles are sources of 
endocannabinoids and express CB1 receptors. CB1 activation by anandamide inhibited 
hair growth and induced apoptosis-driven premature hair follicles regression (catagen) 
in vitro (Telek et al. 2007). Hair follicles are most common arranged in pilosebaceous 
units, which display another adnexal structure of the human skin, the sebaceous gland. 
Dobrosi et al (Dobrosi et al. 2008) by using a human sebaceous gland-derived cell line 
demonstrated that anandamide and 2-AG are produced by epithelial cells of the 
sebaceous glands (sebocytes) and both via CB2 receptor and MAPK pathway, dose-
dependently induce lipid production and cell death (Dobrosi et al. 2008). Moreover, 
endocannabinoids also upregulated the expression of key genes involved in lipid 
synthesis, suggesting that CB2 ligands may be exploited in the management of 
sebaceous glands dysfunctions (Dobrosi et al. 2008). 
Since the original discovery of the CB2 receptors in immune cells, much 
evidence suggest that the endocannabinoid system has important immune modulator 
effects during inflammation (Klein 2005). Karsak et al (Karsak et al. 2007) observed 
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an increase in cutaneous nickel-induced allergic responses in CB1 and CB2 knockout 
mice as well as in the presence of cannabinoid receptors antagonists. In contrast 
FAAH-deficient mice displayed reduced allergic responses in the skin (Karsak et al. 
2007). By using an animal model of induced allergic contact dermatitis it was also 
demonstrated that after allergen exposure, the cutaneous levels of 2-AG and 
anandamide significantly increased and that CB1 receptor RNAm was downregulated 
while CB2 receptor mRNA was upregulated (Karsak et al. 2007). Taken together these 
data suggest a protective role of the endocannabinoid system in contact allergic 
dermatitis (Karsak et al. 2007). A protective role of PEA against inflammation was 
also observed in the same animal model of contact allergic dermatitis and in a 
keratinocyte cell line (HaCat) (Petrosino et al. 2009). 
 Endocannabinoid signals involved in skin inflammation are complex and remain 
poorly understood. Overall, anandamide appears to mediate an anti-inflammatory 
effect since inhibition of its degradation significantly reduced inflammation (Karsak et 
al. 2007) and, on the other hand, there is growing evidence suggesting that 2-AG 
modulates the inflammatory response by acting on the CB2 receptors (Oka et al. 2006). 
By using different animal models for acute and chronic dermatitis, Oka et al (Oka et 
al. 2006) reported elevated 2-AG levels in the affected skin and that CB2 (but not CB1) 
antagonists markedly attenuated cutaneous inflammation. Likewise, others reported a 
decrease in the cutaneous inflammation of CB2 receptor deficient mice (Ueda et al. 
2007).  
In addition the endocannabinoid system has a crucial role in the control of skin-
derived sensory phenomena as pain and itch.  
Despite significant research on the role of endocannabinoid signaling in 
keratinocytes and pilosebaceous units the potential role of endocannabinoid system in 
melanogenesis and the influence of UVR in cutaneous endocannabinoid tone are not 
yet elucidated. 
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Mechanisms regulating melanogenesis 
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Abstract  
The skin pigmentation is an important human phenotypic trait but despite many efforts its regulation is still not 
fully understood. The pigment melanin is produced in melanosomes by melanocytes in a complex process named 
melanogenesis. The melanocyte interacts with endocrine, immune, inflammatory and central nervous systems 
and its activity is also regulated by extrinsic factors such as ultraviolet radiation and drugs. We review current 
understanding of intrinsic and extrinsic factors regulating skin pigmentation, melanogenesis steps and the known 
related gene defects. We focus on melanocyte-keratinocyte interaction, enzymatic components of melanosomes, 
activation of melanocortin receptor type1 (MC1-R) by proopiomelanocortin (POMC) cleavage products 
(melanocyte stimulating and adrenocorticotrofic hormones) and mechanisms of ultraviolet-induced skin 
pigmentation. The identification and understanding of the melanogenesis mechanisms facilitate the knowledge of 
the pathogenesis of pigmentation disorders and the development of potential therapeutic options.
Introduction 
The skin has epidermal units that are responsible 
for melanin production and distribution, in a 
process called melanogenesis. These units are 
composed by a melanocyte surrounded by 
keratinocytes and they are regulated by a closed 
paracrine system. Melanin is the main responsible 
for skin, hair and eyes pigmentation and besides 
defining an important human phenotypic trait, it has 
a critical role in photoprotection due to its ability to 
absorb ultraviolet radiation (UVR) [1-3]. The 
Fitzpatrick system is the most commonly used 
system to distinguish the diversity of cutaneous 
pigmentation phenotypes. It characterizes six 
phototypes (I-VI), by grading the erythema and the 
acquired pigmentation after exposure to UVR [1, 
4]. Constitutive pigmentation reflects the 
genetically determined level of melanin and can be 
changed by several regulator factors [3, 5]. These 
factors may be intrinsic (released by keratinocytes 
and fibroblasts, endocrine, inflammatory and 
neuronal cells) or extrinsic (UVR and drugs) [3, 6]. 
The melanogenesis is a complex process with 
different steps and when disturbed may determine 
different types of pigmentation defects, which are 
classified as hypo or hyperpigmentation and may 
occur with or without altered melanocytes number 
[1, 2, 7]. There are several dermatoses associated 
with pigmentation defects which can be congenital 
or acquired, permanent or temporary and restricted 
to the skin or systemic [7]. Since these dermatoses 
have an important impact on patient’s quality of life 
and their treatment can be unsatisfactory, the 
pharmaceutical and cosmetic industries have been 
continuously seeking for new solutions [8, 9]. The 
understanding of the melanogenesis mechanisms 
helps us to explain the pigmentation defects 
observed in genodermatoses  
and allows the development of potential therapeutic 
strategies [3, 10]. In this review we describe the 
intrinsic and extrinsic factors that regulate human 
skin pigmentation, focusing on melanogenesis 
mechanisms and related genodermatoses. 
Term  Abbreviation  
ACTH Adrenocorticotrophic hormone 
α-MSH Melanocyte stimulating hormone 
bFGF Basic fibroblast growth factor 
BMP Bone morphogenic protein 
cAMP Cyclic adenosine monophosphate 
cGMP Cyclic guanosine monophosphate
c-kit Mast cell growth factor 
CREB cAMP response element 
ET Endothelin 
GM-CSF Granulocyte-macrophage colony-stimulating factor
IL Interleukin 
IP3/DAG Inositol triphosphate / diacylglycerol 
MAP Mitogenic activated protein 
MATP Membrane-associated tranporter protein 
MC1-R Melanocortin recetor type 1 
MITF Microphthalmia-associated transcription factor 
NGF Neuronal growth factor 
NO Nitric oxide 
PG Prostaglandin 
PKA Protein kinase A
PKC-β Protein kinase C-β
POMC Proopiomelanocortin 
ROS Reactive oxygen species
SCF Stem cell factor 
TNF-α Tumor necrosis factor α
TRP Tyrosinase-related protein 
UVR Ultraviolet radiation 
Methods  
This review includes research articles which are 
supported by PubMed (basic electronic 
bibliographic database), are written in English and 
are available over the Internet by using search 
terms as: Human melanogenesis; Melanocyte 
Biology and Pigmentation Skin; Pigmentation 
disorders.  
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2 
Mechanisms of melanogenesis  
Steps in melanogenesis  
Melanocytes originate in neural crest melanoblasts
that, after the closure of the neural tube, migrate to 
different destinations, including the basal layer of 
the epidermis and hair follicles [3, 11, 12]. The 
migration, proliferation and differentiation into 
melanin producing cells depend on mediators 
produced by cells of the dorsal neural tube, 
ectoderm and keratinocytes, such as, respectively, 
the family of glycoproteins WNT, endothelin 3 
(EDN3) and stem cell factor (SCF) that binds the c-
Kit tyrosine kinase receptor on the melanocyte and 
melanoblast [3, 12]. The bone morphogenic 
proteins antagonize these events, and its expression 
is reduced in melanocytes migration. The 
Piebaldism (Table 2), a genodermatose with 
depigmented macules, is caused by mutations in the 
c-kit and SCF genes [3, 10, 12].  
The melanin synthesis occurs in melanosomes,
lysosome-related organelles (LROs), whose defects 
are responsible for Chediak-Higashi Syndrome
and Hermansky-Pudlak Syndrome (Table 2), 
diseases with cutaneous hypopigmentation and 
systemic manifestations [6, 10, 11, 13]. 
The key proteins involved in skin pigmentation, 
such as the components of the fibrillar matrix that 
binds to melanin (glycoprotein Pmel17) and 
melanogenic enzymes, are localized in 
melanosomes. In these organelles, across four 
maturation stages, the structural matrix is arranged, 
the enzyme tyrosinase is acquired and melanin is 
synthesized [2, 3, 6, 13]. The acquisition of 
melanogenic enzymes is regulated by a membrane-
associated transporter protein (MATP) and 
mutations of the respective gene determine 
Oculocutaneous Albinism type 4 [3, 6, 10]. When 
melanin synthesis is completed, melanosomes move 
bi-directionally from the perinuclear area towards 
melanocyte dendrites, in a movement controlled by 
microtubule proteins (kinesin, dynein). This 
transport ends with melanosome linkage to actin 
filament by a complex formed by myosin Va, 
Rab27a and melanophilin (mlph) [2]. Mutations in 
the corresponding genes determine various forms of 
Griscelli Syndrome (Table 2) [6, 10]. An increase 
of intramelanossomal pH from 5 to 6.8, which 
depends on the proton pump p-protein in 
melanosomes membrane, is needed to full 
maturation of melanosomes [14]. The importance 
of this step is supported in on one hand by 
Oculocutaneous Albinism type 2 (Table 2), a 
disease that is caused by the loss of functional p-
protein, and in another hand by the lower response 
to repigmentation treatments observed in Vitiligo  
patients who are also treated with proton pump 
inhibitors [6, 12, 14].  
In the epidermis, each melanocyte interacts through 
dendrites with 30 to 40 keratinocytes allowing the 
transfer of mature melanosomes into the 
cytoplasm of keratinocytes positioned 
strategically over nuclei [1, 11]. This transfer is not 
fully understood and different mechanisms are 
described: exocytosis, citophagocytosis, fusion of 
plasma membranes and transfer by membrane 
vesicles [2].  
Phenotypic diversity of pigmentation and types of 
melanin 
The phenotypic pigmentation diversity is not due to 
a variation in melanocytes number, which is 
relatively constant in different ethnic groups, but to 
the size and number of melanosomes, the amount 
and type of melanin and its transfer and distribution 
in the keratinocytes [1, 3, 11]. The melanosomes of 
dark-skinned individuals are larger, more numerous 
and elongated resulting in a delayed degradation in 
the keratinocytes and consequently in an increased 
visible pigmentation [3, 11, 13]. These differences 
in melanossomes are present at birth and are not 
determined by extrinsic factors such as UVR [3].  
There are two types of melanin (Figure 1): 
eumelanin - brown-black or dark insoluble 
polymer, and phaeomelanin - red-yellow soluble 
polymer formed by the conjugation of cysteine or 
glutathione [11, 13, 15]. The eumelanin is the major 
type in individuals with dark skin and hair and is 
more efficient in photoprotection. The pheomelanin 
is predominantly found in individuals with red hair 
and phototypes I and II, in which skin tumors are 
more common [5, 11].  
Figure 1 – Synthesis of two types of melanin with representation 
of functions of the major enzymes involved.
Enzymes of melanogenesis
Tyrosinase is a glycoprotein located in the 
melanossomal membrane, with an internal, a 
transmembrane and a cytoplasmic domain. It is a 
copper-dependent enzyme that catalyzes the  
  Introduction Annex 1 
 
45 
 
  
  
3 
Table 2 – Genodermatoses with hypopigmentation or depigmentation. LYST (gene of factor that regulates lysosomes transport); OCA2 
(gene of p-protein pumping proton), TR (gene of tyrosinase).  
Genodermatoses  Defect in 
melanogenesis
Affected 
gene
Heredity; clinical characteristics  
Piebaldism  Melanoblasts 
proliferation and 
migration 
C-KIT, SCF  AD; depigmented skin macules and white forelock 
Waardenburg 
Syndrome (WS)  
Melanoblasts 
proliferation and 
migration 
WS1 and 
WS3: PAX3  
WS2 : MITF, 
SOX10  
WS4: SOX10, 
EDN3  
AD; depigmented skin macules and white forelock, 
heterochromia of the iris, deafness  
Tietz Syndrome  Melanoblasts 
proliferation and 
migration 
MITF  AD; hypopigmentation and deafness  
Oculocutaneous 
Albinism (OCA)  
Melanin synthesis  OCA1 : TR  
OCA2:
OCA2 (p 
gene)  
OCA3: TRP1  
OCA4:
MATP  
AR; pink skin, white hair, blonde, brown, red pupils, reduced 
visual acuity, nystagmus, photophobia  
Menkes Syndrome  Melanin synthesis  ATP7A  X-linked recessive; sparse scalp hair, spleen, white or gray, 
neurological disorders  
Chediak-Higashi 
Syndrome  
Melanosomes synthesis LYST  AR; silvery sheen of the skin and hair, hypopigmentation of the 
iris, neurological disorders, ocular albinism, immunodeficiency, 
pancytopenia  
Hermansky-Pudlak 
Syndrome (HPS)  
Melanosomes synthesis HPS  AR; white patches on the skin and ocular albinism, bleeding 
tendency  
Griscelli Syndrome 
(GS)  
Melanosomes transfer  GS1: MYO5A  
GS2, RAB27A  
GS3: HPLM  
AR; skin and hair hypopigmentation, ocular albinism, 
neurological disorders  
conversion of L-tyrosine into L-DOPA, the rate-
limiting step in the melanin synthesis (Figure 1) [2, 
14, 15]. Mutations that inactivate this enzyme are 
responsible for the most severe form of Albinism, 
Oculocutaneous Albinism type 1 (Table 2) [6]. 
The cytoplasmic domain participates in the 
transport of the enzyme from the nucleus to the 
melanosomes. The internal domain contains the 
catalytic region (approximately 90% of the protein) 
with histidine residues, where the copper ions binds 
[2]. Mutations in the copper carrier (ATP7A) result 
in Menkes Disease (Table 2) [6]. If copper is 
oxidized, the enzyme is inactivated and can be 
activated by electrons donors such as L-DOPA, 
ascorbic acid, superoxide anion, and possibly nitric 
oxide (NO) [14, 15]. Due to the fact that this 
enzyme can use superoxide anion as a substrate for 
melanogenesis it may protect melanocytes from 
reactive oxygen species (ROS) [11, 16]. The 
phosphorylation of two serine residues from 
cytoplasmic domain by the protein kinase C-β
(PKC-β) is also important for tyrosinase activation 
[17].  
The tyrosine hydroxylase isoform I (THI) is 
present in melanosome’s membrane adjacent to 
tyrosinase and catalyzes the conversion of L-
tyrosine into L-DOPA promoting the activation of 
tyrosinase.  
In cytosol, the phenylalanine hydroxylase (PAH),
6BH4 (6-tetrahydrobiopterin) cofactor dependent, 
catalyzes the conversion of L-phenylalanine to L-
tyrosine, the tyrosinase substrate, thus also 
promoting its activation [14, 15]. Schallreuter and 
colleagues [14], underlining the central role of 
tyrosinase, consider that these three enzymes are 
required for the beginning of melanogenesis.  
Two proteins similar to tyrosinase (40% 
homologous amino acids), tyrosinase-related 
protein-1 (TRP-1) and tyrosinase-related 
protein-2 (TRP-2), are also present in the 
membrane of melanosomes. Although its precise 
role is not yet clarified, it is possible that the TRP-1 
has a role in the activation and stabilization of 
tyrosinase, melanosomes synthesis, increased ratio 
eumelanin/pheomelanin (Figure 1) and against 
oxidative stress by its peroxidase effect [2, 15]. The 
results of Jimbow and colleagues [18] suggest that 
the premature death of melanocytes in Vitiligo is 
related to an increased sensitivity to oxidative stress 
by changes in the TRP-1.  
Mutations of TRP-1, present in Oculocutaneous 
Albinism type 3 (Table 2), result in skin and hair 
hypopigmentation [6]. TRP-2 acts as a dopacroma 
tautomerase (Figure 1) and like tyrosinase requires 
a metal ion for its activity - zinc instead of copper 
[2, 14, 15]. Figure 1 shows the synthesis of the two 
types of melanin and the functions of the major 
enzymes involved.  
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Table 3 – Effects of paracrine factors secreted by keratinocytes after UVR exposure. (adapted from Fitzpatrick's Dermatology in General 
Medicine [12]). ACTH (adrenocorticotrophic hormone), α-MSH (melanocyte stimulating hormone), bFGF (basic fibroblast growth factor), 
BMP-4 (bone morphogenic protein-4), ET-1 (endothelin-1), GM-CSF (granulocyte-macrophage colony-stimulating factor), IL-1 (interleukin 
1), NO (nitric oxide), NGF (nerve growth factor); PGE2/PGF2 α (prostaglandin E2 and F2α), TNF-α (tumor necrosis factor-α).
Melanocytes 
proliferation  
Dendricity  Melanin 
synthesis  
Melanosomes 
transfer 
Survival / 
Cytoprotection  
ACTH ↑ ↑ ↑
α-MSH ↑ ↑ ↑  ↑
bFGF ↑↑
ET-1 ↑ ↑ ↑
GM-CSF ↑ ↑
NO   ↑   
NGF ↑ ↑
PGE2/PGF2α ↑ ↑ ↑
IL-1 ↓ ↑ ↓
TNF-α ↓
BMP-4 ↓
Melanocortin-receptor type 1 (MC1-R)  
Melanocortin receptors belong to G-protein-
receptors family. MC1-R predominates in 
melanocytes and its agonists include melanocyte 
stimulating hormone (α-MSH) and 
adrenocorticotropic hormone (ACTH), both 
cleavage products of proopiomelanocortin 
(POMC). POMC is cleaved by carboxypeptidase-1 
in ACTH and β-lipotrofina and by 
carboxypeptidase-2 β in endorphin and ACTH. 
ACTH is fragmented in ACTH 1-17 and α-MSH. 
ACTH and α-MSH share the tetrapeptide His-Phe-
Arg-Trp, which is essential to the melanotrophic 
activity. These peptides are the main intrinsic 
regulators of pigmentation, but its pituitary 
production is insufficient to stimulate 
melanogenesis, being keratinocytes and 
melanocytes the main responsible for its production 
on the skin [1, 5, 11, 13, 15, 16, 19]. Addison's 
Disease with high levels of ACTH, ACTH 
producing tumors (Nelson Syndrome) and cases of 
prolonged administration of this hormone are 
associated with hyperpigmentation, particularly in 
sun-exposed areas [1, 2, 15].  
MC1-R genetic polymorphisms are responsible for 
ethnic differences of constitutive pigmentation and 
different responses to UVR exposure [2, 5, 11, 16]. 
In individuals with red hair and light skin there is a 
high incidence of MC1-R mutations that may be 
responsible for a decreased response to α-MSH, 
resulting in a decreased eumelanogenesis and 
reduced pigmentation induced by UVR exposure 
[11]. The Agouti signaling protein, although poorly 
documented, is the only known antagonist of MC1-
R, competing with α-MSH and therefore 
stimulating pheomelanogenesis. MC1-R activation  
by POMC peptides stimulates the accumulation of 
eumelanin instead of pheomelanin.  
MC1-R agonists activate the adenylate cyclase 
enzyme, increasing intracellular cAMP and 
activating protein kinase A (PKA). PKA 
phosphorylates CREB (cAMP response element), 
which acts as a transcription factor in several genes, 
including the microftalmia-associated transcription 
factor (MITF). MITF in its phosphorylated active 
form regulates the expression of melanogenic 
enzymes promoting eumelanogenis [2, 5, 11, 13, 
15]. Its phosphorylation depends on kinases of 
mitogenic activated protein (MAP) whose activity 
is induced by the binding of keratinocyte-produced-
SCF to the c-kit tyrosine kinase receptor [11, 12]. 
In addition to the CREB, the expression of the 
protein MITF is regulated by other transcription 
factors and mediators produced by keratinocytes 
and fibroblasts [6, 20]. Moreover, the protein MITF 
also regulates the expression of the Rab27a protein 
important in melanosome transport, Pmel17 protein 
of the melanosome matrix and of an anti-apoptotic 
protein (bcl-2) of melanocytes often expressed on 
melanoma [2, 10, 12, 20]. MITF gene mutations are 
responsible for Waardenburg Syndrome type 2
with cutaneous and iris hypopigmentation, and 
Tietz Syndrome (Table 2) with hypopigmentation 
and deafness [1, 10, 20]. 
Intrinsic regulation of skin pigmentation  
Melanocytes produce POMC peptides, cytokines, 
NO, prostaglandins and leukotrienes, which act 
through an autocrine or paracrine way on 
keratinocytes, and are involved in immune and 
inflammatory responses. Keratinocytes also 
produce several factors in response to UVR 
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exposure, with paracrine action on melanocytes, 
that may stimulate or inhibit melanogenesis (Table 
3) [2, 6, 11, 12].  
Our group investigated the role of the recently 
described cutaneous endocannabinoid system in 
melanogenesis and we demonstrated that UVR also 
activates endocannabinoid production by 
keratinocytes and that a paracrine cannabinoid 
receptor type 1-mediated endocannabinoid 
signaling negatively regulates melanin synthesis 
[21]. 
Despite POMC/MC1-R/cAMP being the main 
pathway, there are other melanocyte receptors 
associated with adenylciclase and cAMP 
production such as muscarinic receptors and α and 
β estrogen receptors [6]. The increase in estrogen 
levels during pregnancy can cause 
hyperpigmentation (melasma, areola 
hyperpigmentation and line nigricans). 
Catecholamines may be produced by keratinocytes 
from L-DOPA, the melanin precursor, and can bind 
to the melanocyte α1 and β2 adrenergic receptors 
stimulating melanogenesis via cAMP pathway and 
PKC-β [15, 22]. This redundancy of cAMP 
production reveals the importance of this second 
messenger in melanogenesis. However, 
norepinephrine / α1 adrenergic receptor, ACTH 1-
17/MC1-R can also activate the pathway inositol 
triphosphate / diacylglycerol (IP3/DAG), which 
promotes the release of calcium in the cytoplasm of 
melanocytes [2, 14, 22]. DAG is important for the 
activation of PKC-β, which phosphorylates 
tyrosinase, and can also be released from 
melanocyte by UVR action in the lipid membrane 
[3, 14, 17]. Figure 3 illustrates some of the different 
pathways, receptors, second messengers and 
melanogenic enzymes involved in melanogenesis.  
Extrinsic regulation of skin pigmentation by 
ultraviolet radiation (UVR)  
UVR is the most important extrinsic factor in the 
regulation of melanogenesis. It is the main stimulus 
for induced or acquired pigmentation, known as 
"tanning" [1, 2, 6, 11].  
There are two types of induced pigmentation, which 
depends on genetic factors and are more evident in 
individuals with dark skin and hair [3, 23]. The 
immediate pigmentation which appears 5-10 
minutes after exposure to UVR, disappears in 
minutes or days later, is largely due to UVA and is 
not dependent on the increased melanin synthesis 
but on the oxidation of melanin pre-existing and 
redistribution of melanosomes to the epidermal 
upper layers. The delayed pigmentation which 
occurs 3-4 days after exposure to UVR, disappears 
in weeks, is due to the UVA and mainly to UVB 
radiation and results from an increased level of 
epidermal melanin, particularly eumelanin, 
providing photoprotection [3, 12, 13, 16, 23]. 
Figure 2 – Melanocyte role with representation of different 
signaling pathways regulating melanogenesis: activation factors, 
receptors, second messengers and melanogenic enzymes. 
By one hand, UVR increases: proliferation and / or 
recruitment of melanocytes, the number of 
dendrites and the transfer of melanosomes to a 
supranuclear location on the keratinocytes for DNA 
photoprotection. On the other hand, the expression 
of POMC peptides, MC1-R and melanogenesis 
enzymes increases in keratinocytes and 
melanocytes respectively [11, 13, 16, 23].  
DNA, the main cellular chromophore, directly 
absorbs UVR with the formation of thymine dimers 
and other pyrimidine derivatives and defects in 
DNA repair increase the risk of skin cancer [1-3, 5]. 
The key observation that the UVR spectra for 
producing a delayed tan [24] and for induction of 
thymine dimers following UVR [25] were virtually 
identical and within the UVB range suggested for 
the first time a cause effect relation between DNA 
damage and melanogenesis. In the last decade, it 
was recognized that the tumor-supressor protein 
p53 is a transcription factor that plays a pivotal role 
in the tanning response after UVB-induced DNA 
damage [26]. Using an elegant mouse model in 
which UVR causes tanning it was demonstrated 
that α-MSH production is regulated in 
keratinocytes by p53 via a p53 consensus sequence 
in the POMC gene promoter [27]. Furthermore, 
Eller and colleagues [28] demonstrated in vitro that 
small fragments of DNA induced pigmentation by 
increasing tyrosinase expression and activity and 
tumor suppressor protein p53 levels [1].. Even in 
the absence of keratinocytes, there is a strong 
melanogenic response to UVR mediated by p53 in 
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human melanocytes and melanoma cells in vitro [2, 
26], which can be explained by the fact that p53 
regulates in melanocytes the transcription of the 
hepatocyte nuclear factor 1α (HNF-1α), that is a 
tyrosinase transcription factor [14].  
The UVR also enhances reactive oxygen species 
(ROS) formation in keratinocytes and melanocytes, 
with consequent DNA damage [3, 5].  
Regardless of the specific mechanisms, the 
acquired pigmentation is part of the adaptive 
response of skin, mediated by p53, to DNA damage 
caused by exposure to UVR and will provide skin 
protection to future exposures [2, 26].  
It has been shown that plasma membrane lipids are 
also affected by UVR to release membrane-
associated diacylglycerol (DAG) which activates 
PKC-β that in turn activates tyrosinase resulting in 
stimulation of melanogenesis [14].  
An elderly individual, depending on the constitutive 
pigmentation and the cumulative UVR dose, may 
have hyperpigmented lesions (solar lentigines) that 
indicate photoaging. This can be explained by the 
fact that aged melanocytes possess an enhanced 
functional activity after years of cumulative UVR 
exposure. However with aging there is also a 
decrease in the number of functional melanocytes 
[3]. The eumelanin acts as a natural sunscreen 
against photoaging and photocarcinogenesis, in part 
by reducing ROS and increasing repair of DNA 
damage [5, 13, 15].  
Conclusion  
The melanocytes are responsible for the cutaneous 
synthesis and distribution of melanin, an essential 
pigment for photoprotection. This process named 
melanogenesis involves different stages since 
melanocyte embryogenesis to the melanosomes 
transfer to neighbor keratinocytes. The importance 
of each of these stages and their mechanisms is 
evident in the clinical genetic defects 
(genodermatoses with depigmentation or 
hypopigmentation). The identification of these 
defects has contributed to a better understanding of 
the melanocytes biology and the melanogenesis 
regulation. The melanogenesis study has revealed 
different interactions of melanocytes with other 
cells (including keratinocytes) and systems (CNS, 
immune, inflammatory, endocrine and 
endocannabinoid), and this raise the role of skin as 
a neuroendocrine organ.  
Many factors are known as regulators of 
melanin synthesis, and we point UVR as an 
important extrinsic factor and α-MSH as an 
important intrinsic factor. The α-MSH exerts its 
effect mainly as an agonist of the MC1-R, whose 
genetic polymorphisms are part of the justification 
for phenotypic diversity and differential response to 
UVR. In induced pigmentation, the UVR has a 
direct effect mediated by p53 tumor suppressor 
protein, and an indirectly effect by keratinocytes 
production of intrinsic factors, promoting 
eumelanin synthesis. The UVR is responsible for 
the "tanning", but is also associated with aging skin 
with hyperpigmented lesions and development of 
skin tumors.  
The investigation of melanogenesis mechanisms is 
important in the understanding of the pigmentation 
defects and the consequent development of 
potential therapeutic agents. On the other hand, 
allows for the development of photoprotective 
measures, which reduce photoaging and 
photocarcinogenesis. This is an important area of 
research where still there is much to clarify and 
learn.  
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Phototherapy
Phototherapy is the use of UV radiation in the 
treatment of skin disease [1]. Radiation within 
the UV spectrum can be divided by wavelength 
into UVC (200–280 nm), UVB (280–320 nm) 
and UVA (320–400 nm). Owing to the filter-
ing effect of the earth’s atmosphere, almost all 
UVC radiation and approximately 90% of the 
UVB is absorbed. Consequently, UVA makes 
up approximately 95% of the UV radiation that 
reaches the earth. With its longer wavelength, it 
can penetrate deep into the dermis, while UVB 
is absorbed in the epidermis. It is mainly UVB 
that burns the skin because it possesses much 
more energy than UVA (energy is inversely 
proportional to wavelength) [1].
Types of phototherapy include broad-
band-UVB (BB-UVB, 290–320 nm, peaks 
at 313 nm), narrowband-UVB (NB-UVB, 
311–313 nm), UVA1 (340–400 nm, peaks 
at 365 nm), and combination therapy of pso-
ralen plus UVA (PUVA photochemotherapy, 
320–400 nm, peaks at 352 nm) [1,2]. Available 
psoralens include 8-methoxypsoralen (8-MOP; 
only form available in the USA), 5-methoxyp-
soralen (5-MOP; primarily used in Europe) and 
4,5,8-trimethoxypsoralen [2]. The psoralen can 
be administered orally (5-MOP or 8-MOP) or 
topically, either in the form of ointment, cream 
or lotion, either as bath-PUVA (8-MOP, 5-MOP 
or 4,5,8-trimethoxypsoralen) [2,3]. These treat-
ment modalities are generally administered in 
a light booth or by hand and/or foot units [2]. 
Recently, the xenon chloride gas excimer offers 
a means for delivering larger fluences of 308 nm 
UVB selectively to the cutaneous lesions, with 
a decreased carcinogenic potential. Two systems 
have been developed: laser technology (known 
as excimer laser) and a new nonlaser technol-
ogy (known as excimer light). The advantages 
of excimer light over the laser system are low 
operating costs and the fact that a large area can 
be treated quickly [4]. 
Photodynamic therapy and low-level light 
therapy are out of the scope of this review.
Mechanisms of action
The following mechanisms have been proposed 
to explain UV’s efficacy in the treatment of skin 
diseases:
s Apoptosis of pathogenically relevant cells, 
including T-cell apoptosis, in the treatment of 
psoriasis, mycosis fungoids and atopic derma-
titis [5,6], and mast-cell apoptosis, for pruritic 
skin disorders [7];
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s Apoptosis of keratinocytes [8];
s Enhancement of melanocyte proliferation, for vitiligo [2];
s Decreased release of histamine from both basophils and mast 
cells, for histaminic disorders such as urticaria pigmentosa [2];
s Inhibition of ICAM-1 upregulation by keratinocytes in inflam-
matory diseases (which acts as counter-receptor for lymphocyte 
function-associated antigen-1 on the surface of leukocytes) [9];
s Downregulation of Th17 signaling pathway and decreased 
expression of IL-10 by keratinocytes, with a subsequent reduc-
tion of IFN- signaling and an anti-inflammatory effect [10,11]. 
Phototherapy has also been found to decrease the expression of 
IFN--inducing cytokines IL-12, IL-18 and IL-23 [12];
s Increased expression of immunosuppressive cis-urocanic acid 
levels in the skin, resulting in suppression of cellular immune 
response and inhibition of antigen-presenting function of 
Langerhans cells [2,13].
In psoralen plus UVA (PUVA) photochemotherapy, psoralens 
photoconjugate to DNA with subsequent suppression of DNA 
synthesis and cell proliferation [14]. Also, reactive oxygen species 
production (derived from psoralens reacting with molecular oxy-
gen) causes mitochondrial dysfunction and leads to apoptosis of 
Langerhans cells, keratinocytes and lymphocytes [2]. 
Dosing & administration
Before starting UVB phototherapy, the minimal erythema dose 
(MED) should ideally be determined (erythema 24 h after expo-
sure) [2,15]. It is advised that the first treatment of NB-UVB equals 
0.7 MED and that dose increments are made according to postir-
radiation erythema [2,15]. It is also possible to utilize Fitzpatrick 
skin type-dependent starting doses with subsequent fixed incre-
ments [15], and this is the approach we use in our center (Hospital 
de São João, Porto, Portugal). In the clearing phase, treatments 
are given 2–5-times weekly [15].
UVA-1 is further classified as low dose (20 mJ/cm2), medium 
dose (50–60 mJ/cm2) and high dose (120–130 J/cm2). 
Theoretically, full dose can be used as a starting dose because 
UVA1 does not induce erythema. However, to avoid any idiosyn-
cratic reaction, it has been recommended to start at 20 mJ/cm2, 
and then increase by 10 J/cm2 per treatment until the full desired 
medium dose is reached. High-dose UVA-1 is no longer widely 
used [2].
In PUVA, the initial dose of UVA can either be determined 
by minimal phototoxicity dose (MPD; erythema 48–72 h after 
exposure) or by Fitzpatrick skin type [2]. In the first approach the 
initial dose should be 0.5–0.7 MPD for oral PUVA and 0.3 MPD 
for bath PUVA, with subsequent dose increments according to 
postirradiation erythema [15]. Similar to UVB dosing, UVA doses 
should be decreased if topical or systemic retinoids are added 
because they decrease stratum corneum thickness, thereby 
increasing phototoxicity [2]. In the clearing phase, irradiations 
are given 2–4-times weekly [15]. For oral PUVA, 0.6–0.8 mg/kg 
8-MOP or 1.2–1.8 mg/kg 5-MOP is administered 1–3 h before 
phototherapy [3]. Bath-PUVA consists of 15–30 min of whole-
body immersion in solutions of 0.5–5.0 mg/l 8-MOP or 0.33 mg/l 
4,5,8-trimethoxypsoralen [2,3]. Upon exiting the bath, the patient 
must receive the UVA dose within 30 min [2].
Safety
Most phototherapy regimens are very low risk for overall patient 
complications and morbidity [2].
UVB may cause acute phototoxicity, with erythema and blis-
tering, beginning in the first 4–6 h after exposure and peaking 
at 12–24 h [2].
PUVA-induced erythema starts at 24–36 h, peaks at 48–72 h 
and may last 1 week or more. Avoidance of prolonged sun expo-
sure, wearing UVA-absorbing sunglasses when outdoors, appli-
cation of broad-spectrum sunscreens, and wearing of photopro-
tective clothing on the days of PUVA photochemotherapy are 
necessary measures to prevent significant phototoxicity. 8-MOP 
has a greater incidence of gastrointestinal side effects than 5-MOP. 
PUVA’s itch is a subacute side effect of this treatment [2].
Both UVB and PUVA may also lead to tanning (requiring 
UV-dose increment), photo-onycholysis, melanonychia and 
friction blisters of treated areas. Photoaging is a long-term side 
effect, including PUVA lentigines. If proper protective eyewear 
is not worn, UVB-induced keratitis and PUVA-induced cataracts 
may also occur [2]. However, the recommendation for regular 
ophthalmologic evaluation of these patients is still controversial.
With respect to photocarcinogenesis, PUVA is associated with a 
dose-dependent increased risk of nonmelanoma skin cancers [16,17]. 
So far, no increase has been documented with NB-UVB [18], but 
long-term data are missing. Male genitalia should be shielded dur-
ing every treatment session as they are particularly sensitive to the 
development of squamous cell carcinomas (SCCs) [2]. Increase in 
melanoma incidence following UV therapy is controversial [16,19].
Absolute and relative contraindications to phototherapy and 
photochemotherapy are shown in BOXES 1 & 2, as described by Sage 
and Lim [2]. UVB can be used in children as well as in pregnant 
and breast-feeding women, but long-term safety data are missing. 
Even though psoralens have never been proved to be teratogenic, 
they are not generally administered during pregnancy [2]. UVB is 
considered generally safer than PUVA in patients with skin types 
I and II, history of melanoma or nonmelanoma skin cancer, past 
history of x-ray therapy, arsenic exposure, or concomitant use 
of immunosuppressive agents [2]. Photosensitizing drugs usually 
react within the UVA spectrum and NB-UVB is thus generally 
safe in patients taking them [2]. UVB has been shown to be effec-
tive and safe in HIV patients [20], although a small study did show 
activation of the virus in the skin [21].
Indications
Psoriasis 
UVB
Traditional BB-UVB radiation has been used for the treatment 
of psoriasis for more than 75 years. NB-UVB use was initially 
popularized in the UK and Europe in the mid-1980s, and became 
available in the USA approximately one decade later [22].
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NB-UVB is superior to BB-UVB in respect to clearing and 
remission times [22], and it currently represents the phototherapeu-
tic modality of choice for the treatment of psoriasis in Europe [23]. 
However, it is probably not as effective as PUVA, both in terms 
of clearing efficiency and duration of remission [15].
Patients with psoriasis who are compliant, motivated and adher-
ent with instructions and follow-up examinations could, under 
dermatologist supervision, be considered appropriate candidates 
for home UVB therapy [22]. A recent multicenter, single-blind, 
randomized clinical trial demonstrated that home NB-UVB is 
just as effective as outpatient-administered NB-UVB, with supe-
rior patient quality of life [24]. We do not have experience with 
home phototherapy in our center.
In order to improve UVB’s efficacy, it can be combined with 
other treatments, either topical or systemic. 
Topical application of calcipotriol (after irradiation) or tazaro-
tene [25] (before irradiation) may increase therapeutic efficacy of 
phototherapy alone [26]. By contrast, it seems that combining topi-
cal steroids adds little benefit to phototherapy [27]. Emmolients 
can increase UV transmission, increasing efficacy, but thick appli-
cation of petrolatum and water-in-oil creams as well as salicylic 
acid and tar act as sunscreens and should be discouraged [28].
In regard to systemic drugs, retinoids increase efficacy and 
reduce the carcinogenic potential of UVB phototherapy [29,30]. 
Retinoids can be maintained after ceasing phototherapy to pre-
vent recurrence. The short time combination of methotrexate with 
UVB therapy is of potential value because of the synergistic effects 
of these two therapies [22]. We find this combination particularly 
useful in patients with psoriatic arthritis in whom the articular 
disease is successfully managed with low-dose methrotrexate, as 
phototherapy is not efficacious in treating arthritis. The combina-
tion of cyclosporine and UVB has not been studied extensively 
because of the increased risk of nonmelanoma skin cancer with 
cyclosporine monotherapy and it should generally be avoided [22]. 
Combination therapy of UVB with biologics has been reported 
to have a higher response rate than biologics alone, with a similar 
safety profile [22], but further investigation is needed. Potential 
concerns are increased phototoxicity and photocarcinogenesis.
Although UVB may be adequate for maintenance therapy [31], 
it is suggested to consider a rotational therapeutic approach in 
order to minimize a greater cumulative dose [32].
The first report on the use of the excimer laser to treat pso-
riasis goes back to 1997 [33]. Advantages include the possibility 
to treat exclusively the affected skin with higher doses (supra-
erythemogenic) and lower number of treatments [34]. 
PUVA
Compared to oral 8-MOP, oral 5-MOP shows equal clearing rates 
with a similar number of exposures, but higher cumulative doses, 
lower incidence of pruritus or severe phototoxic reactions, and no 
nausea or vomiting [3].
Compared to oral 8-MOP, bath PUVA shows equal clearing 
rates with fewer exposures, similar or lower incidence of ery-
thema and pruritus and no systemic intolerance such as nausea 
or vomiting [3].
Topical PUVA with psoralen creams, ointment or lotions is 
now used only for limited plaque psoriasis and for palmo-plantar 
disease [3]. 
With respect to combination therapy, the same considerations 
are valid as for UVB when it comes to topics. The combination 
of PUVA with systemic retinoids (RePUVA) is one of the most 
potent therapeutic regimens for psoriasis [15]. Methotrexate may 
also be considered for combination therapy, although the long-
term risk of cutaneous malignancies, though never proved, should 
not be forgotten [15]. By contrast, concomitant use of cyclosporine 
has been recognized to enhance skin carcinogenesis [35]. Further 
investigation is needed to verify presumptive additive effects of 
biologics and PUVA [36].
PUVA can be considered for maintenance therapy but atten-
tion should be paid to long-term risks related to total cumulative 
phototoxic doses [3].
Pediatric population: In children, when topical treatment fails, 
NB-UVB phototherapy in combination with topical agents is 
generally the recommended treatment option before considering 
Box 1. Contraindications to UV phototherapy.
Absolute contraindications
s Xeroderma pigmentosum
s Systemic lupus erythematosus
s Basal cell nevus syndrome
Relative contraindications
s Previous history of skin cancer
s Treatment of genital area
s Photosensitive disorders 
s Contact photosensitive substances 
s Photosensitizing medications with an action spectrum with the 
corresponding UVA or UVB wavelengths
Box 2. Contraindications to psoralen plus UVA.
Absolute contraindications
s Xeroderma pigmentosum
s Systemic lupus erythematosus
s Basal cell nevus syndrome
s Photosensitivity disorders
s Age less than 10 years
s Pregnant and breast-feeding patients
s History of melanoma 
Relative contraindications
s Family history of melanoma
s History of dysplastic nevi or nonmelanoma skin cancers
s Photosensitizing medications
s Significant past UV exposure
s History of arsenic exposure, ionizing radiation, methotrexate, 
cyclosporine or tacrolimus
Caution
s Hepatic or renal insufficiency 
s Patients 10–18 years of age
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systemic therapy, including retinoids, metho trexate, cyclosporine 
and biological agents. The long-term risk of NB-UVB light in 
children is yet to be determined. PUVA can also be considered 
as a treatment option [37].
Cutaneous T-cell lymphoma (mycosis fungoides) 
PUVA
The use of PUVA in cutaneous T-cell lymphoma (CTCL) was 
first reported in 1976 [38]. It is an excellent treatment option for 
the early stages of the disease (IA–IIA), achieving long-lasting 
free-disease intervals. It is also capable of reducing tumor burden 
in later stages (IIB–IVB), where it should be combined with other 
treatments, such as retinoids, bexarotene, INF-2a, local x-ray or 
systemic chemotherapy. Even with aggressive combination thera-
pies, these patients experience multiple recurrences. Although 
effective in inducing remission in skin-confined disease, the effect 
of PUVA on the CTCL disease course and overall survival is yet 
to be determined. Currently there is no treatment option known 
to arrest progression of later stages [3,15,39].
After clearing, a maintenance phase is usually recommended, 
with two sessions per week for 1 month, followed by one session 
per week for another. Resolution should be confirmed with a 
biopsy. A follow-up is then performed, either without therapy, 
with one treatment per month or one treatment every other 
month. Relapses respond to therapy as well as initial lesions [3,15].
UVB
The first report of UVB phototherapy for CTCL goes back to 
1982 [40]. NB-UVB can also induce high rates of complete remis-
sion in early disease [39]. Evidence is poor, however, regarding 
the question how NB-UVB compares with other treatments 
[39]. Studies comparing PUVA and NB-UVB have found them 
both effective in the treatment of CTCL [41,42]. NB-UVB and 
BB-UVB therapy have not been compared. 
Excimer laser can also be considered a useful tool in the treatment 
of early-stage mycosis fungoids (MF) [43].
UVA1
UVA1 also appears to be effective [44], although the experience is 
limited. It offers advantages over PUVA in terms of side effects.
Pediatric population: In children, MF is rare and usually limited 
to early patch-stage disease. Both PUVA and UVB have been 
used [37].
Vitiligo 
PUVA
PUVA has been used for longer than UVB in vitiligo and the 
available information for this therapy is greater than for UVB.
Patients should be aware that they will require months of treat-
ment (100–200 treatments), with 70% of patients responding 
after 12–24 months. Responsiveness is defined as development of 
multiple perifollicular macules of repigmentation, or, in the case 
of small (<2 cm) lesions, contraction in size. However, if after 
4–6 months or 30–50 treatments they do not respond, PUVA 
should be terminated. Locations such as lips, distal dorsal hands, 
fingers and toes, palms, soles and nipples are very refractory to 
treatment, as are large areas with only white hairs. Stable disease 
(for at least a year) is usually easier to treat. Duration of disease 
before PUVA therapy does not affect response rate [3,15].
Completely repigmented areas can be stable for a decade or 
more without relapse. But if a lesion is not fully repigmented, 
reversal of acquired pigmentation may occur when treatment is 
discontinued [15].
KUVA and topical PUVA are alternatives to oral PUVA. KUVA 
uses khellin as a photosensitizer and this is not phototoxic. Topical 
PUVA may be suitable for few and small lesions [15]. UVA alone 
is of limited benefit [15].
UVB
Although the action spectrum for phototherapy of vitiligo is not 
known [15], UVB, in particular NB-UVB, is currently more often 
used than PUVA because it has been shown to be at least as effec-
tive and possibly safer [45,46]. As for PUVA, it is not very effective in 
certain anatomic areas (hands and digits, feet and toes) and treat-
ment should be ceased if patients do not respond [23]. Excimer laser 
should be considered as a therapeutic option for localized lesions [47]. 
Pediatric population: In children, NB-UVB is the preferred pho-
totherapeutic option owing to potential increased cancer risks asso-
ciated with PUVA. However, PUVA can also be used in children 
older than 12 years of age [37].
Atopic dermatitis 
Phototherapy of acute, severe atopic dermatitis
UVA1 phototherapy is a highly effective monotherapy for a lim-
ited period of time (ten to 15 exposures), particularly in cases 
of acute, severe atopic dermatitis [48]. It should not be used for 
maintenance therapy or for patients under the age of 18 years 
because its long-term effects are not known [23]. The effectiveness 
is dose-dependent, with high-dose UVA1 being more efficient 
than UVA/UVB phototherapy [49]. 
Phototherapy of chronic, moderate atopic dermatitis
BB-UVB, combined UVA/UVB, broadband UVA, low-dose 
UVA1 and, in particular, narrow-band UVB phototherapy are 
effective treatments in mild and moderate atopic dermatitis and 
they are generally used in combination regimens with topical 
steroids. They are relatively safe when used over extended periods 
of time for long-term management [23]. 
NB-UVB and UVA/UVB phototherapy are superior to 
BB-UVB, broadband UVA or low-dose UVA1 [23]. However, in 
a small number of children, BB-UVB may be less irritating and 
more effective than NB-UVB because it requires smaller doses 
to achieve minimal erythema and lymphocyte apoptosis [37]. The 
excimer laser can also be used to treat localized lesions of atopic 
dermatitis with faster clearance after fewer treatments compared 
with traditional NB-UVB or BB-UVB phototherapy [50]. 
After NB-UVB, the microbial population in atopic dermati-
tis patients is similar to control patients [51], but it is unknown 
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whether this translates clinically into reduced skin infections 
requiring antibiotics or decreased pruritus [37].
PUVA
PUVA can also be used to treat atopic dermatitis, but a high 
number of treatments are usually required and recurrences are 
high and rapid. Long-term treatment should be avoided [15].
Lichen planus 
Oral and topical PUVA are therapeutic options for extensive lichen 
planus (LP) [3,15]. However, LP is usually more resistant than psori-
asis, requiring more treatment sessions and higher cumulative UVA 
doses, with earlier relapses [3]. Combined PUVA-retinoid therapy 
may accelerate clearing [3]. Postinflammatory hyper pigmentation 
should be a potential concern. Besides, LP exacerbation during 
PUVA therapy has occurred in a few patients [15].
NBUVB therapy can represent an effective option for refrac-
tory generalized LP according to a study of 16 patients in which 
complete response was achieved in 56.25% at 30 sessions and in 
68.75% at 40 sessions, confirming the presence of significant cor-
relation between session numbers and improvement of response, 
that had already been found in previous studies [52].
A study of 28 patients, 15 treated with oral PUVA and 13 
with NB-UVB, concluded that even though oral PUVA pro-
duces a better initial clinical response rate, both oral PUVA 
and NB-UVB are effective treatments for LP, producing similar 
long-term outcomes.
Graft-versus-host disease 
Currently, PUVA represents the mainstay for phototherapy of 
graft-versus-host disease (GVHD) [15]. It has been initially evalu-
ated for lichenoid GVHD owing to clinical and histologic simi-
larities with lichen planus, and it can clear or improve chronic 
and acute disease [53,54]. In sclerodermoid GVHD, results are con-
troversial [3,15]. Effects may be systemic because mucosal lesions 
respond to treatment, but there is no improvement in other organs 
[3,15]. Patients should be followed-up for cutaneous tumors because 
there seems to be an overall increased risk of malignancies in bone 
marrow/stem cell recipients, independent of PUVA [3,15]. UVA1 
therapy is also promising for the treatment of chronic GVHD, 
in either of its lichenoid or sclerodermoid variants [44,55]. UVB 
therapy has been described in a limited number of patients [15].
Pityriasis lichenoides 
PUVA seems to be more effective than UVB in pityriasis lichen-
oids, especially in the acute form of the disease, where it has 
been recommended as the phototherapy of choice [15]. In pityriasis 
lichenoides chronic, PUVA may be reserved for cases of that are 
UVB resistant [15]. The experience with UVA1 is limited [56] and 
further investigation is needed. 
Urticaria pigmentosa 
PUVA
In cutaneous mastocytosis, PUVA therapy results in improvement 
of skin lesions [57], but in most patients these recur 5–8 months 
after treatment discontinuation [3]. Response rate in relapses is 
though similar to initial lesions [3]. Systemic symptoms such as 
histamine-induced migraines and flushing also respond to PUVA 
[57]. PUVA therapy should be considered for patients in which 
disease is causing severe distress [3].
UVA1
Cutaneous mastocytosis has also been demonstrated to respond 
to UVA1 therapy, in its skin and systemic manifestations [58,59]. 
In a study of four patients, there were no recurrences more than 
2 years after cessation of high-dose UVA1 therapy [59].
Photodermatoses 
Phototherapy of patients with polymorphous light eruption 
(PMLE) induces tolerance to sunlight in a process known as 
hardening. Involved mechanisms include epidermal thickening, 
pigmentation and probable immunologic effects [3,15]. 
PUVA is the most effective preventive treatment in PMLE [3], 
but NB-UVB is currently the phototherapeutic option of choice, 
with recent studies showing that it is an effective alternative to 
PUVA [60]. 
With PUVA, 70% of patients develop hardening with a 3–4-
week course treatment of 2–3 sessions a week in early spring. 
Patients remain protected if they have regular sunlight exposures. 
However, patients may remain protected for 2–3 months even 
after pigmentation has faded [3,15].
Patients with other photodermatosis, including actinic prurigo, 
hydroa vacciniforme and erythropoietic porphyria, may benefit 
from NB-UVB [61] or PUVA [3,15]. In solar urticaria, PUVA ther-
apy appears to be the most effective therapy available [3]. Single 
UVA irradiation of quadrants of body surface hours before PUVA 
treatment may be useful when patients develop urticarial lesions 
in the beginning of treatment [3]. In therapy-resistant forms of 
solar urticaria, rush-hardening consists of multiple daily UVA 
irradiations at 1-h intervals, providing protection within 3 days 
[62]. Unlike PMLE, extended treatment may be required in solar 
urticaria and chronic actinic dermatitis [3].
Morphea, scleroderma & other sclerosing skin conditions
Morphea was shown to be effectively treated by UVA1 photherapy 
in a dose-dependent manner [63]. Medium-dose UVA1 seems to be 
superior to low-dose UVA1 or NB-UVB [64,65]. The existing evi-
dence indicates that medium–high dose UVA1 therapy delivered 
over 24–30 treatments can provide significant benefit to patients 
with morphea, particularly linear and plaque subtypes of disease 
[44]. UVA1 is likely ineffective in burned out atrophic lesions, deep 
morphea, Parry Romberg/facial hemiatrophy and eosinophilic fas-
ciitis owing to the depth of the pathology, and systemic treatment 
should be considered as first-line therapy in these cases [44]. Little 
to no adverse effects have been reported with this therapy [44].
UVA1 might also be effective in treating patients with systemic 
sclerosis, studies to date showing improvement in hand/forearm 
disease, with a decreased hand score after treatment [66].
Localized scleroderma and pansclerotic morphea have also been 
successfully treated with bath PUVA and oral PUVA [67,68]. In our 
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center we have a good experience with topical PUVA for localized 
scleroderma and we consider this modality worth a try.
Lichen sclerosus has shown to be responsive to UVA1, in both 
genital and nongenital disease [69,70].
Other indications
UVB
NB-UVB was found to be an effective treatment in severe cases of 
seborrheic dermatitis, although flares may occasionally occur [71].
It has been shown that NB-UVB is effective in controlling 
uremic pruritus [72]. Although it can also be beneficial in other 
forms of pruritus, such as idiopathic or that associated with liver 
disease or diabetes [15], we have better results in uremic pruritus.
PUVA 
The experience with PUVA in lymphomatoid papulosis is limited 
to a few successful anedoctal cases [73].
PUVA has been used in pityriasis rubra pilaris, but results are 
inconsistent [15,23]. 
Generalized granuloma annulare has been reported to clear 
completely, but long-term maintenance treatment was required 
to maintain remissions [74]. 
Uncontrolled studies of PUVA treatment for alopecia areata, 
using all types of PUVA (oral or topical psoralen, local or whole 
body UVA irradiation), report success rates of up to 60–65% 
[75], which are in accordance to our experience. Continued treat-
ment might be needed however to maintain hair growth because 
relapse rates are high [75]. 308-nm excimer has also been reported 
as effective [76,77]. 
UVA1
Dyshidrotic hand eczema has been treated effectively with 
UVA1 therapy [78]. Long exposure to low-dose UVA1 might be 
beneficial for patients with systemic lupus erythematous, with 
decreased fatigue, joint pain, malaise, stiffness and mouth ulcers, 
lasting over 3 years [79]. UVA1 therapy has also been shown to 
improve subacute cutaneous lupus erythematosus lesions, but 
not those seen in discoid lupus erythematosus [44]. A consensus 
statement by the North American Rheumatologic Dermatology 
Society has recently confirmed the potential beneficial effects of 
UVA1 phototherapy in systemic lupus erythematous patients, 
but acknowledged that further investigation is needed to address 
its full benefit [44]. In TABLE 1, we summarize phototherapy’s main 
clinical applications.
Photopheresis
Mechanisms of action
Extracorporeal photochemotherapy, also 
known as extracorporeal photopheresis 
(ECP), is a promising form of immuno-
modulatory therapy. In apheresis, the blood 
of a donor or patient is passed through an 
apparatus that separates out one particular 
constituent and returns the remainder to 
the circulation. In photopheresis, a par-
ticular kind of apheresis, the majority of 
white blood cells are treated with 8-MOP, 
which becomes biologically active under 
exposure to UVA light, making pathogenic 
T cells, monocytes, natural killer cells, as 
well as B and T lymphocytes, susceptible to 
apoptosis. Furthermore, an immunological 
response follows the reinfusion of irradi-
ated cells, with activation and differen-
tiation of antigen-presenting cells (APCs, 
monocytes). APCs recognize apoptotic 
leukocytes through receptors that stimu-
late production of anti-inflammatory cyto-
kines such as IL-10 and TGF-. ECP also 
induces immune tolerance through the 
induction of Tregs, with increased pro-
duction of IL-10 and TGF-. ECP alters 
lymphocyte proliferation favoring a shift 
from a Th1 to a Th2 cytokine profile. Sub-
cellular particles from apoptotic lympho-
cytes known as blebs show increased CD5 
and CD8 and decreased CD28 and CD26 
Table 1. Summary of the applications of phototherapy.
Condition Standard of care Other therapeutic options
Psoriasis NBUVB PUVA, Excimer
Cutaneous T-cell lymphoma 
(IA–IIA)
PUVA NBUVB, Excimer, UVA1
Vitiligo NBUVB PUVA, Excimer
Atopic dermatitis:
sAcute, severe
sChronic, mild
UVA1
NBUVB, UVA/UVB
Lichen planus PUVA NBUVB
Lichenoid graft-versus-host disease PUVA UVA1, NBUVB
Pityriasis lichenoides PUVA NBUVB
Urticaria pigmentosa PUVA UVA1
Photodermatosis:
s Polymorphic light eruption
s Solar urticaria
sOthers
NBUVB
PUVA
NBUVB, PUVA
PUVA
Morphea, systemic sclerosis UVA1 PUVA
Lichen sclerosus UVA1
Other conditions:
s Seborrheic dermatitis
sUremic pruritus
s Lymphomatoid papulosis
s Pytiriasis rubra pilaris
sGranuloma annulare
sAlopecia areata
sDesydrotic hand eczema
s Systemic lupus erythematosus
NBUVB
NBUVB
PUVA
PUVA
PUVA
PUVA, Excimer
UVA1
UVA1
Summary of phototherapy’s main clinical applications.
NBUVB: Narrow band-UVB; PUVA: Psoralen plus UVA. 
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expression, surface markers consistent with an immunosuppres-
sive phenotype. Apoptotic cells show increased expression of phos-
phatidylserine which is recognized by phagocyting macrophages, 
thereby leading to their anti-inflammatory clearance [80]. 
Administration
ECP involves three stages – leucapheresis, photoactivation with 
a photosensitizer plus UVA and re-infusion of buffy coat – each 
treatment taking 3–4 h. One main difficulty of performing 
photopheresis results from the venous access. One cycle of ECP 
consists of two treatments on consecutive days, and one cycle is 
typically given every 2–4 weeks [81].
Safety
ECP’s side effects are listed in BOX 3 [80]. Side-effects are typically 
mild and transient and severe reactions such as vasovagal syn-
cope or infections are uncommon. The lack of major side effects, 
including malignancies or infections, is very valuable in diseases 
for which alternative treatments are highly immunosuppressive 
[81]. Contraindications to ECP include severe renal, hepatic or 
cardiac impairment, coagulation disorders and hypersensitivity 
to psoralen compounds.
Indications
CTCL
Erythrodermic CTCL was the first disease to be treated with 
ECP in the early 1980s [82], an indication for which it received 
US FDA approval in 1988.
ECP is currently approved for the treatment of skin manifesta-
tions in all stages of CTCL, but there is good evidence to support 
the rejection of the use of ECP for the treatment of nonerythro-
dermic MF and fair evidence to support the use of ECP for eryth-
rodermic MF, including stage III and IVA, and Sézary syndrome 
[80,83]. There are several guidelines on the use of ECP in patients 
with CTCL [83–85].
The role of ECP in treating earlier stages of CTCL may be 
limited. One plausible explanation are the low levels of circulating 
Sézary cells in the peripheral blood of these patients [80].
Other attempts to better characterize those CTCL patients who 
are more likely to respond to ECP revealed that patients with a 
ratio CD4:CD8 of<10 are more likely to respond than those with 
a ratio >10 and that a nonelevated LDH at the start of treatment 
tends to predict a better response to ECP compared with patients 
with an elevated LDH [15].
GVHD
Steroids and other immunosupressive agents are the mainstay 
initial modes of therapy in the treatment of GVHD after allogenic 
bone-marrow transplantation. ECP has been successfully used in 
refractory acute (aGVHD) and chronic (cGVHD) disease for the 
past 10 years [80,83,86].
Studies have found good results on cutaneous improvement of 
cGVHD but they were not as consistent in respect to liver and 
lung involvement [87,88]. Patients with progressive development of 
cGVHD may be more likely to respond to therapy versus those 
with de novo onset [89]. Another study reported a higher response 
rate in participants who started therapy earlier than 1 year after 
onset of cGVHD [88]. ECP may also work as a steroid-spering 
treatment, more effective than conventional steroid-spearing 
immunosuppressants, as shown in a multicenter, prospective, 
Phase II clinical trial involving 95 patients with cutaneous 
cGVHD [90]. This may represent an advantage owing to its fairly 
safe profile [80].
ECP also seems promising in the treatment of patients with 
aGVHD, particularly those with cutaneous manifestations but 
also liver and gut involvement [80].
Solid organ transplants
In a randomized controlled trial, the addition of ECP to triple-
drug immunosuppressive therapy significantly decreased the risk 
of cardiac rejection without increasing the incidence of infection 
[91]. Multiple case reports and other anecdotal data involving the 
use of ECP in transplant recipients of lung, liver, kidney and allo-
geneic stem cell transplantation can also be found in the literature 
[80]. ECP is effective for patients resistant to conventional treat-
ment, particularly if started early [3]. Besides reversal of allograft 
rejection, a reduction in immunosuppressive therapy has also been 
frequently achieved [92,93].
Autoimmune diseases
Limited data has also been published regarding the use of ECP 
in a variety of autoimmune diseases [80].
A small number of patients with pemphigus vulgaris have been 
successfully treated with ECP, with tapering of concomitant 
immunosuppressive therapy. However, since clinical trials with 
a large cohort of patients have not yet been conducted, there is 
not sufficient evidence to support the use of ECP in patients with 
this disease [80].
Two randomized clinical trials found improvements in skin 
and joint severity scores in patients with systemic scleroderma 
after ECP [94,95], pointing to a favorable outcome when ECP is 
started early in the course of the disease, with a low incidence of 
side effects [94].
Box 3. Side effects of extracorporeal 
photopheresis.
Common side effects
s Headache 
s Nausea
s Chills 
s Low-grade fever
Other side effects
s Hypotension 
s Vasovagal syncope
s Septicemia
s Anemia 
s Abnormal clotting response
s Skin infections over the venous access site
s Bacterial endocarditis
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An open-label pilot study published in 1992 stated an 
improvement of clinical skin and joint scores in seven of ten 
patients with systemic lupus erythematosus, although no sig-
nificant changes were noted in laboratory parameters [96]. Since 
then only a few anecdotal cases have been reported in the lit-
erature [80].
Although at one time promising, the role of ECP for the treat-
ment of rheumatoid arthritis is still questionable [80].
Other applications
Severe atopic dermatitis has been successfully treated with ECP, 
the first report going back to 1994 [97]. It has also been effective in 
the treatment of recalcitrant mucous and cutaneous erosive lichen 
planus [98,99]. Other recently reported potential applications of 
ECP might be refractory Crohn’s disease, Type 1 diabetes mellitus 
and the prevention of restenosis in patients after percutaneous 
transluminal coronary angioplasty [80]. In BOX 4, we summarize 
ECP’s main clinical applications.
Expert commentary
Phototherapy is an important treatment 
option for psoriasis and other skin diseases 
and is the first choice in case of contraindica-
tions for immunosupression, such as patients 
with infections or cancer-prone patients. 
There are some discrepancies in the litera-
ture, regarding dosimetry recomendations, 
efficacy, risk of phototoxicity and long-term 
risks, particularly for NB-UVB and UVA-1 
therapies. More data are needed in order to 
optimize these phototherapy modalities. 
Besides advanced cutaneous T-cell lym-
phoma, theoretically, photopheresis is an 
exciting tool for the treatment of a variety 
of T-cell-mediated diseases and should be 
considered in severe and difficult-to-treat 
conditions, particularly in systemic scleroderma. 
Five-year view
Phototherapy is a time-consuming treatment and this raises the 
question: what is the future position of phototherapy as a classical 
treatment for psoriasis in the era of biologics? The better under-
standing of phototherapy-induced molecular pathways and the 
identification of clinical and genetic predictors of treatment response 
will contribute to maintain the importance of phototherapy. On 
the other hand, it is attractive to speculate that at least an additive 
or possibly a synergistic effect can be expected in case of combina-
tion of phototherapy with a biologic. Targeted phototherapy using 
high-intensity UV devices may improve safety and efficacy, namely 
in difficult-to-treat cases of morphea, alopecia areata and vitiligo. 
In the near future, more studies will corroborate the role of 
extracorporeal photopheresis in the prevention of solid organ 
transplant rejection and this therapeutic option will be available 
in more institutions worldwide. 
Key issues
s Narrow band-UVB (NB-UVB) currently represents the phototherapeutic modality of choice for the treatment of psoriasis. 
s Psoralen plus UVA (PUVA) is an excellent treatment option for the early stages of cutaneous T-cell lymphoma (IA–IIA), here achieving 
long-lasting free-disease intervals. NB-UVB can also induce high rates of complete remission in early disease. 
s NB-UVB is currently used more than PUVA in vitiligo because it has been shown to be at least as effective and possibly safer.
s UVA1 phototherapy is a highly effective monotherapy for acute, severe atopic dermatitis. NB-UVB and UVA/UVB phototherapy are 
effective treatments in chronic, mild and moderate disease.
s PUVA is a therapeutic option for extensive lichen planus and for lichenoid graft-versus-host disease. 
s NB-UVB is currently the phototherapeutic option of choice in polymorphous light eruption. In solar urticaria, PUVA appears to be the 
most effective therapy available. Patients with other photodermatosis, including actinic prurigo, hydroa vacciniforme and erythropoietic 
porphyria, may benefit from NB-UVB or PUVA.
s Medium–high dose UVA1 therapy can provide significant benefit to patients with morphea, particularly linear and plaque subtypes of 
disease. 
s Photopheresis is used in patients with erythrodermic cutaneous T-cell lymphoma, including stage III and IVA, and those with Sézary 
syndrome with good results. 
s It has also been successfully used in refractory acute and chronic graft-versus-host disease, with cutaneous improvement. Similar 
benefit has also been reported in transplant recipients of heart, lung, liver, kidney and allogeneic stem cell transplantation.
s Limited data has been published regarding the use of extracorporeal photopheresis in a variety of autoimmune diseases, including 
pemphigus vulgaris, systemic scleroderma, systemic lupus erythematosus and rheumatoid arthritis.
Box 4. Summary of the applications of extracorporeal photopheresis.
Main applications
s Erythrodermic CTCL (IIIA, IV), Sézary syndrome
s Acute and chronic graft-versus-host disease
s Rejection in transplant recipients of heart, lung, liver, kidney and allogenic stem cells
Other applications
s Autoimmune diseases: penphigus vulgaris, systemic scleroderma, systemic lupus 
erythematosus, rheumatoid arthritis 
s Atopic dermatitis
s Erosive lichen planus
s Crohn’s disease
s Type 1 diabetes mellitus
s Prevention of restenosis in patients after percutaneous transluminal coronary 
angioplasty
CTCL: Cutaneous T-cell lymphoma.
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Aims 
 
The major aims of this study are described below in two chapters, according to 
the model used. In chapter I, results were obtained in three models of skin cell cultures, 
monoculture of human melanotic melanoma cells (SK-mel-1), monoculture of human 
keratinocytes (HaCat) and co-culture of melanoma cells and keratinocytes and in 
chapter II, results were obtained from psoriasis patients submitted to UVB 
phototherapy. 
 
 
Chapter I 
- To evaluate the presence of a functional endocannabinoid system in the three 
models of skin cell cultures.  
- To assess the role of cannabinoid receptors on melanogenesis in human 
melanotic melanoma cells alone or in co-culture with human keratinocytes (HaCat).  
- To evaluate the influence of ultraviolet B (UVB) radiation on the expression of 
CB1 and CB2 receptor mRNA, endocannabinoid levels and endocannabinoid enzymes 
in the three models of skin cell cultures.  
- To evaluate the influence of cannabinoid drugs in UVB-induced cell death of 
keratinocytes. 
- To evaluate the role of catechol-O-methyltransferase (COMT) on 
melanogenesis and on UVB-induced cell death in human melanoma cells and human 
keratinocytes. 
- To evaluate the influence of UVB irradiation on COMT activity in human 
melanoma cells and human keratinocytes.  
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Chapter II 
- To evaluate erythrocyte catechol-O-methyltransferase activity in patients with 
psoriasis and to determine whether narrowband ultraviolet B (nbUVB) phototherapy 
modifies this activity. 
- To assess the influence of nbUVB phototherapy in vitamin A and vitamin D 
serum levels in patients with psoriasis. 
- To assess endocannabinoid plasma levels in psoriasis patients and to determine 
whether nbUVB phototherapy modifies these levels.  
- To evaluate the impact of nbUVB phototherapy for psoriasis on clinical 
response, inflammatory and metabolic parameters and respective correlation with 
endocannabinoid plasma levels.  
Inhibition of basal and ultraviolet B-induced melanogenesis 
by cannabinoid CB(1) receptors: a keratinocyte-dependent effect
Arch Dermatol Res 2011; 303(3):201-10
Anandamine increases UVB - induced cell death of human 
keratinocytes through transient receptor potential vanilloid-1 channel
Submitted for publication 2012
Effect of ultraviolet B radiation on endocannabinoid metabolizing enzymes
Unpublished data 2012
Ultraviolet B radiation differentially modifies 
catechol-O-methyltransferase activity in keratinocytes and melanoma cells
Photodermatol Photoimmunol Photomed 2012; 28(3):137-141
Chapter I
Ultraviolet B radiation on melanocyte and keratinocyte cell lines
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Abstract Ultraviolet radiation is the major environmental
insult to the skin and stimulates the synthesis of melanin in
melanocytes, which then distribute it to the neighboring
keratinocytes where it confers photo-protection. Skin color
results from the paracrine interaction between these two
cell types. Recent studies suggest that endocannabinoids
are potential mediators in the skin. Here, we investigated
whether cannabinoid drugs play a role in melanogenesis
and if ultraviolet radiation modifies the cutaneous endo-
cannabinoid system. We used human melanotic melanoma
cell line (SK-mel-1) in monoculture or co-culture with
human keratinocytes (HaCat). Endocannabinoid levels,
cannabinoid receptors expression, and melanin content
were evaluated under basal conditions and after ultraviolet-
B irradiation (311 nm). We provide evidence that human
melanoma cells (SK-mel-1) express CB1 receptors, and
when in co-culture with keratinocytes (HaCat), the selec-
tive CB1 receptor agonist arachidonyl-2-chloroethylamide
(ACEA 1 and 10 lM) inhibited (by 33.4 and 37.3%,
respectively) basal melanogenesis. In addition, ultraviolet-
B-induced melanogenesis in co-cultures was abolished
by ACEA 10 lM. Both ACEA inhibitory effects were
reversed by AM251 (1 lM), a selective CB1 antagonist.
Furthermore, ultraviolet-B radiation increased endocan-
nabinoids levels only in keratinocytes, whereas CB1
cannabinoid receptor expression was up-regulated only in
melanoma cells. Our results collectively suggest that ultravi-
olet radiation activates paracrine CB1-mediated endocan-
nabinoid signaling to negatively regulate melanin synthesis.
The endocannabinoid system in the skin may be a possible
target for future therapies in pigmentary disorders.
Keywords Melanin  Melanoma  Ultraviolet radiation 
Cannabinoids  Co-culture
Introduction
In the last two decades, research has dramatically increased
the knowledge of endocannabinoid biology and pharma-
cology. The cloning of two cannabinoid receptors, CB1
and CB2 and the discovery of their endogenous ligands,
anandamide (AEA) and 2-arachidonoyl glycerol (2-AG),
increased the interest in understanding the physiological
role of the endocannabinoid system. This research provided
evidence that there is a wide range of disorders in which
endocannabinoid levels and cannabinoid receptor density
are increased and that this up-regulation can either coun-
teract or contribute to the pathological mechanisms
reviewed by Di Marzo and Pertwee [4, 14].
The skin functions as a neuro-endocrine organ with
functional epidermal units formed by one melanocyte
surrounded by keratinocytes in intimae paracrine
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 regulation. The distribution and expression of CB1 recep-tors were uniformly found in skin biopsies taken from
different body sites [20] and recent studies strongly suggest
the existence of a functional cutaneous endocannabinoid
system reviewed by Biro et al. [2]. There is evidence that
human keratinocytes have the biochemical machinery to
bind, synthesize and hydrolyze endocannabinoids [9] and,
in a CB1 receptor-dependent manner, cannabinoids regu-
late keratinocyte differentiation [12]. More recently, a
protective role of the endocannabinoid system in contact
allergic dermatitis was described [7]. A previous study
carried out in mouse epidermal JB6 P(?) cells showed that
UVB irradiation can increase the levels of AEA and PEA
[1]. In addition, it was demonstrated that human and mouse
melanoma cells contain cannabinoid CB1 and CB2 recep-
tors [3]. As activation of these receptors increases apop-
tosis in melanoma cells, they might represent novel targets
for the treatment of melanoma. Very recent data on CB1
and CB2 knockout mice suggest that cannabinoid receptors
are required for ultraviolet-induced inflammation and skin
cancer development [22]. Melanocytes play a fundamental
role in ultraviolet (UV) protection by synthesizing the
pigment melanin in discrete organelles, the melanosomes.
Once filled with melanin, melanosomes are transferred to
keratinocytes, where they form a supranuclear cap to pro-
tect DNA against UV irradiation reviewed by Schallreuter
[18]. The lack of safe and efficient drugs for skin pigment
regulation or protection of melanocytes against UV light
increases the interest in studying the cutaneous endocan-
nabinoid system and its response to UV. However, direct
evidence for the presence of a functional endocannabinoid
system in melanocytes and data on the pharmacological
effects of cannabinoids on melanin synthesis are lacking in
the literature. Although UV radiation is the major envi-
ronmental insult to the skin, and the endocannabinoid
system is suggested to play a pro-homeostatic role, the
influence of UV radiation on cutaneous endocannabinoid
system activity is unknown. On the other hand, due to their
highly lipophilic nature, the potential use of cannabinoid
drugs for skin diseases is an interesting field of research,
because they can be used as topical preparations without
important side effects.
In order to investigate the response of the cutaneous
endocannabinoid system to UV radiation and the proposed
role of cannabinoid drugs in the regulation of melanogen-
esis, we chose two models of cell cultures, one with human
melanotic melanoma cells alone and the other in co-culture
with keratinocytes. Specifically, we evaluated cell melanin
content under basal conditions and after acute low dose
UVB irradiation in the absence and in the presence of
cannabinoid drugs. Furthermore, we measured the expres-
sion of cannabinoid receptors (CB1 and CB2) and endo-
cannabinoids levels (AEA, 2-AG) in melanoma cells and
keratinocytes under basal conditions and after UVB acute
irradiation. The effect in cell viability was also quantified.
Materials and methods
Materials
Minimum essential medium Eagle (MEM), Dulbecco’s
minimal Eagle’s medium (DMEM), antibiotic antimycotic
solution, HEPES, synthetic melanin, and human anti-can-
nabinoid receptor 1 antibody were purchased from Sigma-
Aldrich, Inc. (St. Louis, MO, USA). Rabbit anti-cannabi-
noid receptors CB1 and CB2 antibodies were purchased
from Chemicon International, Inc. (Temecula, CA, USA).
Fetal bovine serum (FBS) and trypsin were purchased from
Gibco (Paisley, UK). NaHCO3 and EDTA were purchased
from Merck (Germany). Arachidonoyl-20-chloroethyla-
mide (ACEA) was purchased from Biotrend Chemicals AG
(Zurich, Switzerland) and AM251 from Tocris Bioscience
(Bristol, UK).
Cell lines and culture conditions
Human SK-mel-1 melanoma cells (ATCC no. HTB-67)
were grown routinely in MEM supplemented with 10%
FBS, 1% antibiotic antimycotic solution, 25 mM HEPES,
and 0.26 M NaHCO3, at 37C in a 5% CO2 (v/v), humid-
ified atmosphere.
HumanHaCaTkeratinocytes, providedbyProf.N.Fusenig
(Deutsches Krebsforschungszentrum, Heidelberg, Germany),
were grown in DMEM supplemented with 10% FBS, 1%
antibiotic antimycotic solution, and 0.44 M NaHCO3. Cells
were maintained at\80% confluency, at 37C in a 5% CO2
(v/v), humidified atmosphere.
SK-mel-1 and HaCaT cells ratio 1.8:2, as described in
[16] were co-cultivated in six-well tissue culture plates,
96 h prior to the beginning of the experiment, in DMEM
supplemented with 10% FBS, 1% antibiotic antimycotic
solution, and 0.44 M NaHCO3. However, due to their
different proliferation rates, the ratio of melano-
cytes:keratinocytes changes in the first 48 h, eventually
reaching a stable ratio of 1:4 (which is the one used during
the experiments). Co-cultures were incubated 2 h before
the first UVB irradiation with DMEM medium containing
either ACEA 1 lM, ACEA 10 lM, AM251 1 lM, AM251
1 lM ? ACEA 1 lM or AM251 1 lM ? ACEA 10 lM
and the medium containing the different drugs tested was
replaced every 24 h, until the end of the experiment.
Cannabinoid agonists and antagonists were directly applied
at a final ethanol concentration\0.01% (v/v). No signifi-
cant influence of the vehicle was observed on any of the
parameters determined.
202 Arch Dermatol Res (2011) 303:201–210
123
Chapter I  Ultraviolet B radiation on melanocyte and keratinocyte cell lines 
 
69 
 
  
 
Western blot
Western blot analysis was carried out as previously
described [10]. Briefly, the membranes were incubated
with either rabbit anti-cannabinoid receptor 1 antibody
(diluted 1:250) or rabbit anti-cannabinoid receptor 2 anti-
body (diluted 1:500) for 2 h and then were incubated
with the fluorescently labeled secondary antibody (goat
anti-rabbit from Rockland). The specificity of the anti-
cannabinoid receptor antibodies was assessed by antigen
preabsorption with the corresponding blocking peptides.
Membranes were imaged by scanning at 700 nm with the
Odyssey Infrared System (LICOR Biosciences, Lincoln,
NE, USA).
UVB irradiation
Cells in co-culture were washed with phosphate-buffered
saline (PBS) and then exposed to low (3 mJ/cm2) and high
(7 mJ/cm2) dose of UVB light wavelength (312 nm),
emitted by a pre-heated, filtered, UV lamp (VL-6.M, Vilber
Lourmat, France) at t = 0 min, t = 24 and 48 h. This was
followed by 48-h period of incubation after which the cells
were harvested [10 min incubation with EDTA (0.05%,
pH 7.4) and 5 min incubation with trypsin] for analysis.
SK-mel-1 cells in monoculture were washed with PBS,
resuspended in 1 ml of PBS and returned to the plate well
for exposure to low (3 mJ/cm2) and high (7 mJ/cm2) dose
UVB light under the same conditions as the cells in co-
culture. Following the 48-h period of incubation, these
cells did not require incubation with EDTA and trypsin for
harvesting, as they grow in suspension. HaCat cells in
monoculture were washed with PBS and then exposed to
low (30 mJ/cm2) and high (60 mJ/cm2) dose UVB light at
t = 0 min. The low and high irradiation doses were defined
according to cell type based on the UVB radiation effect
on cell viability. With low UVB doses, cell viability was
unchanged; by contrast the high doses produced an
equivalent toxic effect (around 40% loss).
Non-irradiated controls were not exposed to UVB light,
but subjected to all other manipulations. UV dosimetry was
performed with a Waldmann 585.100 UV-meter (Herbert
Waldmann GmbH & Co., Villingen-Schwenningen,
Germany).
Melanin and cell viability determination
Harvested cells were centrifuged at 3009g for 5 min at
room temperature, washed twice with PBS and resus-
pended in 1 ml of PBS. From this suspension, 180 ll were
transferred into a black/clear bottom MicrotestTM 96-well
Assay Plate, OpliluxTM (BD Biosciences, Franklin Lakes,
NJ, USA) for cell viability assay. Cell viability was
measured using calcein-AM (Molecular Probes, Inc.,
Eugene, OR, USA) according to the manufacturer’s
instructions. Each well containing 180 ll of cell suspen-
sion was loaded with 20 ll of calcein-AM (10 lM, in PBS
solution). Fluorescence was measured at 485 nm excitation
and 530 nm emission wavelengths using a SpectraMax,
Gemini XS spectrofluorometer (Molecular Devices, Sun-
nyvale, CA, USA) at 40-min incubation at room
temperature.
The melanin content of cells was determined according
to [17]. Briefly, cells were centrifuged at 3009g for 5 min,
resuspended in 500 ll of a NaOH (1 M, in 10% DMSO)
solution and incubated at 80C for 2 h. This was followed
by centrifugation at 5009g for 10 min, and the resulting
supernatant was used for measurement of melanin at
420 nm in a PowerWaveTM HT microplate scanning
spectrophotometer (BioTek Instruments, Inc., VT, USA).
Synthetic melanin was used to construct a standard curve
for the range of 1–100 lg/ml. Melanin absorbance was
measured at 420 nm wavelength.
Real-time polymerase chain reaction (RT-PCR)
Real-time polymerase chain reaction (RT-PCR) was car-
ried out as previously described [6]. Total RNA from
keratinocytes and melanoma cells in co-cultures (n = 5,
per group) was isolated using the PureZOL RNA isolation
reagent (Bio-Rad, CA, USA). Total RNA (1 lg per sam-
ple) was DNase treated and reverse transcribed according
to the manufacturer’s instructions (iScriptTM cDNA Syn-
thesis Kit, Bio-Rad). For RT-PCR, 50 ll of amplification
mixture (iQTM SYBR Green Supermix, Bio-Rad) was
used containing 20 ng of reverse transcribed RNA and
specific primers (250 nM) (Sigma) for CNR1 (sense: 50-TG
ACATTCAGTACGAAGACATCAA-30; anti-sense: 50-CA
CTCTATGTCCATGAAGTTCTCC-30), CNR2 (sense: 50-TG
GGAGAGGACAGAAAACAACT-30; anti-sense: 50-GAG
CTTGTCTAGAAGGCTTTGGG-30) and GAPDH (sense:
50-AGCCACATCGCTCAGACAC-30; anti-sense: 50-GCC
CAATACGACCAAATCC-30). Reactions were run in
duplicates (20 ll) on a MJ Mini detector (Bio-Rad, CA,
USA). The cycling conditions were 15 min polymerase
activation at 95C and 40 cycles at 95C for 15 s, at 58C
for 30 s, and at 72C for 30 s. Results were normalized to
GAPDH values and expressed as log2 (sample/control).
Extraction, purification, and quantification
of endocannabinoids and PEA
Cells were homogenized in chloroform:methanol:Tris–HCl
50 mM (2:1:1) containing 10 pmol of d8-AEA, d4-palmito-
ylethanolamide (PEA) and d5-2-arachidonoylglycerol (2-AG)
as internal standards. Homogenates were centrifuged at
Arch Dermatol Res (2011) 303:201–210 203
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 13,0009g for 16 min (4C), the aqueous phase plusdebris were collected and extracted again twice with
1 vol. of chloroform. The organic phases from the three
extractions were pooled and the organic solvents evap-
orated in a rotating evaporator. Lyophilized extracts were
resuspended in chloroform:methanol (99:1, v/v). The
solutions were then purified by open bed chromatography
on silica as previously described [15]. Fractions eluted
with chloroform:methanol (9:1, v/v) and containing
AEA, PEA, and 2-AG were collected, the excess solvent
evaporated with a rotating evaporator, and extracts ana-
lyzed by isotope dilution-liquid chromatography/atmo-
spheric pressure chemical ionization/mass spectrometry
(APCI–LC–MS) carried out under conditions described
previously [15] and allowing the separations of 2-AG,
PEA and AEA. Results are expressed as pmol/mg of
lipid extract.
Statistical analysis
Data are presented as mean ± SD. Student’s t test was
used to analyze differences. Values of P\ 0.05 are con-
sidered significant.
Results
Expression of cannabinoid receptors
Cannabinoid CB1 and CB2 receptors mRNA expression
was identified by quantitative real-time PCR using RNA
extracted from SK-mel-1 and HaCat cells. Cannabinoid
CB1 and CB2 receptors protein expression was identified
by western blot using SK-mel-1 cell extracts (Fig. 1).
Time-course of basal melanogenesis
In non-irradiated control situation, basal melanin produc-
tion increased in a time-dependent manner, both in co-
cultures of human melanotic melanoma cells (SK-mel-1)
with human immortalized keratinocytes HaCat (SK-mel-1-
HaCat) and monocultures of human melanoma cells (SK-
mel-1) alone. However, melanin content was significantly
increased in co-culture model when compared to mela-
noma cells alone. After 48-h incubation, this difference
was already evident, reaching a 2.5-fold increase at 96 h
(Fig. 2).
Effect of CB1 receptor activation on basal
melanogenesis
In co-culture model, time-course experiments showed that
the CB1 selective agonist ACEA 1 lM, had an inhibitory
effect on melanogenesis. Although this inhibitory effect
was already observed after 72 h, it was more evident
(37.3% reduction) after 96 h (Fig. 2). By contrast, until
96-h incubation time, ACEA 1 lM did not change melanin
content in melanoma cells alone (data not shown).
Since the 96-h time point was the one at which we found
more significant differences, we chose this incubation time
to evaluate the effect of all tested compounds.
Fig. 1 Western blot analysis of cannabinoid CB1 and CB2 receptors
in SK-mel-1 cell extracts. Molecular mass markers (MW) are shown
on the left in kDa. A single band of the expected size (37 kDa for CB1
and 60 kDa for CB2) was revealed following incubation with the
respective anti-cannabinoid receptor antibody. The specificities of the
anti-cannabinoid receptor antibodies were assessed by antigen
preabsorption with the corresponding blocking peptides (not shown)
Fig. 2 Time-course of basal melanogenesis. Basal melanogenesis in
monoculture of SK-mel-1(filled square), in co-culture of keratino-
cytes (HaCat) with melanocytes (SK-mel-1) under control situation
(filled circle) and in the presence of ACEA 1 lM (open circle).
Values are mean ± SD (n = 6) *P\ 0.05 compared to monocul-
tures, #P\ 0.05 compared to co-cultures under control conditions
204 Arch Dermatol Res (2011) 303:201–210
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In the co-culture model, both 1 and 10 lM of ACEA
had a similar inhibitory effect in melanogenesis (37.3 and
33.4%, respectively), however, in melanoma cells alone,
even the higher concentration tested (10 lM) did not
change melanin content (Fig. 3a).
The specific CB1 antagonist AM-251 (1 lM), which
alone did not modify melanin content, completely reverted
the melanogenesis-inhibitory effect of both 1 and 10 lM of
ACEA in the co-culture (Fig. 3a).
Two well-known melanogenesis inhibitors, kojic acid
and hydroquinone, were used as positive controls. The
ACEA inhibitory effect on melanin content had the same
magnitude as kojic acid (1 mg/ml) in co-cultures.
Interestingly, unlike ACEA, kojic acid inhibited melano-
genesis also in melanoma cells monocultures (Fig. 3a).
On the other hand, both kojic acid and hydroquinone
had a significant cytotoxic effect while ACEA (1 and
10 lM) did not change cell viability (Fig. 3b).
Effect of UVB irradiation on melanogenesis
Initially, we investigated the effect of different UVB irra-
diation doses (3–24 mJ/cm2) on melanogenesis in co-cul-
tures and melanoma cells alone (data not shown). We
found that, in the co-culture model, three consecutive, daily
UVB exposures at 3 mJ/cm2 significantly increased cellu-
lar melanin content (*40% over the controls) (Fig. 4a).
Interestingly, the same UVB treatment did not significantly
Fig. 3 Melanin content and cell viability in monocultures (SK-mel-
1) and co-cultures (SK-mel-1-Ha-Cat). a Cellular melanin content in
monocultures (SK-mel-1) and co-cultures (SK-mel-1-Ha-Cat), after
96-h incubation. Melanin content was determined in total cell extracts
and expressed in lg/ml. The results were normalized to respective
cell viability. b Cell viability in monocultures (SK-mel-1) and co-
cultures (SK-mel-1-Ha-Cat), after 96 h incubation. Cell viability was
expressed as the percentage of untreated controls, set to 100. Bars
represent mean ± SD (n = 10) *P\ 0.05 compared to respective
control values, #P\ 0.05 compared to respective ACEA values
Fig. 4 Effect of UVB irradiation on melanin content and cell
viability. a Effect of UVB irradiation (3 mJ/cm2) on melanogenesis
in monocultures (SK-mel-1) and in co-cultures (SK-mel-1-HaCat).
Results were expressed as percentage of increase in melanin content
after irradiation, over the non-irradiated controls. b Effect of UVB
irradiation (3 mJ/cm2) on cell viability in monocultures (SK-mel-1)
and in co-cultures (SK-mel-1-HaCat). Cell viability results were
expressed as the percentage of untreated controls set to 100. Bars
represent mean ± SD (n = 15) *P\ 0.05 compared to monocultures
Arch Dermatol Res (2011) 303:201–210 205
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 modify melanin content of melanoma cells alone (Fig. 4a).On the other hand, this UVB dose (3 mJ/cm2) did not lead
to a significant decrease in cell viability (Fig. 4b). UVB
irradiation with doses [3 mJ/cm2 had a dose-dependent
cytotoxic effect in SK-mel-1 monocultures (data not
shown).
Effect of CB1 receptor activation on UVB-induced
melanogenesis
We also evaluated whether stimulation of CB1 receptors
could modulate the increase in melanin content observed in
co-culture model after UVB irradiation. Therefore, we
performed UVB experiments after 96-h incubation with the
CB1 receptor-selective agonist ACEA (1 and 10 lM) and
with the CB1 receptor selective antagonist AM-251 (1 lM)
(Fig. 5). We found that ACEA 10 lM abolished the
increase in melanin content observed after UVB irradia-
tion. Furthermore, AM-251, which alone did not modify
UVB-induced melanogenesis, reversed the inhibitory effect
of ACEA 10 lM. Again, the melanogenesis inhibitor, kojic
acid was used as a positive control but, comparatively,
ACEA 10 lM exhibited a stronger effect on UVB-induced
melanogenesis (Fig. 5).
Effect of UVB irradiation on cannabinoid receptor
mRNA expression
CB1 and CB2 cannabinoid receptors mRNA expression was
identified by quantitative real-time PCR using RNA
extracted from SK-mel-1 and HaCat cells from co-cultures
under basal conditions and after UVB irradiation. We
found that, in melanoma cells, acute UVB irradiation
(3 mJ/cm2) significantly up-regulated CB1 receptor mRNA
(Fig. 6a), whereas in keratinocytes neither CB1 nor CB2
mRNA expression was modified by UVB (Fig. 6b, d).
Effect of UVB irradiation on endocannabinoids levels
We quantified the levels of the two most studied endo-
cannabinoids, AEA and 2-AG, and of palmitoylethanola-
mide (PEA), in SK-mel-1 monocultures, in HaCat
monocultures and in co-cultures (SK-mel-1, HaCat) under
basal conditions and after acute low and high dose UVB
irradiation. Our results, shown in Fig. 7, indicate that AEA
and PEA were elevated in HaCat cells irradiated with low
UVB dose (1.59 ± 1.09 and 16.64 ± 3.78 pmol/mg of
lipid extract) when compared with non-irradiated control
cells (0.15 ± 0.08; 6.37 ± 0.59 pmol/mg of lipid extract).
The levels of 2-AG were even more strongly elevated in
irradiated HaCat cells (13.95 ± 1.91 pmol/mg of lipid
extract) when compared with non-irradiated controls
(2.87 ± 1.18 pmol/mg of lipid extract). By contrast,
although basal levels of AEA and 2-AG were higher in
melanoma cells (3.49 ± 2.09 and 14.32 ± 1.22 pmol/mg
of lipid extract) than in keratinocytes (0.15 ± 0.08 and
2.87 ± 1.18 pmol/mg of lipid extract), they remained
unaltered by UVB irradiation. In co-cultures, the ratio
2-AG:AEA is 0.6 under baseline conditions and increases
to 8.7 and 8.1 after low and high dose UVB irradiation,
respectively. In contrast to AEA, both 2-AG and PEA
levels were significantly increased by UVB irradiation. In
general, the levels of 2-AG and AEA after irradiation were
lower in co-cultures than in melanoma cell line mono-
cultures, whereas the levels of PEA were significantly
higher (Fig. 7).
Discussion
In the present study, we provide the first evidence that
cannabinoid CB1 receptors exert an inhibitory effect on
melanin production both under basal conditions and after
UVB irradiation. Furthermore, we show that the endocan-
nabinoids AEA and 2-AG, and PEA, a non-cannabinoid
receptor active congener of AEA with anti-inflammatory
actions [15], are produced by human melanoma cells at
physiologically relevant concentrations. We demonstrated
that UVB increases the mRNA expression of CB1 receptors
in melanoma cells but not in keratinocytes, and that
keratinocytes respond to UVB radiation with an elevation
of 2-AG and AEA levels not observed in melanoma cells.
Taken together, our data support the concept that human
melanoma cells are both sources and, particularly, targets
Fig. 5 Effect of cannabinoids on UVB-induced melanogenesis in co-
cultures (SK-mel-1-HaCat). Results were expressed as percentage of
variation in melanin content after irradiation, over the non-irradiated
controls. Bars represent mean ± SD (n = 18) *P\ 0.05 compared to
control values, #P\ 0.05 compared to respective ACEA 10 lM
values
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of endocannabinoids, which function as negative regulators
of melanin synthesis after UVB radiation. Our data suggest
that endocannabinoids produced by keratinocytes after
UVB radiation might act at melanocyte CB1 receptors in a
paracrine way, to counteract the excessive melanin
production.
Although, melanoma cell lines have been extensively
used to study melanogenesis [17, 21] this may constitute a
limitation when extrapolating our results to normal skin
physiology. Several co-culture models with keratinocytes
and melanocytes have been developed, namely with HaCat
cells [19], furthermore, a co-culture identical to the one
used here (SK-mel-1 and HaCat cells) was previously
described as a suitable in vitro model to study the transfer
of melanin/melanosomes from melanocytes to keratino-
cytes [16]. The present co-culture model evaluates mela-
nogenesis without the proliferative capacity and donor
phototype variability limitations of normal human mela-
nocytes. In fact, melanoma cells co-cultured with kerati-
nocytes are a better model to study the melanogenic
response and the cannabinoid influence on the melanogenic
response is only observed in the co-culture model. In the
‘‘epidermal melanin unit’’, the close contact between
melanocytes and keratinocytes allows not only the transfer
of newly synthesized melanin into keratinocytes, but also
an intensive cross-talk between the two cell types. The
observed inhibitory effect of CB1 on melanogenesis in co-
cultures but not in monocultures underlines the important
symbiotic relationship between melanocytes and keratino-
cytes. Since both cells express CB1 receptors, it can be
speculated that cannabinoids acting on these receptors in
keratinocytes inhibit the release of keratinocyte-derived
paracrine melanogenic mediators. Alternatively, it is pos-
sible that CB1 receptors directly act on melanoma cells to
inhibit melanogenesis only when the conditions to produce
melanin are optimized by the presence of keratinocytes.
To investigate whether there is a difference in the
melanogenic response to UVB irradiation of melanoma
cells in monoculture as compared to those co-cultured with
keratinocytes, we exposed both types of culture to UVB
irradiation. Unlike co-cultures, which exhibited a melano-
genic response to UVB irradiation (3 mJ/cm2), melanoma
Fig. 6 Effect of UVB irradiation on cannabinoid receptors mRNA
expression. Cannabinoid CB1 receptor mRNA expression before
(Control) and after 3 mJ/cm2 UVB irradiation (Low) in melanocytes
(SK-mel-1) (a) and in keratinocytes (HaCat) (b). Cannabinoid CB2
receptor mRNA expression before (Control) and after 3 mJ/cm2 UVB
irradiation (Low) in melanocytes (SK-mel-1) (c) and in keratinocytes
(HaCat) (d) Bars represent mean ± SD (n = 5) *P\ 0.05 compared
to respective non-irradiated controls
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cells alone did not show any increase in melanin content
after irradiation with the same dose. It is known that UVB
irradiation of keratinocytes triggers the release of cyto-
kines, growth factors, and other mediators such as endo-
thelin-1, nitric oxide or proopiomelanocortin-derived
peptides known to be effective modulators of melanin
synthesis in a paracrine way [5, 13]. This may explain the
differences observed between mono- and co-cultures in
their response to UVB. Under basal co-culture conditions,
the CB1-mediated inhibitory effect was also observed on
UVB-induced melanogenesis, and was comparable to the
effect of the well-known hypo-pigmentary agent, kojic
acid. From these results, we suggest that keratinocytes play
a major role in cannabinoid-mediated inhibition of basal
and, particularly, UVB-induced pigmentation.
Endocannabinoid levels were stimulated by UVB irra-
diation in keratinocytes and co-cultures but not in mela-
noma cells alone. Interestingly, the co-cultures contain
Fig. 7 Effect of UVB irradiation on endocannabinoids and PEA
levels. Anandamide (a), 2-AG (b) and PEA (c) levels in HaCat
monocultures, SK-mel-1 monocultures and in co-cultures (HaCat-SK-
mel-1), either non-irradiated (CT) or after irradiation with UVB at
low and high doses. Data are mean ± SD (n = 4 separate determi-
nations). *P\ 0.05 compared to respective non-irradiated controls
#P\ 0.05 compared to respective experimental condition in co-
cultures
208 Arch Dermatol Res (2011) 303:201–210
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overall less endocannabinoids (except PEA) than mela-
noma cells alone under basal conditions, and even more
following UVB irradiation. This phenomenon may be due to
the presence of endocannabinoid-degrading enzymes in
keratinocytes [9] in levels possibly up-regulated by UVB.
This could suggest a new endocannabinoid-mediated
mechanism tightly regulating UVB-induced melanogenesis.
Besides melanogenesis, acute UVB irradiation also
induces skin inflammation and immunosuppression. The
standard model for studying UVB-induced immunosup-
pression is the UVB-ability to block either induction or
elicitation of cutaneous allergic sensitization. It is well
known that UVB irradiation of keratinocytes induces the
synthesis and secretion of a whole set of pro-inflammatory
and immunosuppressive soluble factors. Interestingly, a
recent study [7] demonstrated that endocannabinoids
attenuate the cutaneous allergic response and, more
recently, a protective role of PEA in the same context was
described [15]. Also antagonism of CB1 cannabinoid
receptor in human HaCat keratinocytes was associated with
the increased expression of pro-allergic chemokines [8].
Since we found here that UVB irradiation is accompanied
by up-regulation of both 2-AG and PEA levels, we
hypothesize that, whilst cutaneous endocannabinoids may
play a role in both UVB-induced melanogenesis and
immunosuppression, PEA might represent an endogenous
protective agent against UVB-induced inflammation. These
phenomena might contribute to the well-known therapeutic
effect of UVB radiation in chronic inflammatory skin dis-
eases. Endocannabinoid signals involved in skin inflam-
mation are complex and remain poorly understood.
Overall, anandamide appears to mediate an anti-inflam-
matory effect since inhibition of its degradation signifi-
cantly reduced inflammation [7] and there is growing
evidence suggesting that 2-AG modulates the inflammatory
response by acting on the cannabinoid CB2 receptor [11].
Interestingly, we found a significant increase in 2-AG:AEA
ratio after UVB irradiation in co-cultures, suggesting
that endocannabinoids, namely 2-AG, may play a role in
UVB-induced inflammation.
A recent study by Zheng et al. [22] suggested that CB
receptors and the related signaling pathways might be
involved in the promotion of in vivo skin carcinogenesis.
In CB1 and CB2 double gene-deficient mice, there was a
marked decrease in UVB-induced skin carcinogenesis.
This finding was quite surprising in view of previous data
indicating that the endocannabinoid system is protective
against the growth and spreading of skin cancer and mel-
anoma [3]. Since the major known function of melanin is to
provide protection against ultraviolet-induced DNA dam-
age by absorbing and scattering UV radiation, our in vitro
results provide a possible explanation to the findings of
Zheng and colleagues.
In conclusion, the present study suggests that ultraviolet
radiation activates paracrine CB1-mediated endocannabi-
noid signaling to negatively regulate melanin synthesis.
Furthermore, endocannabinoids might act as hypopig-
mentary agents either under basal conditions or after
ultraviolet exposure. Although the use of cannabinoids in
medicine is limited by their psychotropic effects, in cuta-
neous diseases these effects could be avoided by their
topical use on the skin.
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Abstract 
Endocannabinoids like anandamide (AEA) play a key role in skin biology. Exposure to high-dose ultraviolet B 
(UVB) radiation induces keratinocyte apoptosis and increases the synthesis of anandamide (AEA) in 
keratinocytes. Published data on the effects of cannabinoids on the regulation of keratinocyte cell death are 
conflicting. Moreover the influence of cannabinoids on UVB-induced cell death has never been studied. Here, 
we investigated whether AEA and other cannabinoid receptors ligands modify keratinocyte survival and UVB-
induced keratinocyte death. Cell viability in human immortalized HaCat keratinocytes was evaluated under basal 
conditions and 48 h after high-dose (70 mJ/cm2) UVB (311 nm) irradiation. Pretreatment of HaCat cells with 
AEA at high concentrations (30 µM) significantly increased UVB-induced cell death. This effect was replicated 
by the transient receptor potential vanilloid-1 channel (TRPV1) agonist capsaicin (10 µM). The selective CB1
antagonist AM-251 (1 µM) did not modify the effect of AEA.  In contrast, the selective TRPV1 antagonist, 
capsazepine (5 µM), which alone did not modify cell viability, abolished the increase in UVB-induced cell death 
of either AEA or capsaicin. Our results suggest that AEA potentiates cell death induced by UVB radiation 
through TRPV1 in human keratinocytes.  Endocannabinoids participate in the adaptive skin response to UVB 
radiation and could be useful in combination to phototherapy for treatment of hyperproliferative dermatoses such 
as psoriasis.  
Introduction 
The endocannabinoid system is not limited to the 
central nervous system [4] [9] and has a role in skin 
physiology [1]. Several human skin cells produce 
the major endocannabinoids, anandamide (AEA) 
and 2-arachidonoylglycerol (2-AG) and express the 
enzymes responsible for their synthesis and 
metabolism [8,11,7].  
Endocannabinoids bind to G-protein-coupled 
cannabinoid receptors, CB1 and CB2 [10]. AEA but 
not 2-AG is also an agonist of the transient receptor 
potential vanilloid-1 channel (TRPV1) [10]. 
TRPV1, CB1 and CB2 receptors were identified, 
both in situ and in vitro, on different cutaneous 
cells, including human keratinocytes [8] [7] [12]. 
Cannabinoids may induce apoptosis in different cell 
types and they have been tested as potential 
antitumoral agents. However, published data on the 
effects of cannabinoids on the regulation of 
keratinocytes cell death are conflicting. Wilkinson 
et al [16] found that ∆9-tetrahydrocannabinol as 
well as synthetic cannabinoid agonists inhibited 
growth of cultured transformed human epidermal 
keratinocytes, yet these effects were CB1 and CB2
independent. In another study, activation of both 
types of cannabinoid receptors by synthetic agonists 
induced the apoptotic death of tumorigenic 
epidermal cells whereas the viability of non- 
tumorigenic human (HaCat cells) and murine 
(MCA3D) keratinocytes remained unaffected [3]. 
In addition, it was observed that metabolism of 
AEA by cyclooxygenase-2 (COX-2) is important 
for AEA-induced cell death in tumorigenic 
keratinocytes and that neither CB1 nor CB2 nor 
TRPV1 receptors were required for this response 
[13] [5].We have recently reported that the 
cutaneous endocannabinoid system responds to 
ultraviolet B (UVB) irradiation corroborating the 
known pro-homeostatic role of the 
endocannabinoid system in other tissues [8]. UVB 
irradiation increases the levels of AEA and 2-AG in 
human keratinocytes [8]. Furthermore UVB 
increases TRPV1 expression in both keratinocytes 
and human skin in vivo [6] and increases COX-2 
expression in cultured human keratinocytes [2]
[14]. UVB radiation decreases keratinocyte 
viability, however the role of cannabinoid receptor 
ligands in UVB-induced keratinocyte cell death has 
not yet been studied.Therefore we evaluated in 
human cultured keratinocytes (HaCat), the effect of 
the most extensively studied endocannabinoid, 
AEA, and of synthetic cannabinoid receptor 
agonists and antagonists on cell survival in basal 
conditions and after acute UVB irradiation. 
2 
Materials and Methods 
Materials 
Dulbecco's minimal Eagle's medium (DMEM), 
antibiotic antimycotic solution, HEPES, 
anandamide (AEA), capsaicin (CAPS), capsazepine 
(CPZ) and indomethacin (IND) were purchased 
from Sigma-Aldrich, Inc. (St. Louis, MO, USA). 
Foetal bovine serum (FBS) and trypsin were 
purchased from Gibco (Paisley, UK). NaHCO3 and 
EDTA were purchased from Merck (Germany). 
Arachidonoyl-2’-chloroethylamide (ACEA) was 
purchased from Biotrend Chemicals AG (Zurich, 
Switzerland) and AM251, AM630, JWH133 from 
Tocris Bioscience (Bristol, UK).
Cell line and culture conditions 
Human HaCaT keratinocytes, provided by Prof. N. 
Fusenig (Deutsches Krebsforschungszentrum, 
Heidelberg, Germany), were grown in DMEM 
supplemented with 10% FBS, 1% antibiotic 
antimycotic solution and 0.44 M NaHCO3. Cells 
were maintained at <80% confluency, at 37ºC in a 
5% CO2 (v/v), humidified atmosphere.  HaCat cell 
cultures were incubated 2 h before the UVB 
irradiation with DMEM medium containing the 
different drugs studied and the medium was 
replaced every 24 h until the end of the experiment. 
Cannabinoid receptor agonists and antagonists were 
directly applied at a final ethanol concentration less 
than 0.3% (v/v). No significant influence of the 
vehicle was observed on the parameters 
determined.  
UVB irradiation 
HaCat cells in monoculture were washed with PBS 
and then exposed to acute UVB (312 nm) 
irradiation (70 mJ/cm2) emitted by a pre-heated, 
filtered, UV lamp (VL-6.M, Vilber Lourmat, 
France) at t = 0 min. 
This was followed by a 48 h period of incubation 
after which the cells were harvested [10 min 
incubation with EDTA (0.05%, pH 7.4) and 5 min 
incubation with trypsin] for analysis. 
The irradiation dose was defined according to UVB 
radiation cytotoxic effect. Non-irradiated controls 
were not exposed to UVB light, but subjected to all 
other manipulations. UV dosimetry was performed 
with a Waldmann 585.100 UV-meter (Herbert 
Waldmann GmbH & Co., Villingen-Schwenningen, 
Germany). 
Cell viability determination 
Harvested cells were centrifuged at 300 x g for 5 
min at room temperature, washed twice with PBS 
and resuspended in 1 ml of PBS. From this 
suspension, 180 µl were transferred into a 
black/clear bottom Microtest™ 96-well Assay 
Plate, Oplilux™ (BD Biosciences, Franklin Lakes, 
NJ, USA) for cell viability assay. Cell viability was 
measured using calcein-AM (Molecular Probes, 
Inc., Eugene, OR, USA) according to the 
manufacturer’s instructions. Each well containing 
180 µl of cell suspension was loaded with 20 µl of 
calcein-AM (10 µM, in PBS solution). 
Fluorescence was measured at 485 nm excitation 
and 530 nm emission wavelengths using a 
SpectraMax, Gemini XS spectrofluorometer 
(Molecular Devices, Sunnyvale, CA, USA) at 40 
min incubation at room temperature. 
Statistical analysis 
Data are presented as means ± SEM. Student’s t-
test connected by the Newman Keuls method for 
multiple comparisons was used to analyze 
differences. Values of P<0.05 are considered 
significant.  
Results 
Effect of anandamide on keratinocytes (HaCat) 
cell viability in basal conditions and after UVB 
irradiation
In basal conditions, we used AEA 3 and 30 µM and 
in the lowest concentration AEA (3 µM) slightly 
increased cellular viability while AEA 30 µM had 
no effect (Fig.1a). This effect of AEA (3 µM) was 
not reverted by CB1 antagonist (data not shown). 
Initially, we investigated the effect of different 
UVB irradiation doses (30-100 mJ/cm2) on 
keratinocytes cell viability (data not shown). We 
found that after high-dose (70 mJ/cm2) UVB 
irradiation a 60% reduction on cell viability was 
observed in control situation (Fig. 1a). AEA 30µM 
significantly increased (P<0.05, n=12) UVB-
induced cytotoxic effect (Fig. 1a).  
To assess whether the metabolism of anandamide 
by COX-2 was necessary for endocannabinoid-
induced cell death as previously proposed, cells 
were incubated with AEA and the COX-2 inhibitor, 
indomethacin. Indomethacin (1 µM) did not modify 
the AEA effect on cell viability in irradiated 
keratinocytes (fig.1b). 
As anandamide can activate both cannabinoid 
receptors and TRPV1 we then investigated which 
“AEA-receptor” was mediating this effect of AEA. 
Cells were treated with AEA 30 µM and the CB1
selective antagonist AM251 (1 µM) and the specific 
TRPV1 antagonist, capsazepine (5 µM). Figure 1b 
shows that CB1 antagonist did not revert AEA 
effect. In contrast, capsazepine (5 µM), which alone 
did not modify cell viability, completely abolished 
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the increase in UVB-induced cell death by AEA 
(Fig.1b).  
Figure. 1. Effect of anandamide on keratinocytes (HaCat) 
cell viability in basal conditions and after UVB irradiation. 
Cell viability was evaluated before (CT) and after UVB (70 
mJ/cm2) irradiation (UV) a) HaCat keratinocytes were treated 
for 48 h by vehicle (CT) and AEA (3-30 µM) b) HaCat
keratinocytes were incubated with AEA 30 µM, COX-2 
inhibitor, indomethacin (IND) 1µM, CB1 selective antagonist, 
AM251 (1 µM) and TRPV1 selective antagonist, capsazepine 
(CPZ) 5 µM. Cell viability was expressed as the percentage of 
untreated controls, set to 100. Bars represent means ± SEM (n = 
12) *P<0.05 compared to respective control values. #P<0.05
compared to AEA 30 µM after UVB. 
Effect of cannabinoid receptors and TRPV1 on 
UVB-induced keratinocytes cell death 
In basal conditions neither the CB1 selective agonist 
ACEA (1 µM) nor the CB1 selective antagonist 
AM251 (1 µM) modified keratinocytes cell 
viability (Fig.2a). The CB2 selective agonist JWH 
133 (1-10µM) and the CB2 selective antagonist AM 
630 (1µM) had no effect (data not shown).  
Neither the CB1 selective agonist nor the CB1
selective antagonist modified modified UVB-
induced keratinocytes cell death (Fig. 2a). 
As a positive control, we used the TRPV1 agonist 
capsaicin (10 µM), which had no effect in basal 
conditions but after UVB irradiation replicated the 
effect of AEA 30 µM increasing the UVB-induced 
cytotoxic effect (Fig. 2b). This effect of capsaicin 
was also dependent on TRPV1 since it was 
completely reverted by capsazepine (Fig.2b).  
Figure. 2. Effect of CB1 receptor and TRPV1, in basal 
conditions and after UVB irradiation. Cell viability was 
evaluated before (CT) and after UVB (70 mJ/cm2) irradiation 
(UV).a) HaCat keratinocytes were incubated with CB1 selective 
agonist, ACEA (1 µM) and CB1 selective antagonist AM251 (1 
µM) b) HaCat keratinocytes were treated for 48 h with TRPV1 
agonist, capsaicin (CAPS) 10 µM and TRPV1 selective 
antagonist, capsazepine (CPZ) 5 µM. Cell viability results were 
expressed as the percentage of untreated controls set to 100. Bars 
represent means ± SEM (n = 12) * P<0.05 compared to controls. 
#P<0.05 compared to CAPS 10 µM after UVB. 
Discussion 
In this study we provide evidence that the 
prototypic endocannabinoid AEA that is produced 
in keratinocytes after UVB irradiation [8] increases 
UVB-induced human keratinocytes cell death. We 
also demonstrated that this AEA effect is TRPV1 
dependent.  Anandamide produced by keratinocytes 
after UVB irradiation might act at TRPV1 in a 
paracrine or autocrine manner and negatively 
regulates their survival. 
Acute UVB irradiation causes keratinocyte 
apoptosis and this programmed cell-death of UV-
damaged skin cells is a definitive cancer-prevention 
pathway. Furthermore keratinocyte apoptosis after 
UVB irradiation is a key mechanism in psoriatic 
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plaques clearance after phototherapy [15]. Our data 
support the concept that the fine-tuned endogenous 
endocannabinoid tone of the skin could contribute 
to eliminate damaged keratinocytes after UVB 
irradiation.    
In basal conditions, neither AEA nor the other CB1
and CB2 cannabinoid receptors agonists used 
suppressed keratinocyte cell viability. Indeed a 
slight increase of HaCat viability was observed 
with AEA at lower concentrations. This increase 
has already been described in a previous study [13]. 
By contrast, another research found that AEA, 
dose-dependently, inhibits proliferation and cell 
viability of human epidermal keratinocytes in 
culture [12].  However in that study a shorter 
incubation period with AEA was used and the 
effect of UVB radiation was not investigated. The 
authors proposed that AEA-induced keratinocyte 
death resulted from the sequential engagement of 
CB1 receptor and TRPV1 with consequent calcium 
influx [12]. UVB increases TRPV1 expression in 
both keratinocytes and human skin in vivo [6] and 
this could explain that we only observed TRPV1-
mediated AEA effect after UVB exposure.  The 
need for higher concentrations of AEA to reduce 
cell viability after UVB radiation is consistent with 
the lower affinity of AEA for TRPV1 in 
comparison to CB1, as clearly demonstrated in vitro 
through binding assays [10]. Furthermore the lack 
of effect of the CB1 selective agonist ACEA also 
corroborates this TRPV1 dependent pathway. 
Previous studies have shown that metabolism of 
AEA by COX-2 was important for AEA-induced 
cell death in tumorigenic keratinocytes and that 
neither CB1 nor CB2 nor TRPV1 receptors were 
required for this response [13] [5]. Interestingly, in 
our model with non-tumorigenic HaCat cells, COX-
2 inhibition by indomethacin did not modify the 
AEA effect in irradiated keratinocytes.  
In conclusion, our results suggest that AEA through 
TRPV1 decreases cell viability in keratinocytes 
after ultraviolet exposure. Endocannabinoids 
participate in the adaptive skin response to UVB 
radiation and could be in the future useful in 
combination to phototherapy for the treatment of 
hyperproliferative dermatoses such as psoriasis.  
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plaques clearance after phototherapy [15]. Our data 
support the concept that the fine-tuned endogenous 
e docannabinoid tone of the skin could contribute 
to eliminate damaged kera inocytes after UVB 
rradiation.    
In basal conditions, neither AEA nor the other CB1
and CB2 cannabinoid receptors agonists used 
suppressed keratinocyte cell viability. Indeed a 
slight increase of HaCat viability was observed 
with AEA at lower concentrations. This increase 
has already been described in a previous study [13]. 
By contrast, another research found that AEA, 
dose-dependently, inhibits proliferation and cell 
viability of human epidermal keratinocytes in 
culture [12].  However in that study a shorter 
incubation period with AEA was used and the 
effect of UVB radiation was not investigated. The 
authors proposed that AEA-induced keratinocyte 
death resulted from the sequential engagement of 
CB1 receptor and TRPV1 with consequent calcium 
influx [12]. UVB increases TRPV1 expression in 
both keratinocytes and human skin in vivo [6] and 
this could explain that we only observed TRPV1-
mediated AEA effect after UVB exposure.  The 
need for higher concentrations of AEA to reduce 
cell viability after UVB radiation is consistent with 
the lower affinity of AEA for TRPV1 in 
comparison to CB1, as clearly demonstrated in vitro 
through binding assays [10]. Furth rmore the lack 
of effect of the CB1 selectiv  agonist ACEA also 
orroborates this TRPV1 dependent pathway. 
Previous studies have show  that metabolism of 
AEA by COX-2 was important for AEA-induced 
cell death in tu origenic keratinocytes an  that 
neither CB1 nor CB2 nor TRPV1 receptors were 
required for this response [13] [5]. Interestingly, in 
our model with non-tumorigenic HaCat cells, COX-
2 inhibition by indomethacin did not modify the 
AEA effect in irradiated keratinocytes.  
In onclusion, our r sults suggest that AEA through 
TRPV1 decreases cell viability in keratinocytes 
after ultraviolet exposure. Endocannabinoids 
participate in the adaptive skin response to UVB 
radiation and could be in the future useful in 
combination to phototherapy for the treatment of 
hyperproliferative dermatoses such as psoriasis.  
References 
1.  Biro T, Toth BI, Hasko G, Paus R, Pacher P (2009) The 
endocannabinoid system of the skin in health and 
disease: novel perspectives and therapeutic 
opportunities. Trends Pharmacol Sci 30:411-420 
2.  Buckman SY, Gresham A, H le P, Hruz  G, Anast J, 
Masferrer J, Pentland AP (1998) COX-2 expression is 
induced by UVB exposure in human skin: implications 
for the development of skin cancer. Carcinogenesis 
19:723-729 
3.  Casanova ML, Blazquez C, Martinez-Palacio J, 
Villanueva C, Fernandez-Acenero MJ, Huffman JW, 
Jorcano JL, Guzman M (2003) Inhibition of skin tumor 
growth d angiogenesis in vivo by activati n of 
ca nabinoid receptors. J Clin Invest 111:43-50 
4.  Di Marzo V (2008) Tar eting the endocan abinoid 
sys em: to enhance or r duce? Nat Rev Drug Discov 
7:438-455 
5.  Kuc C, Jenkins A, Van Dross RT (2012) Arachidonoyl 
ethanolamide (AEA)-in uced apoptosis is mediated by 
J-series prostaglandins and is enhanced by fatty acid 
amide hydrolase (FAAH) blockade. Mol Carcinog 
51:139-149 
6.  Lee YM, Kim YK, Kim KH, Park SJ, Kim SJ, Chung 
JH (2009) A novel role for the TRPV1 channel in UV-
induced matrix metalloproteinase (MMP)-1 expression 
in HaCaT cells. J Cell Physiol 219:766-775 
7.  Maccarrone M, Di Rienzo M, Battista N, Gasperi V, 
Guerrieri P, Rossi A, Finazzi-Agro A (2003) The 
endocannabinoid system in human keratinocytes. 
Evidence that anandamide inhibits epidermal 
differentiation through CB1 receptor-dependent 
inhibition of protein kinase C, activation protein-1, and 
transglutaminase. J Biol Chem 278:33896-33903 
8.  Magina S, Esteves-Pinto C, Moura E, Serrao MP, 
Moura D, Petrosino S, Di arzo V, Vieira-Coelho MA 
(2011) Inhibition of basal and ultraviolet B-induced 
melanogenesis by cannabinoid CB(1) receptors: a 
keratinocyte-depe dent effect. Arch Dermatol Res 
303:201-210 
9.  Pacher P, Mechoulam R (2011) Is lipid signaling 
through cannabinoid 2 receptors part of a protective 
system? Prog Lipid Res 50:193-211 
10.  Pertwee RG (2010) Receptors and channels targeted by 
synthetic cannabinoid receptor agonists and antagonists. 
Curr Med Chem 17:1360-1381 
11.  T lek A, Biro T, Bodo E, Toth BI, Borbiro I, Kunos G, 
Paus R (2007) Inhibition of human hair follicle growth 
by endo- and exocannabinoids. FASEB J 21:3534-3541 
12.  Toth BI, Dobrosi N, Dajnoki A, Czifra G, Olah A, 
Szollosi AG, Juhasz I, Sugawara K, Paus R, Biro T 
(2011) Endocannabinoids modulate human epidermal 
keratinocyte proliferation and survival via the 
sequential engagement of cannabinoid receptor-1 and 
transient receptor potential vanilloid-1. J Invest 
Dermatol 131:1095-1104 
13.  Van Dross RT (2009) Metabolism of anandamide by 
COX-2 is necessary for endocannabinoid-induced cell 
death in tumorigenic keratinocytes. Mol Carcinog 
48:724-732 
14.  Van Dross RT, Hong X, Essengue S, Fischer SM, 
Pelling JC (2007) Modulation of UVB-induced and 
basal cyclooxy enase-2 (COX-2) expr ssion by 
apigenin in m use keratinocytes: role of USF 
trans ription factors. Mol Carcinog 46:303-314 
15.  Weatherhead SC, Farr PM, Jamieson D, Hallinan JS, 
Lloyd JJ, Wipat A, Reynolds NJ (2011) Keratinocyte 
apoptosis in epidermal re odeling and clearance of 
psoriasis induced by UV radiation. J Invest Dermatol 
131:1916-1926 
16.  Wilkinson JD, Williamson EM (2007) Cannabinoids 
inhibit human keratinocyte proliferation through a non-
CB1/CB2 mechanism and have a potential therapeutic 
value in the treatment of psoriasis. J Dermatol Sci 
45:87-92 
 
plaques clearance after phototherapy [15]. ur data 
support the concept that the fine-tuned endogenous 
endocannabinoid tone of the skin could contribute 
to eli inate d aged keratinocytes after  
irradiation.  
In basal conditio s, neither  nor the o r 1
and 2 cannabinoid receptors agonists used 
suppre sed keratinocy e e l viability. Indeed a 
slight increase of a at viability as ob erved 
ith  at lo er concentrations. his increase 
has already been described in a previous study [13]. 
y contrast, another research found that , 
dose-dependently, inhibits proliferation and ce l 
viability of hu an epider al keratinocytes in 
culture [12].  o ever in that study a shorter 
incubation period ith  as used and the 
effect of  radiation as not investigated. he 
authors proposed that -induced keratinocyte 
death resulted fro  the sequential engage ent of 
1 receptor and P 1 ith consequent calciu  
influx [12].  increases P 1 expression in 
both keratinocytes and hu an skin in vivo [6] and 
this could explain that e only observed P 1-
ediated  effect after  exposure.  he 
need for higher concentrations of  to reduce 
ce l viability after  radiation is consistent ith 
the lo er affinity of  for P 1 in 
co paris n to 1, as clearly de onstrated in vitro 
through binding assays [10]. Further re the lack 
of effect of the 1 selective agonist  also 
corrobo ates this P 1 dependent pa h ay. 
Previous studies have sho n tha  etabolis  of 
 by -2 as i portant fo  -induced 
ce l death in tu origenic keratinocytes and that 
neither 1 nor 2 nor P 1 receptors ere 
required for this response [13] [5]. Interestingly, in 
our odel ith non-tu origenic a at ce ls, -
2 inhibition by indo ethacin did not odify the 
 effect in irradiated keratinocyt .  
In conclusion, our results suggest that  through 
P 1 decreases ce l viability in keratinocytes 
after ultraviolet exposure. ndocannabinoids 
participate in the adaptive skin response to  
radiation and could be in the future useful in 
co bination to phototherapy for the treat ent of 
hyperproliferative der atoses such as psoriasis.  
eferences 
1.  Biro T, Toth BI, Hasko G, Paus R, Pacher P (2009) The 
endocannabinoid syste  of the skin in health and 
disease: novel perspectives and therapeutic 
opportunities. Trends Phar acol Sci 30:411-420
2.  Buck an SY, Gresha  A, Hale P, Hruza G, Anast J, 
asfe rer J, Pentland AP (1998) COX-2 expression is 
induced by UVB exposure in hu an skin: i plications 
for the develop ent of skin cancer. Carcinogenesis 
19:723-729 
3.  Casanova L, Blazquez C, artinez-Palacio J, 
Vi lanueva C, Fernandez-Acenero J, Hu f an J , 
Jorcano JL, Guz an  (2003) Inhibition of skin tu or 
growth and angiogenesis in vivo by activation of 
cannabinoid receptors. J Clin Invest 111:43-50 
4.  Di arzo V (2008) Targeting the endocann bino d 
syste : to enhance or reduce? Nat Rev Drug Discov 
7:438-455 
5.  Kuc C, Jenkins A, Van Dross RT (201 ) Arachidonoyl 
ethanola ide (AEA)-induced apoptosis is ediated by 
J-series prostaglandins a d is enhanced by fa ty acid 
a ide hydrolase (FAAH) blockade. ol Carcinog 
51:139-149 
6.  Lee Y , Ki  YK, Ki  KH, Park SJ, Ki  SJ, Chung 
JH (2009) A novel role for the TRPV1 channel in UV-
induced atrix eta loproteinase ( P)-1 expression 
in HaCaT ce ls. J Ce l Physiol 219:766-775 
7.  acca rone , Di Rienzo , Ba tista N, Gasperi V, 
Gue rieri P, Rossi A, Finazzi-Agro A (2003) The 
endocannabinoid syste  in hu an keratinocytes. 
Evidence that ananda ide inhibits epider al 
di ferentiation through CB1 receptor-dependent 
inhibition of protein kinase C, activation protein-1, and 
transgluta inase. J Biol Che  278:33896-33903 
8.  agina S, Esteves-Pinto C, oura E, Se rao P, 
oura D, Petrosino S, Di arzo V, Vieira-Coelho A 
(2011) Inhibition of basal and ultraviolet B-induced 
elanogenesis by cannabinoid CB(1) receptors: a 
keratinocyte-dependent e fect. Arch Der atol Res 
303:201-210 
9.  Pacher P, echoula  R (2011) Is lipid signaling 
through cannabinoid 2 r ceptors part of a protective 
syste ? Prog Lipid Res 50:193-211 
10.  Pertwee RG (2010) Receptors and cha nels targeted by 
synthetic cannabinoid receptor agonists and antagonists. 
Cu r ed Che  17:1360-1381 
11.  Telek A, Biro T, Bodo E, Toth BI, Borbiro I, Kunos G, 
Paus R (2007) Inhibition of hu an hair fo licle growth 
by end - and exocannabinoids. FASEB J 21:3534-3541 
12.  Toth BI, Dobrosi N, Dajnoki A, Czifra G, Olah A, 
Szo losi AG, Juhasz I, Sugawara K, Paus R, Biro T 
(2011) Endocannabinoids odulate hu an epider al 
keratinocyte proliferation and survival via the 
sequential engage ent of cannabinoid receptor-1 and 
transient receptor potential vani loid-1. J Invest 
Der atol 131:1095-1104 
13.  Van Dross RT (2009) etabolis  of ananda ide by 
COX-2 is necessary for endocannabinoid-induced ce l 
death in tu origenic keratinocytes. ol Carcinog 
48:724-732 
14.  Van Dross RT, Hong X, Essengue S, Fischer S , 
Pe ling JC (2007) odulation of UVB-induced and 
basal cyclooxygenase-2 (COX-2) expression by 
apigenin in ouse keratinocytes: role of USF 
transcription factors. ol Carcinog 46:303-314 
15.  eatherhead SC, Fa r P , Ja ieson D, Ha lin n JS,
Lloyd JJ, ipat A, Reynolds NJ (2011) Keratinocyte 
apoptosis in epider al re odeling and clearance of 
psoriasis i duced by UV radiation. J Invest Der atol 
131:1916-1926 
16.  ilkinson JD, i lia son E  (2007) Cannabinoids 
inhibit hu an keratinocyte proliferation through a non-
CB1/CB2 echanis  and have a potential therapeutic 
value in the treat ent of psoriasis. J Der atol Sci 
45:87-92 
E fect of ultraviolet B radiation on cutaneous endocannabinoid syste  
 
 
 
  
 
4 
plaques clearance after phototherapy [15]. Our data 
support the concept that the fine-tuned endogenous 
endocannabinoid tone of the skin could contribute 
to eliminate damaged keratinocytes after UVB 
irradiation.    
In basal conditions, neither AEA nor the other CB1
and CB2 cannabinoid receptors agonists used 
suppressed keratinocyte cell viability. Indeed a 
slight increase of HaCat viability was observed 
with AEA at lower concentrations. This increase 
has already been described in a previous study [13]. 
By contrast, another research found that AEA, 
dose-dependently, inhibits proliferation and cell 
viability of human epidermal keratinocytes in 
culture [12].  However in that study  shorter 
incubation period with AEA was used and the
effect of UVB radiation w s not inve tigated. The 
authors proposed that AEA-induced keratinocyt  
death resulted from th  sequential ngagement of 
CB1 receptor and TRPV1 with consequent calci m 
influx [12]. UVB increases TRPV1 expression in 
both keratinocytes and human skin in vivo [6] and 
this could explain that we only observed TRPV1-
mediated AEA effect after UVB exposure.  The 
need for higher concentrations of AEA to reduce 
cell viability after UVB radiation is consistent with 
the lower affinity of AEA for TRPV1 in 
comparison to CB1, as clearly demonstrated in vitro 
through binding assays [10]. Furthermore the lack 
of effect of the CB1 selective agonist ACEA also 
corroborates this TRPV1 dependent pathway. 
Previous studies have shown that metabolism of 
AEA by COX-2 was important for AEA-induced 
cell death in tumorigenic keratinocytes and that 
neither CB1 nor CB2 nor TRPV1 receptors were 
required for this response [13] [5]. Interestingly, in 
our model with non-tumorigenic HaCat cells, COX-
2 inhibition by indomethacin did not modify the 
AEA effect in irradiated keratinocytes.  
In conclusion, our results suggest that AEA through 
TRPV1 decreases cell viability in keratinocytes 
after ultraviolet xposure. Endocannabin ids
participate in the ad ptive skin r sponse to UVB 
radiation and could be in the future useful in 
combination to h totherapy for the treatment f 
hyperproliferative dermatoses such as psoriasis.  
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plaques clearance after phototherapy [15]. Our data 
support the concept that the fine-tuned endogenous 
e docannabinoid tone of the skin could contribute 
to eliminate damaged kera inocytes after UVB 
rradiation.    
In basal conditions, neither AEA nor the other CB1
and CB2 cannabinoid receptors agonists used 
suppressed keratinocyte cell viability. Indeed a 
slight increase of HaCat viability was observed 
with AEA at lower concentrations. This increase 
has already been described in a previous study [13]. 
By contrast, another research found that AEA, 
dose-dependently, inhibits proliferation and cell 
viability of human epidermal keratinocytes in 
culture [12].  However in that study a shorter 
incubation peri d with AEA was used and the 
effect f UVB radiation was not investig te . The 
auth rs propose  that AEA-induc d keratinocyte 
death resulted from the sequential engagement of 
CB1 r ceptor and TRPV1 with consequent calcium 
influx [12]. UVB increases TRPV1 expression in 
both keratinocytes and human skin in vivo [6] a d 
t is could explain that we only observed TRPV1-
mediated AEA effect after UVB exposure.  The 
need for higher concentrations of AEA to reduce 
cell viability after UVB radiation is consistent with 
the lower affinity of AEA for TRPV1 in 
comparison to CB1, as clearly demonstrated in vitro 
through binding assays [10]. Furth rmore the lack 
of effect of the CB1 selectiv  agonist ACEA also 
orroborates this TRPV1 dependent pathway. 
Previous studies have show  that metabolism of 
AEA by COX-2 was important for AEA-induced 
cell death in tu origenic keratinocytes an  that 
neither CB1 nor CB2 nor TRPV1 receptors were 
required for this response [13] [5]. Interestingly, in 
our model with non-tumorigenic HaCat cells, COX-
2 inhibition by indomethacin did not modify the 
AEA effect in irradiated keratinocytes.  
In onclusion, our r sults suggest that AEA through 
TRPV1 decreases cell viability in keratinocytes 
after ultraviolet exposure. Endocannabinoids 
participate in the adaptive skin response t  UVB 
radiation and could be in the future useful in 
combination to photo h rapy for the treatment of 
hyperproliferative ermatoses such as psoriasis.  
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Effect of ultraviolet B radiation on endocannabinoid metabolizing enzymes 
1,2,3S Magina *, 4Di Marzo V, 1,2E Moura, 4Petrosino S, 1D Moura1,2M A Vieira-Coelho 
1Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, 2Institute for Molecular and 
Cell Biology, 3Dermatology and Venereology Department, H. S. João, 4Endocannabinoid Research Group, Institute of 
Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Pozzuoli, NA, Italy 
Introduction Endocannabinoids are produced on demand and are rapidly cleared by a process of 
cellular uptake, followed by enzymatic metabolism. There is general consensus that the enzyme 
fatty acid amide hydrolase (FAAH) is the key-enzyme of the breakdown of anandamide, On the 
other hand, monoacylglycerol lipase (MAGL) is the major contribution for 2-AG metabolism. 
Aim To evaluate the influence of ultraviolet B (UVB) radiation on endocannabinoid enzymes in the 
three models of skin cell cultures. 
Methods Human SK-mel-1 melanoma cells (ATCC no. HTB-67), human HaCat keratinocytes, 
provided by Prof. N. Fusenig (Deutsches Krebsforschungszentrum, Heidelberg, Germany), were 
used. SK-mel-1 and HaCat cells, ratio 1.8:2, were co-cultivated. Cells in co-culture were exposed to 
high (7 mJ/cm2) dose of UVB light wavelength (312 nm). SK-mel-1 cells in monoculture were 
exposure to UVB light under the same conditions as the cells in co-culture. HaCat cells in 
monoculture were exposed to high (60 mJ/cm2) dose UVB light. The irradiation doses were defined 
according to cell type based on the UVB radiation effect on cell viability. Non-irradiated controls 
were not exposed to UVB light, but subjected to all other manipulations. MAGL activity and FAAH 
activity were measured as previously described (De Petrocellis L et al., 2011). 
Results 
Basal activity of both MAGL and FAAH was higher in HaCat cells than in SK-mel cells (Vmax;
84.13 and 16.65 versus 45.7 and 2.08 pmol/min/mg, respectively). 
Table 1- Influence of UVB irradiation on the activity of endocannabinoid metabolizing enzymes. Results expressed in 
percentage of the respective control value. 
  MAGL  (% control)  
FAAH  
(% control)
Sk-mel-1 
CT 100 100 
High UVB dose 103.8 159.6 
HaCat 
CT 100 100 
High UVB dose 135.0 108.1 
Co-cultures 
CT 100 100 
High UVB dose 94.3 130.4 
Conclusions The metabolizing enzymes in keratinocytes respond to UVB with an increase of 
MAGL activity whereas in melanoma cells and co-cultures only FAAH activity increases. 
De Petrocellis L et al. Br J Pharmacol. 2011 Aug;163(7):1479-94 
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Summary
Background: Catechol-O-methyltransferase (COMT) is a ubiquitous enzyme inactivating cat-
echolic compounds. COMT is expressed also in human skin samples, and in melanoma cells
it may be cytoprotective. A role of COMT in keratinocytes (HaCat) is unknown.
Objective: The objective of this study is to investigate whether ultraviolet-B (UVB) radiation
modifies COMT activity in melanocytes and HaCat and whether COMT inhibition plays a
role in UVB-induced cell death.
Methods: Human cell lines of melanotic melanoma (SK-mel-1) and HaCat were used. COMT
activity was evaluated under basal conditions and after UVB irradiation (311 nm) at a low
(8 mJ/cm2) and a high dose (60 mJ/cm2). Tolcapone 1 mM was used to inhibit COMT.
Results: Both SK-mel-1 and Ha-Cat cells express COMT activity. In SK-mel-1, COMT activity
is reduced nearly 50% both 24 h and 48 h after a high dose UVB. In Ha-Cat cells, COMT
activity increased 24 h after a high dose UVB but decreased at 48 h. Tolcapone increases
significantly the cytotoxic effect of high dose UVB irradiation only in HaCat. High concen-
trations of tolcapone reduced melanin levels in melanoma cells parallel to reduced cell
numbers.
Conclusions: Ultraviolet radiation differentially modifies COMT activity in melanoma cells
and HaCat. Furthermore, tolcapone increased death of HaCat after irradiation but did not
affect melanoma cells.
Keratinocytes (HaCat) and melanocytes are exposed tonumerous environmental insults, including ultraviolet
(UV) radiation, against which they form the body’s first line of
defense. UV radiation, particularly its ultraviolet-B (UVB) com-
ponent, initiates complex molecular processes, resulting in
tanning, inflammation, apoptosis, and skin cancer. In skin cells,
UVB exposure produces reactive oxygen species (ROS) and qui-
nones resulting in several types of DNA and lipid components
damage (1). Skin is endowed with a variety of enzymes and
oxidative stress-specific pathways, modified following UV
exposure that can reduce cell damage (2). Catechol-O-
methyltransferase (COMT) is an ubiquitous enzyme that cata-
lyzes the transfer of a methyl group from S-adenosylmethionine
(SAM) to endogenous and exogenous subtracts containing a
catechol moiety (3). Catecholic compounds may be oxidated
to quinones and again reconverted to the original catechols.
This redox cycling process produces potentially hazardous free
radicals that are all substrates of COMT (3). It has been
demonstrated by different authors that COMT is present in
melanocytes and that, during melanin synthesis, COMT may
reduce the formation of reactive quinones and therefore being
considered as one of the protective mechanisms of melanocytes
(4–6). The association of COMTval158met polymorphism with
low COMT activity with an increased risk of vitiligo in Chinese
population underscores this protective role of COMT (7). More
recently, a high mRNA expression level of COMT was found in
a reconstructed epidermis model prepared from human HaCat,
and a detoxifying effect was speculated, but the role of the
enzyme in HaCat has not been studied yet (8). Although UV
radiation is the major environmental stress to the skin, and
COMT is suggested to play a cytoprotective role, the influence
of UV radiation on COMT activity and the effect of COMT
inhibition on UV-induced cell death are unknown.
In order to investigate the influence of UV radiation on COMT
activity and the effect of COMT inhibition on UV-induced cell-
death, we chose two models of cell cultures, one with human
melanotic melanoma cells and the other with human HaCat.
COMT activity and cell viability in the absence and in the pres-
ence of a COMT inhibitor (tolcapone) were evaluated before and
after two irradiation doses of UVB (cytotoxic and noncytotoxic).
O R I G I N A L A R T I C L E
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Materials and methods
Materials
Minimum essential medium Eagle (MEM), antimycotic solution,
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES),
and synthetic melanin were purchased from Sigma-Aldrich, Inc.
(St. Louis, MO, USA).Tolcapone was synthesized at laboratory of
Chemistry, Department of Research and Development, BIAL
(Porto, Portugal). Fetal bovine serum (FBS) and trypsin were
purchased from Gibco (Paisley, UK). NaHCO3 and ethylenedi-
aminetetraacetic acid (EDTA) were purchased from Merck
(Darmstadt, Germany).
Cell line and culture conditions
Human SK-mel-1 melanoma cells (ATCC n°. HTB-67) were
grown routinely in MEM, supplemented with 10% FBS, 1%
antimycotic solution, 25 mM HEPES, and 0.26 M NaHCO3, at
37°C in a 5% CO2 (v/v) humidified atmosphere. Human HaCat,
provided by Prof. N. Fusenig (Deutsches Krebsforschungszen-
trum, Heidelberg, Germany), were grown in Dulbecco’s modi-
fied eagle’s medium (DMEM) supplemented with 10% FBS, 1%
antimycotic solution, and 0.44 M NaHCO3. Cells were main-
tained at < 80% confluency, at 37°C in a 5% CO2 (v/v), humidi-
fied atmosphere.
For experiments without irradiation, cultures were incubated
for 48, 72, and 96 h with MEM medium containing tolcapone
(0.01–100 mM), and the medium was replaced every 24 h until
the end of the experiment. COMT inhibitor was directly applied
at a final dimethyl sulfoxide (DMSO) concentration less than
0.01% (v/v). No significant influence of the vehicle was
observed on any of the parameters determined.
Melanin determination
The melanin content of cells was determined according to Rad
et al. (9). Briefly, cells were centrifuged at 300¥g for 5 min,
resuspended in 500 ml of a NaOH (1 M, in 10% DMSO) solution
and incubated at 80°C for 2 h. This was followed by centrifuga-
tion at 500¥g for 10 min, and the resulting supernatant was used
for measurement of melanin absorbance at 420 nm in a Power-
Wave™ HT microplate scanning spectrophotometer (BioTek
Instruments, Inc., Winooski, Vermont, USA). Synthetic melanin
was used to construct a standard curve for the range of
1–100 mg/ml.
Cell viability and protein content determination
Harvested cells were centrifuged at 300¥g for 5 min at room
temperature, washed twice with phosphate-buffered saline (PBS)
and resuspended in 1 ml of PBS. From this suspension, 180 ml
were transferred into a black/clear bottom Microtest™ 96-well
Assay Plate, Oplilux™ (BD Biosciences, Franklin Lakes, NJ, USA)
for cell viability assay. Cell viability was measured using
calcein-AM (Molecular Probes, Inc., Eugene, OR, USA) according
to the manufacturer’s instructions. Each well containing 180 ml
of cell suspension was loaded with 20 ml of calcein-AM (10 mM,
in PBS solution). Fluorescence was measured at 485 nm excita-
tion and 530 nm emission wavelengths using a SpectraMax,
Gemini XS spectrofluorometer (Molecular Devices, Sunnyvale,
CA, USA) at 40 min incubation at room temperature.
The protein content in the samples was determined by the
method of Bradford (10) with bovine serum albumin as standard.
UVB irradiation
Melanocytes in culture were washed with PBS and then resus-
pended in 1 ml of PBS and returned to the plate well for exposure
to low (8 mJ/cm2) and high (60 mJ/cm2) doses of UVB light
(312 nm), emitted by a preheated, filtered, UV lamp (VL-6.M,
Vilber Lourmat, Marne-La-Vallée, France) at t = 0 min. This was
followed by 24 or 48 h incubation period after which the cells
were washed with PBS. HaCat cells in monoculture were washed
with PBS and then exposed to low (8 mJ/cm2) and high (60 mJ/
cm2) dose UVB light at t = 0 min.
The low and high irradiation doses were defined according to
UVB radiation effect on cell viability. With low UVB doses, cell
viability was unchanged; by contrast, the high doses produced a
cytotoxic effect. Nonirradiated controls were not exposed to UVB
light but subjected to all other manipulations. UV dosimetry was
performed with aWaldmann 585.100 UV-meter (HerbertWald-
mann GmbH & Co., Villingen-Schwenningen, Germany).
For experiments with UVB and COMT inhibition, cultures
were incubated for 24 and 48 h with MEM medium containing
tolcapone (1 mM), and the medium was replaced every 24 h
until the end of the experiment.Tolcapone (1 mM) was present in
incubation medium 1 h before irradiation.
COMT assay
COMT activitywas evaluated by the ability tomethylate adrenaline
to metanephrine, as previously described (3). Aliquots of 100 ml
of enzyme preparation were preincubated for 20 min with 80 ml
of phosphate buffer (5 mM); thereafter, the reaction mixture was
incubated for 5 min with increasing concentrations of adrenaline
(0.1–30 mM) in the presence of a saturating concentration of the
methyl donor (SAM, 100 mM), the incubationmedium contained
also pargyline (100 mM), MgCl2 (100 mM) and EGTA (1 mM).
The preincubation and incubation were carried out at 37°C, in
conditions of light protection, with continuous shaking and
without oxygenation. In experiments conducted with the aim of
studying the effect of the COMT inhibitor, the reaction mixture
was preincubated for 20 min with adrenaline 30 mM and increas-
ing concentrations of tolcapone. KM and Vmax values for COMT
activity were calculated from nonlinear regression analysis using
the GraphPad Prism statistics software package (version 5.0;
GraphPad Software, La Jolla, California, USA). For the calculation
of the IC50, the parameters of the equation for one site inhibition
were fitted to the experimental data.
For irradiation experiments COMT activity was evaluated 24
and 48 h after UVB irradiation (low and high dose), and the
mediumwas replaced every 24 h until the end of the experiment.
Magina et al.
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Na+, K+-ATPase assay
Na+-K+-ATPase activity in melanoma cells was used to exclude a
nonspecific effect of UVB irradiation on cellular enzymatic activ-
ity.The activitywasmeasured by themethod ofQuigley &Gotterer
(11), with minor modifications. Briefly, melanocytes were per-
meabilized by rapid freezing, in liquid nitrogen, and thawing.The
reaction mixture contained (in mM): buffer [imidazole 37.5,
NaCl 75, KCl 5, sodium EDTA 1, MgCl2 5, NaN3 6, tris(hydro-
xymethyl)aminomethane(tris)hydrochloride 75] and 100 ml cell
suspension (100 mg protein). The reaction was initiated by the
addition of 4 mM ATP. For determination of ouabain-insensitive
adenosine 5'-triphosphate (ATPase), NaCl and KCl were omitted,
and ouabain (1 mM; 100 ml) and vehicle (water; 100 ml) were
added to the assay. After incubation at 37°C for 20 min, the
reaction was terminated by the addition of 50 ml of ice-cold
trichloroacetic acid. Samples were centrifuged (1500¥g), and
liberated Pi in supernatant was measured by spectrophotometry at
740 nm. Na+, K+-ATPase activity is expressed as nanomoles Pi per
milligram protein per minute and determined as the difference
between total and ouabain-insensitive ATPase.
Statistical analysis
Data are presented as means  standard error of the mean
or 95% confidence intervals. Analysis of variance was used
to analyze differences. Values of P < 0.05 are considered
significant.
Results
Incubation of melanocytes (SK-mel-1) and HaCat homogenates
in the presence of increasing concentrations of adrenaline
resulted in a concentration-dependent formation of metane-
phrine. We showed that SK-mel-1 and HaCat cells express
COMT activity [Vmax = 8.91  0.29 nmol./(mg protein)/h;
KM = 0.78 (0.52-1.03) mM)] and [Vmax = 4.43  0.22 nmol./
(mg protein)/h; KM = 4.65 (3.14- 6.17) mM)], respectively. Tol-
capone produced a concentration-dependent decrease in COMT
activity with an IC50 value of 4.3 (2.8-6.4) nM for SK-mel-1 and
6.3 (2.0–19.6) nM for HaCat cells.
In our culture model, time-course experiments (48, 72 and
96 h) showed that tolcapone (0.01–10 mM) had no influence
on melanin content but 30–100 mM reduced it dose depend-
ently (Fig. 1a). Although this effect was already observed after
72 h (data not shown), it was more evident after 96 h
(Fig. 1a), and it was associated with a reduction in cell viability
(Fig. 1b). Two well-known melanogenesis inhibitors, kojic acid
(1 mg/ml) and hydroquinone (40 mg/ml), were used as posi-
tive controls and both had a significant cytotoxic effect similar
to tolcapone 30 mM and 100 mM, respectively (data not
shown).
COMT activity in HaCat increased 24 h after high dose UVB
irradiation (60 mJ/cm2) but decreased 48 h after this irradiation
(Fig. 2b). By contrast, in melanoma cells, COMT activity has
already decreased 24 h after high dose irradiation (Fig. 2a) when
no cytotoxic effect of UVB was present (Fig. 3a). Na+-K+-ATPase
Fig. 1. (a) Cellular melanin content and (b) cell viability in SK-mel-1 cells after 96 h incubation with increasing concentrations of tolcapone
(0.01–100 mM). Melanin and cell viability were determined in total cell extracts and expressed as the percentage of untreated controls. Bars
represent means  SEM of eight experiments. *P < 0.05 compared with respective control values. SK-mel-1, melanocytes, SEM, standard error of
the mean.
UVB radiation modifies COMT activity
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activity in melanoma cells excluded a nonspecific effect of UVB
irradiation on cellular enzymatic activity since, after UVB irradia-
tion in the same conditions, the activity of this enzyme did not
change and the results [in nmol./(mg protein)/min] were
35.38  1.18, 29.67  2.73, and 36.13  4.29, in control situ-
ation, 24 h and 48 h after high dose UVB irradiation, respectively.
Tolcapone (1 mM) did not change cell viability of melanoma
cells after UVB irradiation (Fig. 3a), but it decreased significantly
the viability of HaCat at 48 h after a high dose UVB irradiation
(Fig. 3b).
Discussion
The results presented here show that 24 h after high dose UVB
irradiation, COMT activity was significantly increased in HaCat,
but it was decreased in melanoma cells. The effect in melanoma
cells persisted 48 h after and was not a nonspecific effect on
cellular enzymatic activity since the Na+-K+-ATPase activity was
not modified. On the other hand, the effect in HaCat was inverted
48 h after irradiation, when a reduction in COMT activity was
observed.
As expected, high dose UVB irradiation had a cytotoxic effect
in both HaCat and melanoma cells, but tolcapone significantly
increased this UVB-cytotoxic effect only in HaCat. Although an
effect of tolcapone itself cannot be excluded, this response may
suggest a protective role of COMT in this skin type cell. UV
radiation results in an increase generation of ROS that over-
whelms the antioxidant defense mechanisms of the target system
(1). COMT might be one of the several enzymes that modulate
this oxidative stress in HaCat.
The single COMT gene codes for two separate enzymes are
soluble (S-COMT) and membrane-bound (MB-COMT) forms.
Both COMT isoforms have been reported to be widely distrib-
uted in the brain and peripheral tissues; however MB-COMT, is
more prevalent in the brain tissues and the highest amount of
S-COMT is located in the liver, duodenum, and kidneys (12).The
two isoforms of COMT are proposed to have at least partially
distinct roles; in according with these different tissue distribu-
tions, MB-COMT is believed to be mainly responsible for
O-methylation of neurotransmitters; on the other hand, S-COMT
is thought to have a main detoxification role (12). Despite the
two COMT forms were not separated, we found much lower Km
values for COMT activity in melanoma cells than in HaCat and we
can speculate that MB-COMT is the predominant isoform in
melanoma cells and that S-COMT is more important in HaCat.
These data are in agreement with previous studies reporting that
Fig. 2. COMT activity 24 h and 48 h after
UVB irradiation with low (8 mJ/cm2) and
high (60 mJ/cm2) doses in SK-mel-1 (a)
and HaCat (b). The concentration of
adrenaline used was 30 mM. Bars represent
means  SEM of eight experiments. P < 0.05
compared with respective control values.
COMT, catechol-O-methyltransferase; CT,
control; UVB, ultraviolet-B; SK-mel-1,
melanocytes; HaCat, keratinocytes; SEM,
standard error of the mean; UV, ultraviolet.
Fig. 3. Effect of COMT inhibition by
tolcapone (1 mM) in cell viability 24 h and
48 h after UVB irradiation with low
(8 mJ/cm2) and high (60 mJ/cm2) doses
in SK-mel-1 (a) and HaCat (b). Cell viability
results are expressed as the percentage of
untreated controls. Bars represent
means  SEM of eight experiments.
*P < 0.05 compared with respective control
values, # P < 0.05 compared with respective
irradiation dose without tolcapone. COMT,
catechol-O-methyltransferase; CT, control;
UVB, ultraviolet-B; SK-mel-1, melanocytes;
HaCat, keratinocytes; SEM, standard error of
the mean.
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a substantial part of COMT activity in melanocytes was repre-
sented by the membrane-bound enzyme (4). Since melanocytes
are considered as ‘neurons of the skin’, this distribution is not
surprising. On the other hand, as HaCat are the main barrier to
the transmission of UVB to the underlying melanocytes, they
have several mechanisms to protect themselves from the toxicity
of UV radiation. The immediate increase in COMT activity that
we observed may represent one of these mechanisms. Corrobo-
rating this hypothesis is the increase of UVB-cytotoxic effect
when COMT activity was inhibited by tolcapone. Since this effect
was not observed in melanoma cells, we could hypothesize that
different COMT isoforms may have different responses to UVB
irradiation and consequently different roles in UVB-cell protec-
tion but this needs further investigation.
Although it has been described in the past an induction of
cytotoxicity in melanoma cells through inhibition of COMT (13)
and it was speculated a potential role for COMT in melanogenesis
(5), in our melanoma cell line we did not find these effects.
Tolcapone in concentrations up to 10 mM (IC50 value was
4.3 nM) did not modify either cell viability or melanin content,
and the effect observed with higher concentrations can be
explained by the drug toxicity (14). The rate-limiting step in
melanogenesis is the oxidation of tyrosine to 3,4-dihydroxy-L-
phenylalanine (L-DOPA) by the enzyme tyrosinase, and since it
has been shown that skin tyrosinase activity is significantly
increased in hairless COMT-deficient male pups, an increase in
melanin synthesis could be expected (15). This potential role of
the O-methylation of L-DOPA by COMT in the regulation of
melanogenesis was also suggested in the paper by Axelrod et al.
(16) and substantiated by the finding that highly pigmented
melanomas show less COMT activity than low pigmented
melanomas (17). In our experimental conditions, melanin levels
were not altered with COMT inhibition, although we used a
melanoma cell line instead of a primary human melanocyte
culture and that may constitute a limitation in extrapolating our
results to normal skin physiology. On the other hand, it should be
noted that melanoma cell lines have been extensively used to
study melanogenesis and UV radiation effects (9, 18).
Conclusion
Tolcapone increased death of HaCat after irradiation but did not
affect melanoma cells, and although this suggests a protective
role for this enzyme in HaCat, a direct effect of tolcapone cannot
be excluded. Furthermore UVB, radiation differentially modifies
COMT activity in HaCat and melanoma cells.
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Abstract
Background –Narrowband ultraviolet B (nbUVB) phototherapy is widely used in psoriasis treatment. UVB 
irradiation decreases catechol-O-methyltransferase (COMT) activity in human keratinocytes and melanoma 
cells. COMT activity is higher in psoriatic lesions than in normal skin but the effect of nbUVB on COMT 
activity in patients with psoriasis is unknown.  
Objectives - Evaluate COMT activity in patients with psoriasis and to determine whether nbUVB modifies this 
activity. 
Methods - An open observational study was conducted with 20 psoriasis patients and 15 healthy volunteers. 
Patients were treated with nbUVB thrice weekly during six weeks and evaluated at baseline, three and six weeks 
after phototherapy and four weeks after stopping. In each evaluation body mass index (BMI), Psoriasis Area and 
Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were calculated and blood samples for 
erythrocytes soluble (S-) COMT activity assessment were taken.  
Results – Before phototherapy (baseline), using a single concentration of substrate adreneline (1000µM), S-
COMT activity levels (pmol/mg protein/h) were significantly higher in psoriasis patients (41.95±16.14) than in 
controls (30.38±14.89). After nbUVB treatment for psoriasis, S-COMT activity significantly decreased to 
34.43±9.18. This decrease was positively correlated with baseline activity. Four weeks after stopping 
phototherapy, S-COMT activity returned to levels identical to ones before treatment (baseline levels). After 
phototherapy, PASI score improved significantly but no correlation to baseline S-COMT values or decrease in S-
COMT activity was found. 
Conclusions - This study shows that baseline S-COMT activity is higher in psoriasis patients than in controls 
and that this activity is significantly decreased by nbUVB treatment for psoriasis. This decrease is more evident 
in patients with higher baseline S-COMT activity. Key words nbUVB, psoriasis, COMT 
Introduction 
Psoriasis is a chronic inflammatory disease of the 
skin that has been linked with psychiatric and 
cardiovascular co-morbidities although the 
underlying mechanisms remain unclear [1] [2]. The 
catechol-O-methyltransferase (COMT) enzyme 
degrades dopamine, noradrenaline, adrenaline, and 
other catechol-containing compounds and is 
dynamically regulated in response to environmental 
stimuli. The enzyme has been involved in various 
neurobiological functions including mood, 
cognition, stress response, pain, immunological 
response, cardiovascular control and fat distribution 
[3] [4] [5]. COMT activity in humans can be 
reliably measured in blood samples since its 
activity in erythrocytes reflects central and 
peripheral activities [6] [7]. The gene encoding the 
COMT enzyme has functional polymorphisms 
contributing to the interindividual variability in the 
enzymatic activity [3]. In Chinese population, no 
significant association was found between the low 
COMT activity, COMTval158met polymorphism, 
and the risk of psoriasis [8].  
COMT is expressed at high levels in human skin 
and increased COMT activity in lesional psoriatic 
skin compared with nonlesional skin or with skin of 
normal individuals has been reported, suggesting a 
role for catecholamines on psoriasis lesion [9] [10]. 
However the impact of psoriasis treatment on 
COMT activity has never been studied. We have 
recently shown that ultraviolet B (UVB) irradiation 
decreases COMT activity in human keratinocytes 
and melanoma cells [11]. Since narrowband UVB 
phototherapy (nbUVB) is widely used in psoriasis 
treatment the aim of the present study was to 
evaluate COMT activity in psoriasis patients and 
examine whether this activity is modified by 
nbUVB treatment. 
Effect of ultraviolet B radiation on cutaneous endocannabinoid system 
 
92 
 
  
  
2 
Table 1. Characteristics among the 20 patients before starting phototherapy (baseline), three (W3) and six (W6) weeks after nbUVB 
phothotherapy thrice weekly and one month after the last nbUVB exposure (W10. 
values are mean±SD (range). BMI, body mass index; PASI, Psoriasis Area and Severity Index, DLQI; Dermatology Life Quality Index. 
*P<0.05 (W3 vs. baseline), **P<0.05 (W6 vs. W3), # P<0.05 (W6 vs. baseline),*** P<0.05 (W10 vs. W6).  
Patients and methods
The regional ethical committee approved this open 
observational study and all participants gave 
informed consent. The inclusion criteria were 
patients with chronic plaque psoriasis, indication 
for phototherapy and free of psoriasis medication or 
other systemic therapy, at least 12 weeks before and 
during the study. Patients presenting psoriatic 
arthritis or other inflammatory diseases were 
excluded. We enrolled 20 patients with Fitzpatrick 
skin types II-III and 15 matched controls with no 
evidence of psoriasis or other systemic 
inflammatory disease. Subjects were admitted only 
in winter and early spring. Psoriasis severity was 
measured by Psoriasis Area and Severity Index 
(PASI) and Dermatology Life Quality Index 
(DLQI). To diminish subjectivity, the same 
dermatologist evaluated PASI. All psoriasis patients 
were evaluated before phototherapy (baseline), after 
three (W3) and six (W6) weeks of treatment and 
four weeks after stopping (W10). In each evaluation 
body mass index (BMI), PASI and DLQI were 
calculated and blood samples for red blood cell 
soluble S-COMT assay were taken in the morning, 
in a fasting state.  
The nbUVB irradiation (311±2 nm) was 
administered using a Waldmann 7001 cabin (UVB-
TL01; Waldmannn Medizintechnik, Villigen-
Schwenningen, Germany); the initial dose was 0.3-
0.5 J/cm2, according to patient’s phototype, 
increasing 0.1 J/cm2 in every session until a 
maximum of 2.0 J/cm2, totalizing eighteen nbUVB 
exposures (thrice weekly, six weeks). Only eyes 
and genitalia were shielded during the irradiation.
S-COMT activity was determined according to the 
method of Schultz et al with minor modifications 
[12]. In brief, prewashed erythrocyte samples were 
hemolyzed with four volumes of ice-cold water. 
After vortexing, the samples were left standing on 
ice for 10 minutes and then centrifuged for 20 min 
at 4°C at 20,000 g. The supernatant was used for 
the S-COMT assay, which was carried out 
immediately after sample preparation. The 
incubation mixture contained 300 L enzyme 
preparation, 375 L incubation medium, and 75 L 
10 mM (final concentration 1 mM) adrenaline as 
the enzyme substrate. The final 750 L reaction 
volume contained 100 mM sodium phosphate 
buffer (pH 7.8), 2 mM MgCl2, and 200 M S-
adenosyl-L-methionine. The samples were 
incubated in a water bath at 37°C for 60 min. The 
tubes were transferred to ice, and the reaction was 
 Baseline W3 W6 W10 
Sex, women
men (%) 
9(42.1)/ 
11(57.9) 
- - - 
Age (Years) 
50.5±13.4 
(21-69) 
- - - 
BMI (Kg/m2) 
26.42±4.08 
(18.00-34.20) 
26.49±3.99 
(17.90-33.80) 
26.55±4.02 
(18.20-33.90) 
26.43±3.85 
(18.20-33.10) 
UVB total dose (J/cm2) 
0 
6.62±0.53 
(6.3-8.1) 
21.82 ± 3.97 
(14.0-29.1) 
- 
PASI 
9.74±4.70 
(5-20) 
4.95±3.55* 
(1-14) 
2.16±2.54**#
(0-7) 
2.84±3.17 
(0-12) 
DLQI 
9.95±6.52 
(1-23) 
5.32±5.15* 
(0-17) 
3.74±4.3**#
(0-12) 
3.42±4.19 
(0-12) 
COMT 
KM
(µM) 
212±51 216±51 218±43 212±47 
Vmax
(pmol/mg prot/h) 
51.05±3.22 43.39±2.69 41.39±2.14# 49.59±2.85*** 
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  stopped by adding 75 L of ice-cold 2 M perchloric acid. After 10 min, the samples were centrifuged 
for 10 min at 4°C at 5400 g, and 500 
the supernatant filtered on 0.22-m pore size Spin
X filter tubes (Costar) were used for the assay of 
metanephrine by means of high performance liquid 
chromatography with electrochemical detection. S
COMT activity was expressed as the amount of 
metanephrine formed (in pmol) per mil
protein in the sample, per hour (pmol/mg prot/h), 
by the action of COMT on a single concentration 
(1000 µM) or on increasing concentrations (5
µM) of the substrate adrenaline to perform kinetic 
studies.  
The kinetic parameters, Vmax (maximum
and KM (Michaelis-Menten constant) values were 
calculated from non-linear regression analysis by 
using the Graphpad Prism Software package 
(version 5.0). Data are presented as mean±SD and 
repeated measures of ANOVA followed by 
student’s paired t test was used to determine the 
statistical significance. Values of P<0.05 are 
considered significant. The correlation analysis was 
performed by calculating Spearman coefficient 
correlation. 
Results 
Baseline data and the effect of nbUVB for the 
different parameters studied in psoriasis patients are 
summarized in Table 1. Phototherapy significantly 
reduced PASI and DLQI scores (P<0.0001) but did 
not change BMI. Before phototherapy (baseline) 
there was some interindividual variability of S
COMT activity but, using a single concentration of 
substrate adrenaline (1000µM), mean values were 
significantly higher in psoriasis patients 
(41.95±16.14 pmol/mg prot/h, ranging from 19.20 
to 70.61) compared with controls (30.38±14.89 
pmol/mg prot/h, ranging from 12.39 to 
(Fig.1). In psoriasis patients, nbUVB phototherapy 
significantly decreased (P<0.05) COMT activity, 
resulting in a consistent decrease, to levels identical 
to controls, at the end of treatment (W6) (Fig.2). 
Four weeks after stopping phototherapy (W10
COMT Vmax values returned to baseline levels 
(Table 1). Change in the enzyme activity was due to 
a variation on Vmax values with no change in KM 
values (Table 1). The magnitude of decrease in S
COMT activity after phototherapy (∆
positively correlated with enzyme activity before 
phototherapy (P<0.0001;R2=0.76). No significant 
correlation was found between baseline S
or ∆S-COMT and the following variables: age, 
baseline BMI, baseline PASI, ∆PASI, baseline 
L aliquots of 
-
-
ligram of 
-2000 
 velocity) 
-
54.65) 
), S-
-
S-COMT) was 
-COMT 
DLQI, ∆DLQI, and cumulative nbUV
Figure 1. Red blood cell soluble (S
(pmol/mg prot/h) in psoriatic patients (n=20) and in controls 
(n=15), using a single concentration of substrate adrenaline 
(1000 µM). Each circle represents a patient , *P<0.05. 
Figure 2. Red blood cell soluble (S
prot/h) in psoriatic patients (n=20) before (baseline) and six 
(W6) weeks after nbUVB phototherapy thrice weekly, using 
increasing concentrations of the substrate adrenaline, *P<0.05. 
Discussion 
The present study demonstrates that compared with 
controls, patients with psoriasis have significantly 
higher erythrocyte S-COMT activity. NbUVB 
phototherapy significantly decreased S
activity, while clearing psoriasis. This UVB effect 
is in agreement with our data from human 
keratinocytes and melanoma cell lines where 48h 
after a high dose UVB (311nm) irradiation COMT 
3 
B dose. 
-COMT) baseline activity 
-COMT) activity (pmol/mg 
-COMT 
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activity was significantly decreased in both cell 
types [11].  
The previously reported lack of association between 
low activity COMTval158met polymorphism and 
psoriasis risk [8] is in agreement with the high 
erythrocyte S-COMT activity observed in our 
psoriasis patients. Furthermore, higher activity of 
COMT in lesional compared with nonlesional skin 
was observed in patients with psoriasis, suggesting 
a role for this enzyme in psoriasis [10]. It has also 
been reported that in several neurological cases 
treatment with levodopa, an important substrate of 
COMT, a significant improvement in 
accompanying psoriasis was observed and that in a 
study of nineteen cases of psoriasis treated with 
levodopa, most of them showed improvement [13] 
[14].  
Phototherapy has been shown to induce apoptosis, 
inhibition of cell proliferation and 
immunosuppression but little is known about the in 
vivo effect of phototherapy at the enzymatic level. 
NbUVB reduces tumor necrosis factor  (TNF) 
serum levels [15] and COMT expression is 
regulated by TNFα in a tissue-specific way [16] 
[17]. It can be speculated that the observed 
reduction in COMT activity might in part be related 
to the TNFα pathway.   
COMT has attracted strong neuroscientific interest 
due to its central role in brain catecholamines 
signaling and has been linked to both depression 
and anxiety with contradictory results [4] [18] [3]. 
Patients with psoriasis are at increased risk for the 
development of depression, anxiety, and suicidality 
compared with the general population [1]. However 
the mechanisms by which psoriasis is associated 
with psychiatric outcomes are not completely 
understood and the role of COMT has never been 
studied. On the other hand, it is well known that 
phototherapy for psoriasis results in improved well-
being and we hypothesize that phototherapy-
induced decrease in COMT activity could be 
involved [19]. 
We found a positive correlation between baseline 
COMT activity and the magnitude of nbUVB-
induced decrease in COMT activity. Despite not 
having found a correlation with clinical response 
the hypothesis that COMT activity could be related 
with therapeutic response to nbUVB treatment 
should not be excluded. Keratinocytes express beta 
2 adrenergic receptors and produce adrenaline [20]. 
It has been proposed that the beta 2 adrenergic 
receptor activation plays a major role in calcium 
homeostasis, differentiation and proliferation in 
human keratinocytes [20]. More recently reduction 
of beta 2 adrenergic response in keratinocytes has 
been implicated in the pathogenesis of psoriasis 
reviewed in [21]. Considering the nbUVB-induced 
decrease in S-COMT in psoriasis patients and our 
previous data of UVB-induced decrease in COMT 
activity in human keratinocyte cell lines [11] we 
may speculate that nbUVB in some way improve 
the disease by reducing adrenaline metabolism and 
consequently increasing beta2 adrenergic response 
in keratinocytes. Although erythrocyte S-COMT is 
considered a good indicator of COMT activity in 
other tissues, the effect of nbUVB on cutaneous 
COMT activity in psoriasis patients should be 
addressed. It was previously described [22] higher 
levels of cutaneous COMT activity in vitiligo 
patients than in healthy controls but such 
differences were not found in erythrocyte S-COMT 
activity. Taken together our results from psoriasis
erythrocyte S-COMT activity and Bamshad et al 
[10] data from COMT activity in lesional psoriatic 
skin, we could suggest that contrarily to vitiligo, in 
psoriasis both erythrocytes and cutaneous COMT 
activities are higher than in controls.  
This study has some limitations: it is an 
observational study and a direct causal relationship 
between COMT activity and psoriasis could not be 
established and healthy volunteers were not 
irradiated for obvious ethical reasons. The 
correlation between COMT activity, serum 
cytokine levels and the incidence of psoriasis 
comorbidities remains to be evaluated in future 
studies.  
Our data indicate that COMT activity is higher in 
patients with psoriasis and that nbUVB decreases 
S-COMT activity, particularly in those patients 
with high baseline levels, while clearing psoriasis. 
COMT participates in an adaptive response to 
nbUVB exposure, the clinical and psychological 
impact of this response needs to be further 
iinvestigated. 
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  opment of new blisters. Azathioprine 50 mg daily was startedas adjuvant therapy to create a corticoid-sparing regimen, but
was discontinued soon because of gastrointestinal side-effects.
Two months later, the patient achieved complete remission.
We, for the first time, identify laminin-332 antibodies as the
cause of orf-induced pemphigoid. The mechanism involved in
the relation between orf and pemphigoid is still unclear. There
might be a homology between laminin-332 and virus proteins,
leading to a cross-reactivity also known as molecular mimicry.
We performed a protein-protein blast of all protein sequences
of the four orf strains whose complete genomes are deposited at
NCBI GenBank (NZ2, OV-SA00, OV-18A2 and D1701) against
all seven transcript variants of laminin-332. Unlike the situation
described for the torque teno virus and the 180-kDa bullous
pemphigoid antigen9 we found no overlap that was the size of
an epitope (6–7 amino acids). The largest overlap was restricted
to only four consecutive amino acids. If molecular mimicry of
orf underlies pemphigoid here then it probably is a conforma-
tional epitope, which would also account for it binding to
native skin substrate but not on immunoblot. On the other
hand, it has been suggested that orf could alter basement mem-
brane proteins, making them more antigenic.3 Using knockout
skin for future cases could demonstrate if laminin-332 is the
consistently targeted antigen in orf-induced pemphigoid.
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Narrowband ultraviolet B treatment for psoria-
sis increases serum vitamin A levels
DOI: 10.1111/j.1365-2133.2012.11006.x
MADAM, Vitamin A (retinol) is obtained from diet, stored
mainly in liver and adipose tissue and released ‘on demand’.
It is primarily transported bound to the adipokine, serum reti-
nol-binding protein-4 (RBP4).1,2 The skin contains retinol-
metabolizing enzymes and stores significant amounts of retinol
as retinyl esters (RE).2,3 Retinol regulates several cutaneous
responses but little is known about the mechanisms that
mobilize its stores.2,3
Photodegradation of cutaneous retinol and RE has been
observed following exposure to ultraviolet (UV) radiation
(UVR), either UVA or UVB.3–5 This photolability suggests that
circulating retinol might be affected by phototherapy. No differ-
ences were observed in plasma vitamin A levels in volunteers
exposed to UVR,6 but this issue should be analysed further. Our
aim was to examine whether narrowband UVB (NB-UVB)
phototherapy for psoriasis modifies vitamin A balance.
Patients with psoriasis, indication for phototherapy, and free
of medication at least 12 weeks before and during the study
were included. Psoriasis severity was measured by Psoriasis Area
and Severity Index (PASI) and Dermatology Life Quality Index
(DLQI). All patients were evaluated before phototherapy (base-
line), after 3 (W3) and 6 (W6) weeks of treatment and 4 weeks
after stopping (W10). In each evaluation body mass index
(BMI), PASI and DLQI were calculated and blood samples for
serum vitamin A, 25-hydroxyvitamin D (vitamin D) and folic
acid measurements were taken in the morning, in a fasting state.
The NB-UVB irradiation (311 ± 2 nm) was administered
using a Waldmann 7001 cabin (UVB-TL01; Waldmannn Med-
izintechnik, Villingen-Schwenningen, Germany): initial dose
0Æ3–0Æ5 J cm)2, increasing by 0Æ1 J cm)2 every session up to
2Æ0 J cm)2, thrice weekly for 6 weeks.
Serum retinol was measured by high-performance liquid
chromatography; serum vitamin D and serum folate were
analysed by competitive radioimmunoassay. Data are presented
as mean ± SD, and repeated-measures ANOVA followed by
Student’s paired t-test were used to determine the statistical sig-
nificance. P < 0Æ05 was considered significant. The correlation
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analysis was performed by calculating Spearman correlation
coefficient.
Twenty patients completed the study. Baseline data and the
effects of NB-UVB are given in Table 1. Phototherapy reduced
PASI and DLQI scores, with 70% of the patients achieving PASI
75 (75% reduction in PASI compared with baseline) at W6 and
a positive correlation between DPASI and DDLQI (r = 0Æ25;
P = 0Æ02). Before treatment, 60% of the patients had insuffi-
cient serum vitamin D levels (< 20 ng mL)1), and these levels
increased after phototherapy (Table 1). No correlation was
found between this increase and the studied variables. At onset,
all patients except one had normal serum retinol values
(> 1Æ05 lmol L)1), and these levels increased significantly after
NB-UVB irradiation (Fig. 1a). The serum retinol remained ele-
vated at 1 month after the last treatment (W10) (Table 1). At
baseline, vitamin A levels were not correlated with BMI but the
percentage increase in vitamin A from baseline to W6 (Dvitamin
A) was negatively correlated with BMI (P < 0Æ0001; r2 = 0Æ54)
(Fig. 1b). No significant relationships were found between
Dvitamin A and the studied variables.
RE account for 85–90% of total epidermal vitamin A. Most
are depleted by a single exposure to UVB,4 and are rapidly
replaced by retinol uptake from dermal blood vessels.3–5 It was
reported that the activity of the enzyme that esterifies retinol in
epidermis increased to 167% at 2 days after UVB irradiation,
suggesting a rapid influx of unesterified retinol.7 We showed
that NB-UVB significantly and persistently increased serum reti-
nol levels while clearing psoriasis. One explanation could be
Table 1 Characteristics of the 20 patients before starting phototherapy (baseline), at 3 (W3) and 6 (W6) weeks after narrowband ultraviolet B
(NB-UVB) phothotherapy thrice weekly and 1 month after the last NB-UVB exposure (W10)
Baseline W3 W6 W10
Sex, F ⁄M, n (%) 8 (33) ⁄12 (67) – – –
Age (years),
mean ± SD (range)
51Æ2 ± 13Æ4 (21–69) – – –
BMI (kg m)2),
mean ± SD (range)
26Æ3 ± 3Æ9 (20Æ0–33Æ8) 26Æ2 ± 3Æ8 (20Æ1–33Æ9) 26Æ3 ± 3Æ8 (20Æ0–33Æ9) 26Æ3 ± 3Æ9 (20Æ0–33Æ9)
NB-UVB
total dose (J cm)2),
mean ± SD (range)
0 6Æ5 ± 0Æ5 (6Æ3–8Æ1) 21Æ9 ± 6Æ1 (14Æ0–27Æ9) –
PASI,
mean ± SD (range)
9Æ65 ± 4Æ59 (5–20) 5Æ00 ± 3Æ46* (1–14) 2Æ30 ± 2Æ55** (0–7) 2Æ70 ± 3Æ14 (0–12)
DLQI,
mean ± SD (range)
9Æ75 ± 6Æ40 (1–23) 5Æ30 ± 5Æ02* (0–17) 3Æ75 ± 4Æ19** (0–12) 3Æ35 ± 4Æ09 (0–12)
25-hydroxyvitamin
D (> 30 ng mL)1)a,
mean ± SD (range)
18Æ44 ± 12Æ56 (3–47) 24Æ35 ± 13Æ00* (7–49) 34Æ05 ± 12Æ24** (8–56) 34Æ61 ± 12Æ50 (11–55)
Vitamin A
(> 1Æ05 lmol L)1)a,
mean ± SD (range)
1Æ62 ± 0Æ34 (0Æ87–2Æ3) 1Æ76 ± 0Æ46* (0Æ94–2Æ65) 1Æ86 ± 0Æ44** (1Æ08–2Æ76) 1Æ97 ± 0Æ53 (1Æ12–3Æ16)
Folate
(2Æ2–17Æ5 ng mL)1)a,
mean ± SD (range)
6Æ64 ± 2Æ75 (3Æ2–14Æ6) 6Æ49 ± 2Æ12 (3Æ5–10Æ8) 6Æ38 ± 2Æ31 (3Æ7–11Æ4) 6Æ41 ± 3Æ15 (2Æ4–15Æ5)
BMI, body mass index; PASI, Psoriasis Area and Severity Index, DLQI, Dermatology Life Quality Index. *P < 0Æ05 (W3 vs. baseline),
**P < 0Æ05 (W6 vs. W3). aReference intervals for biochemical parameters.
(a) (b)
Fig 1. (a) Serum vitamin A levels in patients
with psoriasis (n = 20) before (baseline) and
at 3 and 6 weeks after narrowband ultraviolet
B phototherapy thrice weekly. Horizontal lines
indicates means. **P = 0Æ0001, *P = 0Æ02,
#P = 0Æ04. (b) Correlation between body
mass index (BMI) (kg m)2) and the change
in serum vitamin A levels following
phototherapy. Each circle represents a patient
and shows the BMI compared with the
percentage of increase in serum vitamin A
levels from baseline to week 6 (Dvitamin A).
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that phototherapy-induced cutaneous depletion of vitamin A
increases its skin uptake from circulation and consequently
increases mobilization of hepatic and fat stores. Despite this flux
to the skin, mobilization of retinol stores may be disproportion-
ate, contributing to the observed increase in serum levels. Only
two studies have dealt with the relationship between UVR and
serum retinol levels.6,7 One involving healthy subjects irradiated
for 2 weeks with UVA or broadband UVB did not find variation,
and the other with hairless mice showed a transient depletion of
serum retinol a few days after a single broadband UVB irradia-
tion.6,7 Our data indicate that in patients with psoriasis, vitamin
A participates in an adaptive response to NB-UVB exposure; the
physiological role of this response needs to be further investi-
gated.
It is well documented that vitamin A and RBP4 are involved
in lipid metabolism.1 Subjects with nonalcoholic hepatic stea-
tosis had lower retinol liver stores and an association between
obesity and vitamin A deficiency was proposed.8 We found a
negative correlation between BMI and Dvitamin A and we can
hypothesize that overweight patients have less adaptive vita-
min A response.
In agreement with data from higher-latitude regions, we
found a high prevalence of vitamin D insufficiency and a sub-
stantial benefit of NB-UVB.9,10
The limitations of the present study include the absence of
a control group, and cutaneous retinol and serum RBP4 levels
should be addressed in future studies.
In addition to a significant increase of the vitamin D status,
NB-UVB increases serum vitamin A levels while clearing psori-
asis, the magnitude of this increase being determined by the
patient’s BMI.
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Lichen planus is not associated with human
herpesvirus type 7
DOI: 10.1111/j.1365-2133.2012.11009.x
MADAM, Human herpesvirus type 7 (HHV-7) has been proposed
to be associated with lichen planus (LP).1 Furthermore, it has
been postulated that a decrease in HHV-7 replication is
associated with LP remission.2 However, we came to the
opposite conclusion in a case–control study conducted at
Shohada-e-Tajrish University Hospital from June 2007 to
March 2010.
According to the previous study,1 we arrived at a study size
of n = 53 in each group with the power of 0Æ80 to detect a sig-
nificant difference between cases and controls. We ascertained
one control for each case, matched for age. Cases were patients
with a histopathologically confirmed diagnosis of LP during
acute exacerbation of disease. We obtained control group skin
samples from patients admitted for cosmetic procedures who
were otherwise healthy. We examined both skin and plasma
specimens by polymerase chain reaction (PCR) using QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. For amplification and detection of
HHV-7 genome we used the forward primer 5¢-CCC AAC TAT
TTT CAG TAG GGT TGG TG-3¢, reverse primer 5¢-TTT AGT
� 2012 The Authors
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Effect of narrowband ultraviolet B treatment on endocannabinoid plasma levels in psoriasis 
patients 
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ABSTRACT
Background- Psoriasis is associated with increased risk of obesity and metabolic syndrome. Although 
endocannabinoid system dysregulation was demonstrated in these comorbidities, no data exist on 
endocannabinoid plasma levels in psoriasis. We have recently shown that the cutaneous endocannabinoid 
system responds to ultraviolet B (UVB) irradiation, but the effect of narrowband UVB (nbUVB) 
treatment on plasma endocannabinoid levels is unknown.  
Objectives- To evaluate endocannabinoid plasma levels in psoriasis patients. To determine whether 
exposure to nbUVB modifies these levels. To correlate plasma endocannabinoid levels with metabolic 
parameters and leptin levels. 
Methods- An open observational study was conducted with 21 psoriasis patients and 15 matched 
controls. Plasma levels of anandamide, 2-arachidonoylglycerol (2-AG), oleylethanolamide (OEA) and 
palmitoylethanolamide (PEA) were recorded. Patients were evaluated at weeks 0, 3 and 6 of nbUVB 
phototherapy and 4 weeks after stopping the treatment. In each evaluation body mass index (BMI), 
Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were calculated 
and fasting levels of C-reactive protein (CRP), high sensitivity CRP (hsCRP), cholesterol, triglycerides, 
glucose and leptin were measured. 
Results- Endocannabinoid plasma levels did not differ significantly between controls and psoriasis 
patients, in whom, before phototherapy, anandamide levels were positively correlated with hsCPR. The 
nbUVB treatment significantly decreased anandamide levels to an extent positively correlated with BMI. 
PASI score improved but no correlation with the decrease of anandamide levels was found.  
Conclusions- The present study shows that nbUVB treatment significantly decreases anandamide plasma 
levels in patients with psoriasis in a manner that is stronger in patients with higher baseline BMI.  
  
Introduction 
The major endocannabinoids, anandamide and 
2-arachidonoylglycerol (2-AG), are lipid 
mediators that are produced “on demand” from 
membrane phospholipid precursors in the 
central nervous system, peripheral organs, skin 
and adipose tissue 1-2. Anandamide and 2-AG 
act through specific G-coupled cannabinoid 
receptors type 1 (CB1) and type 2 (CB2) 1-2. The 
biological activity of endocannabinoids is 
exerted in all organs and is not limited to the 
central nervous system as previous believed 3 4. 
In the skin, a fully functional endocannabinoid 
system (ECS) has been identified 5. We have 
shown that this cutaneous ECS responds to 
ultraviolet B (UVB) irradiation 6. However the 
effect of narrowband UVB (nbUVB) 
phototherapy on endocannabinoid plasma levels 
in humans is still unknown.  
Several studies found a link between psoriasis, 
obesity, metabolic syndrome and serum levels 
of certain adipokines 7-8. Obesity and metabolic 
syndrome are well known pathological 
conditions where endocannabinoid system 
dysregulation was demonstrated 9 2,10. It has 
been suggested that ECS tone is overall 
increased in human obesity 11. In obese patients, 
elevated endocannabinoid plasma levels were 
associated with coronary circulatory 
dysfunction 12. The relationship between obesity 
and systemic inflammation has been described 
in psoriasis patients and considered detrimental 
8. This interaction provides the inflammatory 
base of the ‘psoriatic march’ that describes the 
development of vascular complications in 
psoriasis 13 8. Recent data support a link 
between the endocannabinoid system and 
obesity-associated inflammation 2. Previous 
studies suggested that mediators released from 
the adipose tissue such as leptin and/or 
endocannabinoids are involved in the initiation 
and development of cardiovascular disease 12. 
At present, the impact of endocannabinoids on 
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psoriasis is unknown. In this context, we aimed 
to evaluate endocannabinoid plasma levels in 
psoriasis patients, the influence of nbUVB 
phototherapy on these levels and their 
correlation with leptin levels and inflammatory 
and metabolic parameters. Since the two 
cannabinoid receptor-inactive and metabolically 
related anandamide congeners, 
oleoylethanolamide (OEA) and 
palmitoylethanolamide (PEA), were recently 
found to be dysregulated in obese rats 14, and are 
known to activate receptors involved in 
inflammation, i.e. the nuclear peroxisome 
proliferator-activated receptor-� (PPAR-�) and 
transient receptor potential vanilloid type-1 
(TRPV1) channels, we have also measured the 
plasma levels of these two lipid mediators.  
Patients and methods
The regional ethical committee approved this 
open observational study and all participants 
gave informed consent. The inclusion criteria 
were patients with chronic plaque psoriasis, 
indication for phototherapy and free of psoriasis 
medication or other systemic therapy, at least 12 
weeks before and during the study. Patients 
presenting diabetes, psoriatic arthritis or other 
inflammatory diseases were excluded. We 
enrolled 21 patients with Fitzpatrick skin types 
II-III patients and 15 age, sex and body mass 
index (BMI) matched controls. Subjects were 
admitted only in winter and early spring. They 
were advised to not make any nutritional or 
lifestyle changes that could interfere with the 
results during the treatment period. Psoriasis 
severity was measured by Psoriasis Area and 
Severity Index (PASI) and Dermatology Life 
Quality Index (DLQI). To diminish subjectivity, 
the same dermatologist evaluated PASI.  
All psoriasis patients were evaluated before 
phototherapy (baseline), after three (W3) and 
six (W6) weeks of treatment and four weeks 
after stopping (W10). In each evaluation BMI, 
PASI and DLQI were calculated and fasting 
venous blood samples were taken in the 
morning, for anandamide, 2-AG, OEA and PEA 
measurement. The blood parameters shown in 
Table 2 were also assessed in the same 
conditions.  
Plasma levels of anandamide, 2-AG, PEA and 
OEA were measured by isotope-dilution liquid 
chromatography-atmospheric pressure chemical 
ionization-mass spectrometry as described 9. 
Fasting plasma leptin was determined by ELISA 
kit (Millipore, Billerica, MA, USA), according 
to manufacturer instructions.  
The nbUVB irradiation (311 ± 2 nm) was 
administered using a Waldmann 7001 cabin; 
(UVB-TL01; Waldmannn Medizintechnik, 
Villigen-Schwenningen, Germany); the initial 
dose, dependent on patient’s phototype, was 
0.3-0.5 J/cm2, increasing 0.1 J/cm2 in every 
session until a maximum dose of 2.0 J/cm2, 
totalizing eighteen nbUVB exposures (thrice 
weekly, during six weeks). Only eyes and 
genital were shielded during the irradiation. 
Data are presented as means ± SD and ANOVA 
with repeated measures was used to determine 
the statistical significance. Values of P<0.05 are 
considered significant. The correlation analysis 
was performed by calculating Spearman 
coefficient correlation. 
Results 
As shown in Table 1, patients and controls were 
not significantly different regarding age or BMI 
with a mean BMI > 25 Kg/m2 (overweight) in 
both groups.  
Endocannabinoid plasma levels did not differ 
significantly between controls and psoriasis 
patients (Table 1). Phototherapy significantly 
reduced PASI and DLQI scores (P<0.0001) but 
did not change BMI (Table 1). We observed a 
significant positive correlation between the 
percentage of decrease in PASI (∆PASI) and the 
percentage of decrease in DLQI (∆DLQI) from 
baseline to week 6 (R2=0.25; P=0.02).  
In psoriasis patients, before phototherapy, 
hsCPR levels, were positively correlated with 
BMI (R2=0.29; P=0.02) and LDL-cholesterol 
(R2=0.43; P=0.004) and negatively with HDL-
cholesterol (R2=0.23; P=0.04). No correlation 
was observed between PASI score and hsCPR 
or CPR values.  
As shown in Fig.1, anandamide plasma levels 
significantly decreased after completion of the 
nbUVB treatment (P<0.001). We found that the 
percentage of decrease in anandamide from 
baseline to week 6 was positively correlated 
with BMI (R2=0.35; P=0.006) and with 
anandamide levels before phototherapy 
(R2=0.57; P=0.0002), but no correlation was 
found with PASI. No significant nbUVB-effect 
on the levels of the other endocannabinoid, 2-
AG, or of OEA and PEA was found (Table 1).  
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Table 1. Characteristics and endocannabinoid levels of controls and psoriasis patients before 
phototherapy (Psoriasis baseline), three (W3) and six (W6) weeks after nbUVB phothotherapy thrice 
weekly and one month after the last nbUVB exposure (W10).  
Values are means ± SD. BMI, body mass index; PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index; 
AEA, anandamide; 2-AG, 2-arachidonoylglycerol; OEA, N-oleylethanolamine; and PEA, N-palmitoylethanolamine *P<0.05 (W3 
vs. baseline), **P<0.05 (W6 vs. W3), # P<0.05 (W6 vs. baseline), ## P<0.05 (W10 vs. baseline). 
Table 2. Inflammatory parameters and lipid profile in psoriasis patients before starting phototherapy 
(Psoriasis baseline), three (W3) and six (W6) weeks after nbUVB phothotherapy thrice weekly and one 
month after the last nbUVB exposure (W10).  
Psoriasis 
baseline 
Psoriasis 
W3 
Psoriasis 
W6 
Psoriasis 
W10 
Total cholesterol 
(mg/dL) 
212.70±40.66 
(116-285) 
211.10±40.35 
(130-281) 
212.40±37.71 
(119-297) 
206.90±43.08 
(108-277) 
LDL-cholesterol 
(mg/dL) 
138.10±42.74 
(77-214) 
137.30±33.39 
(88-202) 
137.50±29.10 
(89-214) 
134.1±39.36 
(73-201) 
HDL-cholesterol 
(mg/dL) 
52.89±10.10 
(35-77) 
52.13±11.24 
(36-80) 
51.71±10.12 
(35-69) 
54.00±11.25 
(33-74) 
Triglycerides 
(mg/dL) 
136.30±74.85 
(50-300) 
137.70±69.30 
(40-290) 
137.10±63.50 
(40-288) 
134.00±59.98 
(54-267) 
Glucose 
(mg/dL) 
87.74±19.10 
(64-132) 
88.76±21.88 
(64-136) 
85.27±23.31 
(63-137) 
90.67±19.65 
(66-137) 
Total Leptin 
(ng/mL) 
10.46±7.19 
(2.38-27.71) 
11.24±6.27 
(3.67-26.26) 
10.19±5.78* 
(3.73-25.52)
12.13±7.41 
(4.44-31.84) 
Males Leptin 
(ng/mL) 
10.19±7.02 
(2.38-21.78) 
10.96±5.47 
(4.32-18.10) 
9.53±4.72* 
(3.73-15.20)
11.60±5.95 
(4.44-21.67) 
Females Leptin 
(ng/mL) 
11.37±8.05 
(3.00-27.71) 
11.40±7.81 
(3.67-26.26) 
11.01±7.36 
(3.78-25.52) 
12.72±9.17 
(6.89-31.84) 
CPR 
(<3.0 mg/L) a
2.53±1.74 
(0.3-6.4) 
2.37±1.77 
(0.3-6.0) 
2.82±1.91 
(0.3-6.0) 
2.68±2.00 
(0.2-7.1) 
hsCPR 
(<5.0 mg/L) a
2.24±1.61 
(0.3-5.9) 
3.55±4.41 
(0.4-8.2) 
2.96±2.83 
(0.2-5.4) 
2.79±2.74 
(0.2-6.5) 
Values are means ± SD (range). CRP, C-reactive protein; hsCRP, high sensitivity C-reactive protein. *P<0.05 (W6 vs. W3). a
Reference intervals for biochemical parameters. 
 Controls Psoriasis baseline 
Psoriasis 
W3 
Psoriasis 
W6 
Psoriasis 
W10 
Sex, women  5 (33.3) /10(66.7) 8 (33.3) /13(66.7) - - - 
Age, Years 46.33±2.36 51.2±13.4 - - - 
BMI (Kg/m2) 25.6±4.2 26.3±3.9 26.2±3.8 26.3±3.8 26.3±3.9 
UVB total dose (J/cm2) - 0 6.5±0.5 21.9±6.1 - 
PASI - 10.20±5.02 5.21±3.42* 2.42±2.57** 2.84±3.16##
DLQI - 9.60±6.23 5.12±5.08* 3.84±4.29** 3.84±4.19##
AEA (pmol/ml) 2.55±0.35 3.19±0.49 2.56±0.28 1.90±0.12# 1.99±0.13##
2-AG (pmol/ml) 7.14±1.17 7.37±0.79 6.88±0.76 6.29±0.58 6.98±1.12 
OEA (pmol/ml) 19.13±1.41 20.80±1.46 21.42±1.85 18.81±1.17 19.24±1.29 
PEA (pmol/ml) 33.64±2.24 32.04±2.14 36.31±4.87 32.35±2.77 32.51±2.85 
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Table 3. Correlation of endocannabinoid plasma levels before phototherapy (anandamide, 2
and PEA) with clinical variables in patients with psoriasis
variable r 
Age 0.20 
PASI 0.005 
DLQI -0.31 
BMI -0.36 
Total cholesterol -0.32 
LDL-cholesterol -0.35 
HDL-cholesterol -0.23 
Triglycerides 0.08 
Glucose 0.29 
Total Leptin -0.02 
CPR 0.64 
CPRhs 0.63 
BMI, body mass index; PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index; AEA, anandamide; 2
AG, 2-arachidonoylglycerol; OEA, N-oleylethanolamine; and PEA, 
Figure 1. Plasma anandamide levels in psoriatic patients 
(n=21) before (baseline) and three and six weeks after 
nbUVB phototherapy thrice weekly. **P<0.01
Regarding to metabolic and inflammatory 
parameters, there was no significant effect of 
phototherapy (Table 2). Only a slight red
of leptin levels was observed in males (Table
AEA 2-AG PEA
P-value r P-value r P-value 
0.39 -0.16 0.50 -0.04 0.85 
0.98 0.30 0.20 -0.28 0.22 
0.18 -0.01 0.95 -0.44 0.05 
0.11 0.23 0.32 -0.33 0.15 
0.18 0.29 0.22 -0.45 0.05 
0.14 0.12 0.63 -0.36 0.13 
0.40 -0.08 0.74 -0.12 0.63 
0.76 0.34 0.15 0.03 0.89 
0.25 0.005 0.99 -0.13 0.59 
0.94 0.56 0.02* 0.33 0.18 
0.002* -0.29 0.21 0.33 0.18 
0.002* -0.29 0.21 0.36 0.15 
N-palmitoylethanolamine *P<0.05 
 
uction 
 2).  
A positive correlation was seen between 
baseline hsCPR and anandamide levels (Table 
3). No correlation was found between baseline 
endocannabinoid, OEA and PEA
other clinical and metabolic parameters (Table 
3). 
Discussion 
The present study provides evidence
nbUVB phototherapy in
decreases plasma levels of anandamide
changing 2-AG, OEA or PEA
We observed that around 65
patients were overweight with body mass index 
(BMI) ≥25 and < 30 kg/m2
decrease in anandamide plasma level
positively correlated with BMI
was previously reported that incre
anandamide plasma levels are 
with binge eating disorder 15
obesity 16. Furthermore, elevated circulating 
anandamide levels are associated with coronary 
circulatory dysfunction in obese individuals 
proposed as a novel endogenous cardiovascular 
4 
4 
-AG, OEA 
OEA
r P-value 
0.16 0.51 
-0.18 0.45 
-0.43 0.06 
-0.37 0.09 
-0.39 0.09 
-0.29 0.24 
-0.09 0.73 
0.16 0.51 
-0.19 0.43 
0.25 0.32 
0.25 0.35 
0.22 0.35 
-
 levels and 
 that 
psoriasis patients 
 without 
 levels.  
% of the studied 
. Interestingly, the 
s was 
 at baseline. It 
ased 
present in women 
or post-menopausal 
and 
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risk factor 12. The observed UVB-induced 
anandamide decrease might, therefore, suggest a 
beneficial effect of phototherapy in psoriasis 
patients at cardiovascular risk. This hypothesis, 
which, however, needs further investigation, is 
supported by the observation that baseline 
anandamide levels were positively correlated 
with hsCRP, a biomarker for both increased 
cardiovascular events and inflammation. In 
another study 12, only anandamide plasma levels 
were correlated with CRP and an 
endocannabinoid-mediated association between 
metabolic and inflammatory cardiovascular 
disease mechanisms was proposed.  
The link between psoriasis and increased 
cardiovascular risk appears to be dependent of 
disease severity 17. A major limitation of our 
study was that patient profiles corresponded to 
those of candidates for phototherapy and, 
therefore, subjects with very severe cutaneous 
disease are not represented in the study 
population. This might explain why anandamide 
plasma levels were not significantly different 
between psoriasis patients and controls, also 
because the two populations did not differ for 
their BMI and were overweight (≥25 kg/m2) 11
16.  
Despite the fact that the clinical response to 
UVB was good, no correlation was observed 
between endocannabinoid levels and disease 
activity. Furthermore, despite the recognized 
role of endocannabinoids in the metabolic 
syndrome, no correlation was observed between 
endocannabinoid levels and leptin, LDL 
cholesterol, HDL cholesterol, triglycerides or 
glucose fasting levels in our populations. 
Indeed, some of these correlations have been 
found so far only for obese patients (BMI>30) 
and/or only for 2-AG 9,16. Unlike 2-AG, 
anandamide, OEA and PEA are all N-
acylethanolamines and share similar metabolic 
pathways 18. Therefore, it was somewhat 
surprising not to find for OEA and PEA similar 
changes or correlations as with anandamide, 
especially considering the fact that for both 
compounds anti-inflammatory actions mediated 
by non-cannabinoid receptors have been 
reported 19. This finding might suggest that the 
observed changes specifically reflect, or impact 
on, the activity of the endocannabinoid system, 
thus supporting their possible relevance to 
psoriasis- and cardiovascular-related 
inflammation 18. However, the mechanism by 
which UVB might specifically alter anandamide 
remains to be explored. 
It will be important to evaluate in the future the 
influence of other psoriasis treatments on 
endocannabinoid plasma levels in order to 
clarify whether the UVB-induced decrease of 
anandamide plasma levels is a radiation effect 
per se or is related with disease remission. 
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Discussion 
 
In chapter I, we report that keratinocytes and melanoma cells express CB1 and 
CB2 receptors, produce physiologically relevant concentrations of the two major 
endocannabinoids (2-AG and anandamide) and of the related N-acylethanolamine 
(PEA), and have the main cannabinoid metabolizing enzymes FAAH and MAGL. 
These findings show that these cutaneous cells are endowed with all the components of 
an endogenous cannabinoid system. Levels of endocannabinoids are much higher in 
melanoma cells than in keratinocytes, but FAAH activity and particularly MAGL 
activity are higher in keratinocytes. This much higher activity of MAGL in 
keratinocytes may explain why the basal levels of 2-AG are lower in co-cultures than 
in melanoma cells alone.  
We have also demonstrated that UVB irradiation increases the levels of 
anandamide, 2-AG and PEA in keratinocytes and significantly increases the ratio 2-
AG/anandamide in co-cultures whereas in melanoma cells endocannabinoid levels 
remain unaltered after UVB. These findings suggest that endocannabinoids are also 
pro-homeostatic in the skin, because UV irradiation is the major environmental insult 
to the skin and elicits an increase in the levels of endocannabinoids.  
Since UVB increases Ca2+ influx in keratinocyte (HaCat) via TRPV1 activation 
(Lee et al. 2009; Masaki et al. 2009) and endocannabinoids are produced “on demand” 
from membrane phospholipids in response to intracellular Ca2+ (Alger and Kim 2011; 
Cluny et al. 2012), we can hypothesize that the observed increase in endocannabinoid 
levels is dependent on UVB-induced Ca2+-influx. Moreover, in human skin and 
keratinocytes, UVR activates phospholipases A2, C and D and diacylglycerol kinase, 
thereby releasing arachidonic acid and DAG (De Leo et al. 1984; Punnonen and Yuspa 
1992; Carsberg et al. 1995) which are the main precursors for endocannabinoid 
synthesis. The UVB-induced release of DAG, which is the 2-AG precursor, may 
explain why 2-AG increases more than anandamide in keratinocytes irradiated with 
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UVB. The increase in the ratio 2-AG/anandamide that we observed in co-cultures after 
exposure to UVB can also be explained by the UVB-induced release of DAG. Our data 
agree with the findings that mouse epidermal JB6P+ cells respond to stress factors 
such as UVB irradiation or serum deprivation with the production of increased levels 
of N-acylethanolamines and their precursors, N-acylethanolamine phospholipids 
(Berdyshev et al. 2000).  
An alternative explanation for the increase in endocannabinoid levels after UVB 
irradiation would be a decrease in metabolizing pathways. However we observed that 
UVB even caused an increase of MAGL and FAAH activities. These results suggest 
that the UVB increased levels of endocannabinoids are mostly due to an increased 
synthesis. 
Total endocannabinoids (except PEA) are less in co-culture than in melanoma 
cells alone under basal conditions, and even less under UVB irradiation. This 
phenomenon may be due to the high levels of endocannabinoid-degrading enzymes in 
keratinocytes and their up-regulation by UVB. 
On the other hand UVB increases the mRNA expression of CB1 receptors in 
melanoma cells but not in keratinocytes. Taken together, our data support the concept 
that endocannabinoids may participate in the important cross talk between 
keratinocytes and melanocytes in the epidermal unit after exposure to UVR. These 
results are in agreement with the classic idea that keratinocytes respond to UVR 
producing several paracrine factors that will act on melanocytes helping in their 
protection.  
Endocannabinoids (Karsak et al. 2007) and PEA (Petrosino et al. 2009) attenuate 
the cutaneous allergic response whereas the antagonism of CB1 cannabinoid receptors 
in human HaCat keratinocytes increases the expression of pro-allergic chemokines 
(Leonti et al. 2010). Acute UVB irradiation is known to cause immunosuppression. 
Since we found, in chapter I, that UVB irradiation is accompanied by up-regulation of 
both endocannabinoids and PEA levels, we hypothesize that the cutaneous 
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endocannabinoid system could play a role in UVB-induced immunosuppression and 
might contribute to the well-known therapeutic effect of UVB radiation.  
Acute UVB exposure also causes inflammation and there is growing evidence 
suggesting that 2-AG modulates the inflammatory response by acting on the 
cannabinoid CB2 receptor (Oka et al. 2006). Interestingly, we found a significant 
increase in 2-AG after UVB irradiation, suggesting a role for endocannabinoids, 
namely 2-AG, in UVB-induced inflammation. In agreement with this hypothesis, 
Zheng et al. (Zheng et al. 2008) suggested that CB receptors and the related signaling 
pathways might be involved in the promotion of in vivo UVB-induced skin 
inflammation. In CB1 and CB2 double gene-deficient mice, the authors observed a 
marked decrease in UVB-induced inflammation and an attenuation of UVB-induced 
activation of MAPK and NF-kB. (Zheng et al. 2008). On the other hand, PEA with its 
anti-inflammatory effect (Petrosino et al. 2010) might represent an endogenous 
protective agent against UVB-induced inflammation. 
The first defense against UVR is the cutaneous melanin produced in 
melanocytes.  However, as reported in chapter I melanoma cells alone did not show 
any increase in melanin content after UVB irradiation. In contrast, co-cultures 
exhibited a marked melanogenic response to UVB irradiation (≈ 40% melanin over the 
controls). It is known that UVB irradiation of keratinocytes triggers the release of 
cytokines, growth factors, and other mediators such as POMC-derived peptides that 
regulate melanin synthesis in a paracrine way (Duval et al. 2001; Park et al. 2009) and 
this may explain the differences that we observed between mono- and co-cultures in 
their response to UVB.  
In chapter I, we showed that the CB1 selective agonist arachidonoyl-2-
chloroethylamide (ACEA), had an inhibitory effect on basal melanogenesis in co-
cultures. Furthermore, in the same model, ACEA abolished the increase in melanin 
content caused by UVB irradiation. The CB1 selective antagonist (AM-251), that alone 
did not modify UVB-induced melanogenesis, reversed this inhibitory effect of ACEA. 
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The inhibitory effect of CB1 receptor activation on melanogenesis was observed in co-
cultures but not in monocultures, which again, underlines the important symbiotic 
relationship between melanocytes and keratinocytes. Since both cells express CB1 
receptors, it can be speculated that cannabinoids acting in keratinocytes inhibit the 
release of keratinocyte-derived paracrine melanogenic mediators. Alternatively, it is 
possible that CB1 agonists directly act on melanoma cells to inhibit melanogenesis 
only when the conditions to produce melanin are optimized by the presence of 
keratinocytes. Our data suggest that human melanoma cells are both sources and, 
mainly, targets of endocannabinoids, which act as negative regulators of melanin 
synthesis after UVB radiation. The endocannabinoids produced by keratinocytes after 
UVB radiation might act at over-expressed melanocyte CB1 receptors in a paracrine 
way, to counteract the excessive melanin production. From these results, we suggest 
that keratinocytes play a major role in cannabinoid-mediated inhibition of basal and, 
particularly, UVB-induced pigmentation. This could suggest a new endocannabinoid-
mediated mechanism tightly regulating UVB-induced melanogenesis. 
UVB irradiation evokes a signaling response through several pathways and is 
known to induce keratinocytes apoptosis as a mechanism to prevent malign 
transformation. The DNA damage-dependent pathway has been extensively 
investigated in recent years, but the underlying biochemical and enzymatic 
mechanisms are not completely understood. In chapter I we report that anandamide 
increases UVB-induced cell death in human keratinocytes through TRPV1 channel. 
Locally synthesized anandamide by keratinocytes, after UVB irradiation, might act at 
TRPV1 receptors in a paracrine or autocrine manner and reduces their survival. In 
basal conditions anandamide and the other cannabinoid agonists did not reduce 
keratinocyte cell viability. Recently anandamide has been found to inhibit proliferation 
and cell viability of human epidermal keratinocytes in culture by a sequential 
engagement of CB1 receptor and TRPV1 channel (Toth et al. 2011). However in that 
study a shorter incubation period with anandamide was used and the effect of UVB 
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radiation was not investigated. Moreover UVB increases TRPV1 expression in both 
keratinocytes and human skin in vivo (Lee et al. 2009), which could explain that we 
observed TRPV1-mediated anandamide effect only after UVB exposure. 
In addition, it was previously observed that metabolism of anandamide by COX-
2 is important for anandamide-induced cell death in tumorigenic keratinocytes (Van 
Dross 2009; Kuc et al. 2012). Interestingly, in our model with non-tumorigenic HaCat 
cells, COX-2 inhibition by indomethacin did not modify the anandamide effect in 
irradiated keratinocytes.  
Using the same experimental model, we decided to investigate other potential 
protective mechanisms against UVB irradiation. Despite the involvement of COMT in 
melanogenesis has been claimed in the past (Axelrod and Lerner 1963; Shibata et al. 
1993), the role of this enzyme in keratinocytes and in UVB adaptive response had 
never been studied. In chapter I, we demonstrated that similarly to melanocytes, 
keratinocytes also have COMT activity and that acute UVB irradiation differentially 
modifies this activity in both cell types. Twenty-four hours after UVB irradiation, we 
observed a decrease in COMT activity in melanocytes while in keratinocyes there was 
an increase, but 48 h after UVB, the COMT activity decreases in both cell types. This 
COMT inhibition by UVB was not a nonspecific effect on cellular enzymatic activity 
since the Na+-K+-ATPase activity was not modified. Furthermore the COMT inhibitor 
tolcapone increased the UVB-induced cell death only in keratinocytes. This response 
suggests that COMT has a protective effect against UVB-induced cell death in 
keratinocytes. Although, one cannot exclude that tolcapone has direct effects 
independent from COMT inhibition. Inhibition of COMT has been described to induce 
cytotoxicity in melanoma cells (Smit and Pavel 1995).  It has also been proposed that 
COMT influences melanogenesis (Smit et al. 1994). In our melanoma cell line, COMT 
inhibition had no effect on cell viability nor on melanogenesis.  
Afterwards we decided to study the effects of UVB radiation in vivo (chapter 
II). As previously mentioned, psoriasis is a common inflammatory skin disease 
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characterized by hyperproliferation of epidermal keratinocytes and it the prototypic 
disease showing a favourable response to nbUVB phototherapy. In addition to 
imunossupression, keratinocyte apoptosis also occurs as a result of nbUVB (Aufiero et 
al. 2006; Weatherhead et al. 2011) and contributes to the beneficial effect of 
phototherapy in psoriasis. In chapter I, we report the effect of UVB irradiation in 
COMT activity in vitro, thus we decided to study COMT activity in patients with 
psoriasis treated with nbUVB (chapter II). For the in vitro studies the same 
wavelength (311nm) as in psoriasis phototherapy was used. 
In agreement with our data from human keratinocyte and melanoma cell lines 
(chapter I) we demonstrated, in chapter II, that nbUVB phototherapy for psoriasis 
significantly decreases erythrocytes soluble COMT (S-COMT) activity.  
UVB irradiation, of the skin is known to activate the NF-kB pathway (Chang et 
al. 2011) which regulates the COMT gene (Tchivileva et al. 2009). Since it was 
demonstrated that NF-kB transcription factor inhibits COMT expression in central 
nervous system (Tchivileva et al. 2009), we might speculate that this pathway could 
also be involved in UVB-induced COMT inhibition. Another explanation could be that 
COMT expression regulated by TNFα (Tchivileva et al. 2009; Tunbridge 2010) 
decreases because nbUVB reduces TNFα serum levels (Coimbra et al. 2010). 
It was previously observed that the activity of COMT in patients with psoriasis is 
higher in lesional than in nonlesional skin and it was proposed that COMT might have 
a role in psoriasis (Bamshad et al. 1970; Barbeau and Giroux 1972). Interestingly, in 
chapter II, we found that patients with psoriasis have significantly higher S-COMT 
activity than controls. COMT has attracted strong neuroscientific interest due to its 
central role in brain catecholamines signaling and has been linked to both depression 
and anxiety with contradictory results (Aberg et al. 2011; Nyman et al. 2011; Witte 
and Floel 2011). Patients with psoriasis are at increased risk of depression, anxiety, and 
suicide compared with the general population (Kurd et al. 2010). The role of COMT in 
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psoriasis lesions and the potential relation between psoriasis, depression and COMT 
activity should be further explored.  
In addition to psychiatric comorbidities (Kurd et al. 2010), it is well documented 
that psoriasis is associated with obesity and metabolic syndrome (McDonald 1989; 
Wakkee et al. 2007; Yiu et al. 2011). Co-occurrence of obesity and psoriasis could 
lead to interactions between the two diseases since adipokine disturbances are present 
in both (Coimbra et al. 2010; Gerdes et al. 2011).  
We observed that around 70% of the studied psoriasis patients were overweight 
(body mass index (BMI) ≥25 kg/m2). Similarly to endocannabinoids, it has been 
recognized that retinol (vitamin A) and retinol binding protein 4 (RBP4), a recently 
described adipokine, are involved in lipid metabolism (Berry and Noy 2012). Recently 
it was observed that the CB1 receptor gene transcription is up-regulated by retinol-
derivate retinoic acid via retinoic acid receptor γ (RAR γ) (Svensson et al. 2006; 
Mukhopadhyay et al. 2010).  
Retinol regulates several cutaneous responses and retinyl esters (RE) account for 
85% to 90% of total epidermal vitamin A (Sorg et al. 2002). Cutaneous retinol and RE 
are depleted by a single exposure to UVB and rapidly replaced by retinol uptake from 
dermal blood vessels (Tran et al. 2001; Sorg et al. 2002; Fu et al. 2007). In chapter II, 
in order to clarify whether circulating retinol might also be affected by phototherapy 
we measured retinol in psoriasis patients treated with nbUVB. We demonstrated that 
nbUVB significantly and persistently increased serum retinol levels in psoriasis 
patients. One explanation could be that phototherapy-induced vitamin A cutaneous 
depletion increases skin uptake of retinol from circulation and consequently increases 
mobilization of hepatic and fat stores. It was reported that the activity of the enzyme 
that esterifies retinol in epidermis increased to 167% two days after UVB irradiation, 
which may cause a rapid influx of unesterified retinol (Torma et al. 1988). Despite its 
increased uptake by the skin, the mobilization of retinol stores may be disproportionate 
contributing to the observed increase in serum levels. We found a negative correlation 
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between BMI and this retinol increase and we hypothesize that overweight patients 
have less adaptive vitamin A response after nbUVB phototherapy.  
As expected, we also identified a substantial benefit of nbUVB on vitamin D 
status but no correlation with the clinical response was found. 
It is increasingly being recognized that in addition to obesity, psoriasis is 
associated with an increased cardiovascular risk (Wakkee et al. 2007; Yiu et al. 2011). 
Although a relationship between systemic inflammation of psoriasis and premature 
atherosclerosis was proposed (Yiu et al. 2011) the mechanisms remain poorly 
understood. The effect of psoriasis treatments on the development of cardiovascular 
and metabolic comorbidities has been a recent focus of awareness but the matter is far 
from clear. However the endocannabinoid system dysregulation has been implicated in 
the development of obesity and several cardiometabolic risk factors (Montecucco and 
Di Marzo 2012) and recent data support a link between the endocannabinoid system 
and obesity-associated inflammation (Cluny et al. 2012) no data exist on 
endocannabinoids plasma levels in psoriasis. In chapter I, we showed that UVB 
radiation modifies cutaneous endocannabinoid levels in vitro thus in chapter II, we 
studied, in psoriasis patients, the influence of nbUVB phototherapy in 
endocannabinoid (anandamide and 2-AG) plasma levels and its correlation with 
inflammatory mediators, metabolic parameters and leptin levels. Furthermore, since 
two cannabinoid receptor-inactive and metabolically related anandamide congeners, 
oleylethanolamine (OEA) and PEA are emerging as potent endogenous ligands of 
peroxisome proliferator-activated receptor alpha (PPARα), a well established target for 
dyslipidemia, we have also measured the plasma levels of these two mediators. 
Phototherapy with nbUVB significantly decreases the plasma levels of the 
endocannabinoid anandamide while the levels of the other endocannabinoids remained 
constant. This decrease in anandamide plasma level was positively correlated with 
BMI. Increased anandamide plasma levels were previously reported to be associated 
with coronary circulatory dysfunction in obese individuals (Quercioli et al. 2011). The 
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observed UVB-induced anandamide decrease might suggest a beneficial effect of 
phototherapy on psoriasis patients cardiovascular risk, but this needs further 
investigation. Interestingly in psoriasis patients anandamide levels were positively 
correlated with high sensitivity C-reactive protein levels (hsCRP), a biomarker for 
increased cardiovascular events and inflammation.   
Despite a good clinical response of psoriasis patients to UVB, no correlation was 
observed between endocannabinoid levels and disease activity. Although the 
recognized role of endocannabinoids on metabolic syndrome, no correlation was 
observed between endocannabinoid levels and leptin, LDL cholesterol, HDL 
cholesterol, triglycerides or glucose fasting levels. 
Further studies are required to understand the cellular and tissue origin of plasma 
endocannabinoids in order to interpret the meaning of these UVB-induced changes. It 
would be important to evaluate in the future the influence of other psoriasis treatments, 
on endocannabinoid plasma levels in order to clarify whether the UVB- induced 
decrease of anandamide plasma levels is a radiation effect per se or is related with the 
disease remission itself. 
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Conclusions 
 
1. Human keratinocytes and melanocytes cells have a fully functional 
endocannabinoid system. Cutaneous endocannabinoids participate in the well-
known cross talk between keratinocytes and melanocytes.   
2. UVB radiation up-regulates the cutaneous endocannabinoid system and activates 
a paracrine CB1-mediated signaling that decreases melanin synthesis. 
3. The major endocannabinoid anandamide increases UVB-induced cell death of 
human keratinocytes through TRPV1 receptors. Anandamide synthesized by 
keratinocytes after UVB irradiation acts at TRPV1 receptors in an autocrine 
manner and reduces their survival.  
4. In our experimental conditions, melanin levels were not altered with COMT 
inhibition, contrary to the previously suggested role of O-methylation of L-
DOPA by COMT in the regulation of melanogenesis.  
5. UVB radiation decreases COMT activity in keratinocytes and melanoma cells.  
COMT inhibition by tolcapone increased UVB-induced cell death only in 
keratinocytes. Although this suggests a protective role for this enzyme in 
keratinocytes a direct effect of tolcapone cannot be excluded.  
6. Patients with psoriasis have significantly higher S-COMT activity than controls. 
UVB significantly decreased this activity in patients as well as in human 
keratinocyte and melanoma cell lines. Further investigation is needed to explain 
the lack of correlation between COMT activity reduction and clinical response.  
7. In addition to a significant increase of the vitamin D status, UVB radiation 
increases serum retinol levels in psoriasis patients. The degree of this UVB-
induced increase in retinol levels is determined by the patients BMI. 
Effect of ultraviolet B radiation on cutaneous endocannabinoid system 
 
120 
 
  
8. Basal anandamide plasma levels, in psoriasis patients, were positively correlated 
with hsCPR levels. After UVB treatment a significantly decrease in the plasma 
levels of anandamide was observed. This UVB-induced decrease was positively 
correlated with the patients BMI. 
9. Phototherapy for psoriasis failed to induce significant changes in LDL 
cholesterol, HDL cholesterol, triglycerides or glucose fasting levels and caused 
only a slight decrease in leptin in males. Although the recognized role of 
endocannabinoids on metabolic syndrome, no correlation was observed between 
endocannabinoid levels and the studied metabolic parameters.  
Summary
Resumo
Summary 
 
123 
 
  
Summary 
 
Ultraviolet radiation (UVR) is a permanent environmental threat, and the skin is 
endowed with several adaptive mechanisms against its damaging effects. In the present 
work a fully functional endocannabinoid system in cell lines of human keratinocytes 
and melanocytes and its response to ultraviolet B (UVB) radiation are described. These 
cutaneous cells express both CB1 and CB2 receptors, produce physiologically relevant 
concentrations of endocannabinoids and have the main cannabinoid metabolizing 
enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). 
We report that UVB radiation up-regulates this cutaneous endocannabinoid 
system. In keratinocytes, UVB increases the levels of anandamide, 2-
arachidonoylglycerol (2-AG) and palmitoylethanolamide (PEA) and the activities of 
MAGL and FAAH. On the other hand, in melanocytes, UVB increases the mRNA 
expression of CB1 receptors. In keratinocyte-melanocyte co-cultures, UVB activates a 
paracrine CB1-mediated signaling that decreases melanin synthesis. Moreover, 
anandamide synthesized by keratinocytes after UVB irradiation acts at transient 
receptor potential vanilloid receptor type 1 (TRPV1) channel in an autocrine manner 
and reduces their survival. Our findings suggest that endocannabinoids have a role in 
the cross talk between keratinocytes and melanocytes, after exposure to UVR. 
The enzyme catechol-O-methyltransferase (COMT) was investigated as another 
potential protective mechanism against UVB irradiation. We show that similarly to 
melanocytes, keratinocytes also have COMT activity and that UVB radiation decreases 
COMT activity in both cell types. COMT inhibition did not modify melanin levels but 
increases UVB-induced cell death in keratinocytes. 
Psoriasis is the prototypic disease successfully treated with UVB. Moreover, 
psoriasis patients have an increased risk of obesity and metabolic syndrome that are 
well-known pathological conditions associated with endocannabinoid system 
dysregulation. Thus psoriasis patients were selected to study UVB effects in vivo.  
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In psoriasis patients, basal anandamide plasma levels were positively correlated 
with the levels of high sensitive C-reactive protein (hsCPR), a biomarker for 
cardiovascular risk and inflammation. After UVB treatment a significantly decrease in 
the plasma levels of anandamide was observed. Although endocannabinoids have a 
recognized role on metabolic syndrome, no correlation was observed between 
endocannabinoid levels and the metabolic parameters studied. 
We also report that UVB significantly decreased S-COMT activity in vivo as it 
was observed in cutaneous cell lines. No correlation was observed between COMT 
activity and clinical response. Interestingly, these patients have significantly higher S-
COMT activity than controls. In addition, we report that UVB significantly increases 
the vitamin A and vitamin D serum levels in psoriasis patients.   
In conclusion, the results presented here show that UVB radiation modifies 
endocannabinoid system activity and that the cutaneous endocannabinoid system may 
participate in the UVB effect on melanogenesis and cell viability. 
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Resumo 
 
A pele dispõe de vários mecanismos que a protegem da agressão pela radiação 
ultravioleta (UV). 
Neste trabalho descreve-se um sistema endocanabinoide funcionalmente reativo 
à radiação ultravioleta B (UVB), em linhas celulares de queratinócitos e melanócitos 
humanos. Estas células cutâneas produzem concentrações fisiologicamente relevantes 
de endocanabinoides, exprimem os recetores dos canabinoides (CB1 e CB2) e têm as 
principais enzimas de degradação dos endocanabinoides, hidrolase das amidas dos 
ácidos gordos (FAAH) e a monoacilglicerol-lipase (MAGL). 
Este sistema endocanabinoide cutâneo é ativado pela radiação UVB. Nos 
queratinócitos, a radiação UVB aumenta os níveis de anandamida, 2-
araquidonoilglicerol (2-AG) e palmitoiletanolamida (PEA), e a atividade das enzimas 
MAGL e FAAH. Nos melanócitos, a radiação UVB aumenta a expressão do RNAm 
dos receptores CB1. Em co-culturas de queratinócitos e melanócitos, a radiação UVB 
ativa uma inibição parácrina da síntese de melanina, mediada pelos recetores CB1. A 
anandamida sintetizada pelos queratinócitos após a radiação UVB atua de forma 
autócrina nos canais de tipo vaniloide 1 do potencial transitório dos fotorrecetores 
(TRPV1) e aumenta a morte celular. Estes resultados mostram que os 
endocanabinoides têm um papel importante na interação entre queratinócitos e 
melanócitos, que se torna mais evidente após exposição à radiação UV. 
A enzima catecol-O-metiltransferase (COMT) foi estudada como um possível 
mecanismo protetor da pele contra a radiação UVB. Verificou-se que tal como os 
melanócitos, também os queratinócitos têm atividade da enzima COMT e que esta é 
diminuída pela radiação UVB. A inibição da COMT não modifica os níveis de 
melanina, mas aumenta a morte celular induzida pela radiação UVB nos 
queratinócitos.  
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A radiação UVB é um dos tratamentos de primeira linha na psoríase. Por outro 
lado os doentes com psoríase têm um risco aumentado de obesidade e síndrome 
metabólico que são patologias reconhecidamente associadas à desregulação do sistema 
endocanabinoide. Assim, escolhemos os doentes com psoríase para estudar in vivo os 
efeitos da radiação UVB. 
Em doentes com psoríase, observamos uma correlação positiva entre os níveis 
plasmáticos basais de anandamida e os níveis de proteína C reativa medidos pelo 
método de alta sensibilidade (hsCPR) que são um marcador de risco cardiovascular e 
inflamação. Após a fototerapia com UVB, os níveis plasmáticos de anandamida 
diminuíram significativamente. Apesar dos endocanabinoides terem um papel 
reconhecido na síndrome metabólica, não se observou qualquer correlação entre os 
níveis de endocanabinoides e os parâmetros metabólicos estudados. 
Em concordância com os resultados em linhas celulares cutâneas verificou-se 
que a fototerapia UVB reduz significativamente a atividade da S-COMT eritrocitária 
em doentes com psoríase. Os doentes com psoríase têm maior atividade basal da 
COMT eritrocitária que os controlos mas não se observou correlação entre a atividade 
da COMT e a resposta clínica à fototerapia. Demonstramos também nestes doentes que 
a radiação UVB aumenta significativamente os níveis séricos de vitamina A e de 
vitamina D.  
Em conclusão, os resultados aqui apresentados mostram que a radiação UVB 
altera a atividade do sistema endocanabinoide e que o sistema endocanabinoide 
cutâneo parece contribuir para os efeitos da radiação UVB na melanogénese e na 
viabilidade celular.  
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